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The study aims mainly to investigate the therapeutic and diagnostic potential of small 
RNA molecules in hepatic diseases. The focus is on hepatitis B infection and 
hepatocellular carcinoma (HCC). HCC is a major health problem worldwide and chronic 
infection with hepatitis B virus (HBV) is a major risk factor for HCC. This study can be 
divided into two parts. The first part of this study was aimed at investigating the use of the 
RNA interference (RNAi) approach for inhibition of HBV gene expression while the next 
was aimed at evaluating the role of microRNAs (miRNAs) in human HCC. 
 
In the first part of this study, small interfering RNAs (siRNAs) that target HBsAg 
transcripts were designed and the effects of these siRNAs on the HBsAg producing cell 
line, PLC/PRF/5 and the HBV producing cell line, 2.2.15 were studied. We showed that 
siRNAs specific for two conserved regions within the HBsAg gene can inhibit the antigen 
production in the two human liver cell lines which constitutively produce and secrete 
HBsAg. The inhibitory effect was concentration-dependent for the PLC/PRF/5 cells as 
well as the 2.2.15 cells. Decreases in the corresponding viral transcript levels were 
observed. The inhibitory effect was observed within 24 hours and was still evident 7 days 
after the initial treatment with siRNAs. Significant reduction in virion production was also 
observed for the 2.2.15 cells. To address the question on the specificity of the 
siRNA-mediated inhibition, we first examined the effects on cell growth and viability. 
This was not affected in both cell lines. cDNA microarrays were also used to examine 
genome-wide changes in gene regulation. No significant off-target gene regulation was 
observed in both cell lines. Our data also showed that unlike the general interferon 
 IX
response to long dsRNA molecules, there is no single siRNA-induced response to siRNA 
duplexes in mammalian cells. Our findings thus indicate that siRNA can be specific in 
mediating down-regulation of viral gene expression leading to reduction in virion 
production. 
 
In the second part of the study, miRNA expression profiling using reverse transcription 
(RT)-real-time PCR was carried out in 10 paired HCC tumor and non-tumor samples. The 
expression profiles showed that of the 157 miRNAs examined, 28 were upregulated while 
14 were downregulated. The deregulation of some of the most frequently upregulated 
miRNAs (miR-15b, miR-25, miR-93, miR-106b, miR-135a, miR-182. miR-221, miR-222 
and miR-224) was confirmed in 56 paired HCC clinical samples and in HCC cell lines. It 
is of interest to note that members of the miR-17-92 cluster and its homology, the 
miR-106b-25 cluster were among those that were upregulated. To date, the miR-17-92 
cluster is one of the best characterized miRNAs and is implicated in the tumorgenesis of 
several types of human cancers including B-cell lymphoma, breast cancer, colon cancer, 
lung cancer and pancreatic cancer. Our data from the knock-down studies in cell lines for 
the miR-106b-125 cluster showed that the expression of the cluster is necessary for cell 
proliferation and for the anchorage-independent growth. Taken together, these data 
indicates that the miR-106b-25 cluster, like its homology, the miR-17-92 cluster, may also 
have oncogenic properties. 
 
In conclusion, siRNAs can be used as an efficient tool to inhibit HBV gene expression and 
viral replication in vitro. It is possible to design siRNAs which have little off-target effects, 
 X
although care should always be taken to verify that this is indeed so. In addition, our study 
on miRNAs in HCC indicates that miRNAs are deregulated in HCC, and the 
miRNA-106b-25 cluster together with some of the most frequently upregulated miRNAs 
in HCC may function as oncogenic genes. Our data also indicates that miRNA profiling 
might aid in cancer diagnosis and understanding of miRNA function in cancers may 
provide therapeutic targets.  
 
 
Keywords: Short interfering RNA, microRNA, hepatocellular carcinoma, hepatitis B, 
expression profiling, cDNA microarray
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Hepatocellular carcinoma (HCC) is currently identified as the sixth most common cancer 
(Parkin et al., 2005). Chronic Hepatitis B virus (HBV) infection especially in Asia puts 
patients at a great risk of developing HCC (Beasley et al., 1981). Current therapeutic 
approaches for chronic hepatitis B infection, such as cytokine treatment, chemotherapy and 
sequence-specific inhibition, only have limited clinical benefits and none of them is 
satisfactory in terms of cure rate. The development of new antiviral agents is highly desired. 
As a powerful tool to downregulate gene expression, RNA interference (RNAi) has been 
attracting great interest in exploring its potential role in the treatment of HBV infection (Will 
and Grundhoff, 2006). Besides small interference RNAs (siRNAs), another group of small 
RNA molecules, microRNAs (miRNAs), which have been linked to many types of human 
diseases, have also attracted the attention of many academic communities studying liver 
diseases. It is now well acknowledged that miRNAs may hold great potential in diagnosis and 
treatment of human cancers, including HCC. In this chapter, previous studies on HCC, 
current therapies for HCC and hepatitis B, RNA interference and miRNAs will be discussed.  
 
1.1 HCC 
HCC is a malignant tumor that arises from hepatocytes, the major cell type of the liver. 
HCC is characterized by spongy, plate-like, or sinusoidal growth patterns with vascular 
invasion (Crawford, 2002). Although HCC is the leading cause of death in many parts of 
the world, especially in Asia and Africa, the molecular mechanism of development and/or 
progression of HCC still remain unclear and current approaches for screening and 
treatment of HCC remain disappointing. In the next section, I will review the incidences of 
HCC, the risk factors and the current diagnoses and therapies. 
  3
1.1.1 Epidemiology of HCC 
As the sixth most common cancer worldwide, HCC constitutes about 5.7% of new cancer 
cases and continues to be a global health problem (Parkin et al., 2005). Based on statistics, 
the situation is becoming even worse. In 2000, about 398,000 new HCC cases were 
diagnosed (Parkin et al., 2001). As a highly lethal malignancy, HCC resulted in nearly 
384,000 deaths in the same year (Ferlay et al., 2001). However, in 2002, new incidences of 
HCC increased to 626,000 and the death toll increased to 598,000 (Parkin et al., 2005). 
This could be partially attributed to the very poor prognosis and little improvement in the 
treatment of HCC. HCC is the third most common cause of death from cancer and the 
survival rate is low, varying from 3% to 5% for the United States and the developing 
countries (Parkin et al., 2005). The incidence of HCC varies with geography, race, age, 
and sex. 
 
The incidence of HCC is not uniform across the world (Bosch et al., 2005; Sherman, 
2005). 82% of cases (and deaths) occur in the developing countries. The highest incidence 
of HCC is seen in China (~52 per age standardized 100,000 population). Other areas of 
high incidence rate are Central Africa (~41 per age standardized 100,000 population), 
Japan (~31 per age standardized 100,000 population), Eastern Africa (~30 per age 
standardized 100,000 population) and Southeast Asia (~24 per 100,000). The incidence is 
low in the developed areas (only in southern Europe is there any substantial risk, ~16 per 
age standardized 100,000 population), Latin America, and South-Central Asia. However 
HCC incidence in developed countries such as the United States is rising rapidly and this 
is most likely due to hepatitis C virus (HCV) infection (El-Serag, 2002). 
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The incidence of HCC is age associated. In the developed countries, the incidence of HCC 
only starts to increase over the age of 45 and continues to increase till the 70s (Bosch et al., 
2005; Sherman, 2005). In contrast, in the less developed countries, the HCC rates increase 
between the age of 20 and 50 (median age 45). In these areas, such as in South-East Asia, 
it is not rare to see HCC patients among people younger than 45. It is possible that these 
age differences arise from a difference in the age of exposure to hepatitis viruses. In the 
high-incidence countries, the exposure happens at younger ages, in contrast to much later 
exposure in the low-incidence countries.  
 
The incidence of HCC is also sex associated. The overall sex ratio (male:female) is about 
2.4. It has also been shown that women who had HCC and hepatic resection had better 
survival rates and a lower rate of tumor recurrence than male patients (Ng et al., 1995). 
There are no satisfactory explanations for the sex ratio observations yet (Bosch et al., 2005; 
Sherman, 2005). 
 
1.1.2 Risk Factors of HCC 
HCC is one of the few cancers with well-defined major risk factors. In 80% of the cases, 
HCC develops in cirrhotic liver, and cirrhosis is the strongest predisposing factor 
(Colombo, 2003). Liver cirrhosis is frequently the result of long-term viral infection. 
Worldwide, chronic infections with HBV or HCV are the two major risk factors for liver 
cancer, both of which increase the risk of liver cancer by about 20 fold (Donato et al., 
1998). More than 75% of HCC cases worldwide are caused by these two viruses (Parkin et 
al., 1999). However, the incidence of infection with HBV or HCV has a geographical 
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difference. In developed countries, HCC arises in cirrhotic liver mainly because of HCV 
infection which accounts for 60-70% of the incidences of HCC in Europe, 50-60% in 
North America and 70% in Japan. In contrast, in the less developed countries, such as in 
Asia (except Japan) and Africa, HBV infection is the most common risk factor, accounting 
for 70% of the incidences of HCC (Llovet et al., 2003). 
    
Other risk factors include excessive alcohol intake, haemochromatosis, coinfection with 
other viruses or exposure to aflatoxins which are hepatoxins produced by the fungus 
Aspergillus fumigatus. Exposure to aflatoxins has been implicated as a major risk factor 
for causing HCC, especially in tropical areas of the world where contamination of food 
grains with Aspergillus fumigatus is common (McGlynn and London, 2005). 
 
1.1.3 Diagnoses of HCC 
Current diagnoses of HCC can be simply classified into 3 categories: i) blood test, ii) 
image studies, and iii) biopsy or liver aspiration. The combination of an abnormal image 
found during imaging studies (ultrasound, computerized axial tomography (CT) or 
magnetic resonance imaging (MRI) scans) and an elevated blood level of 
alpha-fetoprotein (AFP), a protein normally made by the immature liver cells in the fetus, 
most effectively diagnoses liver cancer. A liver biopsy can be used to make a definitive 
diagnosis of HCC. Sometimes, the mass is biopsied using a laparoscope, a fiber optic 
instrument that is inserted into the abdomen. Occasionally, open surgical biopsy is 
necessary. The procedure requires a specialist of liver pathology (Worman et al., 1998). 
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It has no doubt that early diagnosis of HCC is critical for the survival of patients, but 
current common diagnostic approaches, namely CT scans, ultrasound scans and biopsy, 
can only be made when the tumor is obvious. In addition, many patients with HCC do not 
develop symptoms until the advanced stages of the tumor. When these patients have 
developed symptoms, the prognosis is usually very poor. Therefore, it is necessary to 
identify new biological markers of HCC and develop new diagnostic tools. 
 
1.1.4 Current Treatments of HCC 
Treatments of HCC can be conventionally divided into 3 categories: i) surgical treatments, 
ii) locoregional treatments, and iii) pharmacological treatments (Di Maio et al., 2002; 
Sherman and Takayama, 2004). 
 
Surgical treatments include surgical resection and liver transplantation. Both of these 
treatments can induce complete responses in a high proportion of patients and improve 
survival. However, surgical resection or liver transplantation may not be possible in all 
cases. Surgical resection can only be carried out if the tumor is small and it also requires 
careful patient selection and surgical expertise, while the application of liver 
transplantation is severely hampered by the shortage of donors (Poon and Fan, 2004).  
 
Many patients with malignant liver tumors are not good candidates for surgery, either 
because the tumor is very large or has spread beyond the liver or there may be the other 
medical conditions that make surgery risky. If this is the case, locoregional treatments fall 
into physician’s consideration. Locoregional treatments include radiofrequency ablation 
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(RFA), percutaneous ethanol injection (PEI), and the experimental cryoablation or 
microwave coagulation (Ng and Poon, 2005; Sherman and Takayama, 2004). These 
approaches make use of the altered physical and chemical properties of HCC cells. 
Compared to healthy liver cells, HCCs are generally more sensitive to heat, low 
temperature and microwave radiation. It is also much easier for ethanol to diffuse into 
HCC tumors because of the softer consistency and hypervascularity of the tumors. 
Another approach that has been used extensively in the palliative treatment of unresectable 
HCC is transcatheter arterial chemoembolization (TACE). TACE interrupts HCC blood 
supply and enables focused administration of chemotherapy. It has produced results 
superior to those of surgery in some patients with resectable HCC (Gates et al., 1999). 
 
Pharmacological treatments include chemotherapy (systemic or locoregional), hormone 
therapy and anti-angiogenesis therapy. These therapies are generally inexpensive, safe and 
easy to administer. However, research has shown that current pharmacological treatments 
are largely ineffective in the treatment of HCC. Chemotherapy produced a response rate 
lower than 20 percent, while hormonal therapy produced no survival benefit in male 
patients with advanced HCC (Groupe d'Etude et de Traitement du Carcinome 
Hépatocellulaire (GRETCH), 2004), and anti-angiogenesis therapy often failed because 
liver tumours can counteract it by expressing multiple potential endothelial mitogens that 
could replace the function of the most common anti-angiogenesis therapy target, vascular 
endothelial growth factor (VEGF) (Mohr et al., 2002).  
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In conclusion, unfortunately there have been no significant new developments in the 
diagnoses and treatments of HCC. Current diagnoses and treatments of HCC remain 
unsatisfactory. It is thus crucial to develop new approaches for the diagnosis and treatment 
of HCC. 
 
1.2 HBV-the Virus and the Disease 
HBV is a small enveloped DNA virus which can cause acute and chronic infection of the 
liver (Robinson, 1994). HBV infection remains a global health problem. It is estimated 
that hepatitis B infection affects more than 400 million people worldwide and 1-2 % of 
them die each year from virus related complications (Lin and Kirchner, 2004). Among 
these carriers, 5-10% of the adults and 29-40% of the children develop chronic HBV 
infection. In 20-50% of the chronic patients, the natural progression over 10-20 years leads 
to liver cirrhosis and eventually to HCC (Beasley, 1988). 
 
1.2.1 HBV: the Virus 
HBV is a member of the Hepadnaviridae family which primarily causes necrosis and 
inflammation of the liver. The hepatitis B virus can be transmitted in several ways 
including blood transfusion, sexual contact and childbirth. The comprehensive 
understanding of the structure and the activities of the virus is essential for the 























During HBV infection in human, virus particles are present in a large quantity in patient 
blood. Both infectious and non-infectious particles can be found in the serum of acutely 
infected patients (Figure 1.1).  
 
The hepatitis B virion, also known as the Dane particle, is the infectious particle found in 
the serum of an infected patient. Dane particles are 42 nm in diameter and possess an inner 
nucleocapsid which is 27 nm in diameter and made up of 180 to 240 hepatitis B core 
proteins (hepatitis B core antigen (HBcAg), 20 kDa in size). The nucleocapsid also 
encloses at least one hepatitis B polymerase protein (P) along with the HBV genome 
(Figure 1.2). The nucleocapsid is surrounded by an outer protein (termed "surface antigen" 
or hepatitis B surface antigen (HBsAg)) coat which is approximately 4 nm thick and 





Figure 1.2 Illustration of the structure of a Dane particle. 
P protein = HBV polymerase; L = large surface proteins; M= 
middle surface proteins; S = small surface proteins; TP: 
terminal protein. 
: HBV 
Figure 1.1 Illustration of HBV particles 
found in patient’s serum. 
1) Dane particles: infectious virions 
2) Spherical structures – no viral DNA 
3) Tube-shaped structures – no viral DNA 
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Two non-infectious particles, the filamentous and spherical particles, can also be found in 
large amounts in the serum of the patients with HBV infection (Figure 1.1). These 
non-infectious particles (22 nm in diameter) are purely composed of the HBsAg which is 
generally produced in vast excess and contain no hepatitis B core protein, no HBV 
genome DNA and no polymerase (Hollinger and Liang, 2001). Because these empty 
particles have the same antigenic sites as the infectious Dane particles, it is generally 
believed that when present in large amounts they help the infectious viral particles to 
transverse the blood stream without being detected by the neutralizing antibodies. 
 
1.2.1.2 The HBV genome 
The HBV genome is one of the smallest genomes of human viruses. It is a relaxed circular, 
partially double-stranded DNA molecule at 3.2 kb in length. One strand of the viral DNA, 
which is complementary to the viral mRNA and termed the minus strand, is unit length 
and covalently linked to proteins at its 5' end. The other strand of viral DNA, the plus 
strand, is always incomplete and has a capped oligoribonucleotide at its 5' end. The 
single-stranded region or gap is of fixed polarity but variable length (Robinson, 1995). A 
virion-associated polymerase can repair the gap in the viral DNA and generate a 
completely double-stranded HBV DNA molecule (Figure 1.3). The minus strand DNA is 
the template for the synthesis of the viral mRNA transcripts. 
 
HBV has a very compact genome containing four defined partially overlapping open 
reading frames (ORFs). The four ORFs are named S, C, X and P respectively. ORF P 






















the presence of in-frame start codons. As a result, seven known proteins are translated 
from the four ORFs. ORF S encodes the three viral surface glycoproteins; ORF C encodes 
HBcAg and hepatitis e antigen (HBeAg); ORF P encodes the viral polymerase and a 





























Figure 1.3 HBV genome and the organization of the ORFs. The numbers on the genome (0-3221 bp) 
are based on the sequences of HBV adw2 subtype. Transcription of the covalently closed circular DNA 
(cccDNA) is governed by the enhancer I and II, the glucocorticoid response elements (GRE) and the 
promoter upstream of mRNA transcripts start sites. S: S ORF; P: P ORF; C: C ORF; X: X ORF; DR: 




1.2.1.3 Life cycle of HBV  
The key steps in the HBV replication cycle have been elucidated over the past two decades. 
Like other viruses, the life cycle of HBV can be divided into several steps: attachment and 
entry of the virus to the host cell, release of viral genome, expression of viral gene 
products, replication of HBV genome DNA, assembly of virions and lastly, the release of 
viruses into the circulation of the host. 
 
The initial phase of HBV infection involves the binding of HBV virion to the membrane of 
the host hepatocyte through certain surface receptors (Ganem and Schneider, 2001). A 
number of candidate receptors have been identified, including the transferrin receptor, the 
asialoglycoprotein receptor molecule and human liver endonexin. However, the exact 
mechanism of HBV virion binding to a specific receptor and its entry into cells remain 
unclear. The virus then enters the host cell by fusing its membrane with that of the host. At 
the same time, the core particle enters the cell and migrates to the nucleus, where the viral 
genome is repaired and converted from a relaxed circular DNA into a cccDNA that serves 
as a template for the transcription of viral messenger RNAs. Four viral transcripts are 
transcribed in the HBV life cycle. They are approximately 3.5, 2.4, 2.1, and 0.7 kb in 
length. These transcripts are then polyadenylated at an identical polyadenylation site and 
transported to the cytoplasm, where they are translated into the viral envelope, core, 
polymerase, and X proteins. The 3.5 kb transcript, spanning the entire genome and termed 
pregenomic RNA (pgRNA), is packaged together with the HBV polymerase and a protein 
kinase into the HBV core particle where it is reverse transcribed into the viral minus strand 
DNA. The resulting new, mature core particle can either bud into the endoplasmic 
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reticulum to be enveloped and exported from the cell via the Golgi apparatus or recycle its 
genome into the nucleus to amplify the intranuclear pool of cccDNAs (Figure 1.4).  
 
Figure 1.4 HBV life cycle. The HBV virion binds to the surface receptors and is internalized. The viral 
core particle migrates to the hepatocyte nucleus, where The HBV genome DNA is repaired to form a 
cccDNA that is the template for the viral messenger RNA (mRNA) transcription. The viral mRNA is 
translated in the cytoplasm to produce the viral surface, core, polymerase, and X proteins. Then, the 
progeny viral capsid assembles, incorporating the genomic viral RNA (RNA packaging). This RNA is 
reverse-transcribed into the viral DNA. The resulting core can either bud into the endoplasmic 
reticulum to be enveloped and exported from the cell or recycles its genome into the nucleus for 
conversion to a cccDNA. The small, peach-colored sphere inside the core particle is the viral DNA 
polymerase (Reproduced with permission from Ganem and Prince, 2004). 
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1.2.2 Hepatitis B: the Disease 
Viral hepatitis is an inflammation of the liver caused by hepatitis viruses. Five different 
hepatitis viruses have been identified. The term “hepatitis B” was first coined by 
MacCallum in 1947 in order to categorize infectious (epidemic) and serum hepatitis 
(MacCallum, 1947). It was eventually adopted by the World Health Organization (WHO) 
on viral hepatitis in 1973 (World Health Organization, 1973). Chronic active hepatitis is 
severe and often progresses to cirrhosis, which eventually leads to HCC. 
 
1.2.2.1 Prevalence 
Hepatitis B is one of the world’s most common and serious infectious diseases. It is 
estimated that more than 400 million people worldwide are HBV carriers. The incidence 
of HBV infection varies in different geographical areas. The prevalence is low in the 
developed areas with the highest standards of living, such as the United States and the 
European countries where the incidence is only about 0.1-2%. In contrast, the prevalence 
is high in the developing countries where the medical facilities are primitive or limited, 
such as Southeast Asia, China and sub-Saharan Africa and the HBV carrier rate in these 
places range from 10-20%. In Singapore, the overall HBV carrier rate is about 4.1% as 
estimated in 1999 (James et al., 2001). 
 
1.2.2.2 Clinical diagnosis and prevision 
HBV infection induces a spectrum of clinical manifestations, ranging from mild, 
unapparent disease to fulminant hepatitis, severe chronic liver disease and cirrhosis. 
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Symptoms include fatigue, jaundice, abdominal pain, intermittent nausea, loss of appetite, 
vomiting, dark urine and light stools (MacCallum, 1947). 
 
The definite diagnosis of HBV infection is from the results of specific HBV blood tests 
(serologies) that reflect the various components of the virus. There are three standard 
blood tests for HBV infection which are the test for HBsAg, the test for the antibody to 
hepatitis B surface antigen (anti-HBsAg) and the test for the antibody to hepatitis B core 
antigen (anti-HBcAg). Another clinical useful antigen-antibody system that has been 
identified for hepatitis B is hepatitis B e antigen (HBeAg)/antibody to HBeAg (anti-HBe) 
system. Persistance of HBeAg is indicative of active viral replication and the patient is 
infectious. Seroconversion form HBeAg to HBeAb is prognostic for resolution of HBV 
infection. Tests for HBeAg/anti-HBe are quite useful for diagnostic purposes following 
the progress of therapy. In addition, PCR-based methods are also widely used now to 
confirm the existence of HBV viral genome in the serum of the patients. 
 
Current treatments for HBV infection are far from satisfactory. Thus, prevention is the 
best option in dealing with this disease. Hepatitis B is a vaccine-preventable disease. 
Immunization with hepatitis B vaccine is the most effective means of preventing HBV 
infection and its consequences. The hepatitis B vaccine has been available since 1982 
(Mahoney and Kane, 1999). The vaccines currently in use are made with the recombinant 
DNA technology and are safe as they contain only the antigenic protein portions of HBV 
and no live virus. Global control of hepatitis B is achievable through worldwide 
vaccination. However, the ultimate goal has not been attained because of the existence of a 
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large pool of carriers and the limited coverage of vaccination in the developing countries. 
Hence, it is still necessary to continue to promote the global vaccination campaign.  
 
1.2.2.3 Therapeutic treatment of hepatitis B 
Treatment of chronic hepatitis B is aimed at clearing HBV from patients and thereby 
preventing transmission to other people and the progression to the advanced stages of liver 
diseases. An efficacious treatment against chronic HBV infection has not been found yet. 
Current treatments include the use of interferon-α (IFN-α) and nucleoside analogues. The 
research on developing new therapeutic agents is ongoing. One new sequence-specific 
approach, RNAi, is considered to be promising. 
 
1.2.2.3.1 Interferon-α 
The interferons (IFNs) are a family of cytokines that are best known for their ability to 
induce cellular resistance to virus infection. IFNs exert multiple effects on virus infected 
cells. These include antiviral, antiproliferative and immunomodulatory effects. Based on 
the structural and functional differences, IFNs have been subdivided into two classes: type 
I and type II. Being a member of type I IFNs, IFN-α is synthesized by leukocytes. As a 
defensive factor, IFN-α can trigger target cells to respond to viral invasion by stimulating 
synthesis of several antiviral gene products (Lengyel, 1982). IFN-α is the first Food and 
Drug Administration (FDA)-approved drug of therapy for chronic hepatitis B infection. 
However, only 15% of patients who receive IFN-α achieve a complete virological 
response with the clearance of HBV from the serum, and the treatment is always 
  17
accompanied by side effects, such as flu-like symptom, depression, neutropenia and 
thrombocytopenia.  
 
1.2.2.3.2 Nucleoside analogues 
There is a range of nucleoside analogues that can serve as antiviral agents to prevent vrial 
replicaion in HBV infected cells. Nucleoside analogues, such as lamivudine, famciclovir 
and the most recently licensed entecavir, have been shown to be potent suppressors of 
hepatitis B viral replication. These analogues lack of the equivalent of the 3’ hydroxyl 
group on the (deoxy) ribose sugar and act as terminators of growing viral DNA chain. All 
the nucleoside analogues have to be phosphorylated intracellularly before they can act as 
competitive inhibitors and execute their antiviral activity. These analogues are very 
effective in inhibiting active viral replication and reducing viral load at low intracellular 
drug concentrations. However, the long-term use of these drugs may lead to the 
undesirable emergence of drug-resistant virus (Klein et al., 2003).  
 
1.2.2.3.3 Sequence-specific approaches 
The genome of HBV has been fully sequenced and the uniqueness of the viral genetic 
information can be exploited for developing effective therapies. It is thus possible to 
design oligonucleotides targeting the HBV genome to selectively inhibit HBV activity in a 
sequence-specific manner. Antisense oligonucleotides (ASO) and ribozymes are two 
examples of the use of oligonucleotides which can specifically inhibit HBV gene 
expression and viral replication.  
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The antisense concept originated as early as in 1967 before the discovery of naturally 
existent antisense RNAs (Belikova et al., 1967). ASOs refer to short DNA or RNA 
oligomers used to target mRNAs at specific complementary regions thereby resulting in 
the inhibition of the expression of these mRNAs. Binding of ASO to its target mRNA 
generally leads to the blockage of protein translation. In some cases, intracellular RNase H 
could cleave the mRNA following the formation of the RNA-DNA hybrid when the 
RNA-DNA hybrid may be as short as ten base pairs (Walder and Walder, 1988). It has 
been reported that ASO can inhibit HBV gene expression and replication both in vitro and 
in vivo (Goodarzi et al., 1990; Yao et al., 1996). 
 
The ribozymes are RNA molecules that catalyze the cleavage of mRNAs and the concept 
was originally described by Kim and Cech in 1987 (Kim and Cech, 1987). The 
hammerheaded ribozyme consists of the antisense flanking sequences and a conserved 
catalytic domain and is capable of autocatalytically cleaving target RNAs to which it 
hybridizes in a sequence-specific manner. This ability of cleaving target mRNA is the 
main advantage of ribozymes compared to ASOs. It is thus possible to design ribozymes 
to selectively destroy HBV transcripts. Studies have shown that ribozymes could 
specifically inhibit HBV activities (Feng et al., 2001; Tan et al., 2002). 
 
Both antisense oligonucleotides and ribozymes were once the most exciting findings that 
held the promise of the better treatment for HBV infection. The specificity of these two 
approaches is high. However, their instability and low efficacy strongly decrease their 
potentials as therapeutic tools.  
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Because all the currently available therapies show limited potentials in the treatment of 
chronic HBV infection, development of new approaches is urgently needed. One of these 
new approaches is that of RNAi. 
 
1.3 RNAi 
RNAi occurs in a wide variety of eukaryotic organisms. It provides the mechanism by 
which specific post-transcriptional silencing (PTGS) of gene expression can happen. 
RNAi is one of the most exciting discoveries of the past decade. It has been accepted that 
RNAi is one of the most influential tools for analyzing the functions of genes in 
eukaryotes and holds promise for the development of therapeutic gene silencing (Cheng et 
al., 2003). In 2006, Andrew Z. Fire and Craig C. Mello won the Nobel Prize in Physiology 
or Medicine for their discovery of “RNA interference – gene silencing by double stranded 
RNA”. 
 
1.3.1 The Mechanism of RNA Interference 
RNAi is induced by double-stranded RNA (dsRNA) molecules that vary in length and 
origin (Fire et al., 1998). The long dsRNAs have first to be cleaved by the ribonuclease 
III-like enzyme Dicer into siRNAs of 21-23 base pairs (Hamilton and Baulcombe, 1999; 
Zamore et al., 2000; Bernstein et al., 2001). The siRNAs are the effector molecules which 
mediate the silencing process by facilitating the degradation of homologous mRNA via the 
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formation of the RNA-induced silencing complex (RISC) (Nykanen et al., 2001; Schwarz 
et al., 2002) ( Figure 1.5).  
 
Dicer was first identified by Bernstein and co-workers (Bernstein et al., 2001). It is 
evolutionarily conserved in worms, flies, plants, fungi and mammals. Dicer is a ~200 kDa 
multidomain, RNase III family enzyme that functions in processing dsRNA to siRNA and 
assembling the guide strand into the RISC. The enzyme has a distinctive structure, which 
includes an ATPase/RNA helicase domain, two catalytic RNase III domains, a C-terminal 
dsRNA binding domain (dsRBD) and a conserved PAZ domain which is shared with the 
Argonaute family that has been genetically linked to RNAi. Dicer progressively cleaves 
the dsRNA at 21–25 bp intervals to generate siRNAs with 2-nt 3' overhangs and 
phosphorylated 5' ends. A recent structural study of Dicer has confirmed that Dicer indeed 
acts as a molecular ruler to cleave double-stranded RNA substrates at a set distance from 
one end (Macrae et al., 2006). 
 
The RISC was first defined as a large RNA–protein complex with sequence-specific RNA 
cleavage activity that could be purified by chromatographic fractionation from cells 
programmed with longer dsRNAs or siRNAs in vivo or in vitro (Hammond et al., 2000; 
Zamore et al., 2000). Biochemical approaches and genetic screens in plants, fungi and C. 
elegans have unambiguously identified the members of the Argonaute protein family as 
the essential protein components of RISCs (Hammond et al., 2001; Liu et al., 2004b; Qi et 
al., 2005). Argonaute orthologues have been identified in bacteria, archea and most 
eucaryotes (Cerutti and Casas-Mollano, 2006). Argonaute has four conserved protein 
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domains: N terminal, Mid, PAZ and PIWI domains. Structural studies have revealed that 
the PAZ domain initiates the incorporation of a small RNA into RISC by binding the 
single-stranded 2nt 3’overhang of the siRNA duplexes and the PIWI domain determines 
the endonuclease cleavage activity of the RISC by adopting an RNase H fold (Lingel et al., 
2003; Ma et al., 2005b). Once the guide strand of a siRNA duplex is loaded onto the 





Figure 1.5 Schematic illustration of the mechanism of RNA interference. dsRNA processing proteins 
(RNase III-like enzymes) bind to and cleave dsRNA into siRNA. The siRNA forms a multicomponent 
nuclease complex, the RISC. The target mRNA recognized by RISC is cleaved in the center of the 
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1.3.2 History of RNAi Study 
In 1990, RNAi was firstly observed in plants (Figure 1.6). By introducing a 
pigment-producing gene under the control of a powerful promoter, Jorgensen and his 
colleagues tried to enhance the purple color of petunias. To their surprise, instead of the 
expected deeper purple color, many of the flowers appeared variegated or even white. 
Jorgensen named the observed phenomenon "cosuppression", since the expressions of 
both the introduced gene and the homologous endogenous gene were suppressed (Napoli 
et al., 1990). 
 
In 1992, a similar phenomenon was observed in the fungi, Neurospora crassa and the 
phenomenon was termed ‘quelling’ (Romano and Macino, 1992). At that time, it was 
thought that this bizarre phenomenon was strictly limited to plants and fungi, and did not 
occur in other organisms.  
 
In 1998, Fire and Mello and their colleagues successfully carried out RNAi experiments in 
C.elegans. This is considered as one of the milestones of RNAi study (Figure 1.6). They 
injected the artificial long dsRNA into cells and observed the corresponding suppression 
of the target gene. Actually the dsRNA induced much more efficient silencing than either 
the sense or the antisense strand alone. Injection of just a few molecules of dsRNA per cell 
was sufficient to completely silence the exoression of the homologous gene (Fire et al., 
1998). Shortly after this, dsRNA-mediated gene silencing was also successfully utilized in 
Drosophila (Kennerdell and Carthew, 1998). So how does dsRNA lead to gene silencing? 
A key clue was found by Hamilton and Baulcombe. They identified the RNAs of ~25 
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nucleotides in plants undergoing cosuppression as the key effector molecules. These 
RNAs were complementary to both the sense and antisense strands of the gene being 
silenced. These small interference RNAs were shown to be essential for PTGS (Hamilton 
and Baulcombe, 1999). In 2000, the RISC was partially purified by Hammond and his 
colleagues (Hammond et al., 2000). Although components of this multiprotein-RNA 
complex have not been completely identified, it has been shown that the complex includes 
the antisense strand of the siRNA, a helicase and an RNA-directed nuclease (Nykanen et 
al., 2001; Hammond et al., 2000; Hammond et al., 2001; Grishok et al., 2000).  
 
Although dsRNA-triggered gene suppression provided a fast and reliable alternative to the 
tedious gene manipulation in the reverse genetics, such an approach was thought to be of 
little use in mammalian systems, which react to dsRNA larger than 30 base-pairs in length 
by global (non-specific) inactivation of transcription through the PKR/interferon I 
pathway. Fortunately, for the mammalian biology community, a critical breakthrough was 
made in 2001 by Tuschl’s group who generated synthetic siRNAs (21-nt duplexes having 
symmetric 2-nt 3’ overhangs) and demonstrated that these could trigger RNAi in cultured 
mammalian cells without needing cleavage by Dicer and without generating a 
PKR/interferon response (Elbashir et al., 2001a). In the same year, Dicer was identified by 
Bernstein et al and was characterized as a ribonuclease III-like enzyme that cleaves long 
dsRNA into the effectors siRNAs (Bernstein et al., 2001). By then the theory of RNAi had 
been largely established and well accepted by biologists. In 2002, siRNA quickly became 
a powerful tool to down regulate gene expression of a wide variety of species.  
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Figure 1.6 Timeline of RNAi study 
 
 
1.3.3 RNAi and Applications 
 
Although the history and the mechanisms of RNAi and PTGS are intriguing, researchers 
are most excited about RNAi's potential use as a functional genomics tool and as potential 
therapeutics for human diseases. Therefore, RNAi in mammalian systems has been widely 
investigated in the past few years. 
 
1.3.3.1 RNAi as a tool for functional genomics  
The classic genetic (forward genetic) approach seeks to find the genetic basis of a 
phenotype or trait. In contrast, the reverse genetics discovers the function of a gene in the 
opposite direction. It aims to find the possible phenotypes that may be derived from a 
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of the RNAi technology, common techniques used in reverse genetics were gene deletions, 
insertions and point mutations. All these gene manipulation approaches are often difficult 
or cumbersome. The ability of RNAi to specifically and efficiently knock down the 
expression of any given gene promises to revolutionize the reverse genetic approaches.  
 
RNAi has already been used to ascertain the functions of many genes in Drosophila, C. 
elegans, and several species of plants. In C. elegans the direct injection of dsRNA has 
been used to establish or confirm the functions of numerous genes and to assign 
phenotypic effects to many genes identified only by computational approaches (Fraser et 
al., 2000; Gonczy et al., 2000). In Drosophila the direct injection of dsRNA into embryos 
has been used to study the functions of genes expressed during the development (Schmid 
et al., 2002). RNAi was also employed to study the functions of the minor and regulatory 
components of the plant cytoskeleton (Klink and Wolniak, 2000). 
 
For more than 30 years, it has been known that exposure of mammalian cells to long 
dsRNAs results in a non-specific shut down of global gene expression through innate 
immune pathways, including the interferon-regulated responses that serve as antiviral 
mechanisms. Although it was shown that long dsRNAs could trigger gene-specific 
responses when they were introduced into mammalian embryos and embryonic cell lines 
in which nonspecific antiviral responses to dsRNAs are not prevalent (Hannon, 2002), the 
existence of these innate immune pathways seemed incompatible with the use of dsRNA 
for silencing a particular target gene in most of the mammalian systems. The problem has 
to be tackled before RNAi can be established as a genetic tool in mammalian cells and 
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animals. Fortunately, with the deep understanding of RNAi pathway, Tuschl and 
colleagues demonstrated that the sequence-specific RNAi could be achieved in the 
mammalian systems when the RNAi was induced directly by siRNAs instead of being 
initiated by dsRNAs. Moreover, they demonstrated that siRNAs did not trigger the global 
anti-virus response (Elbashir et al., 2001a). So the barrier to the use of RNAi as a genetic 
tool in mammals was ‘suddently’ overcome. With the knowledge that specific RNAi can 
be induced in mammalian cells by the introduction of siRNAs, many more researchers 
have being trying to harness RNAi as a functional genomic tool in human, mouse and 
other mammalian cell culture systems. Reports using siRNAs in human cells to determine 
gene functions have been published (Elbashir et al., 2002; McManus et al., 2002; 
Tachibana et al., 2006). Besides using RNAi for analyzing the function of one single gene, 
researchers are constructing the genome-wide libraries of siRNAs to unlock the potential 
of the human genome (Hannon and Rossi, 2004). 
 
1.3.3.2 RNAi as gene-specific therapeutics 
Before RNAi, antisense oligonucleotides and ribozymes were two approaches that held 
promise for the treatment of human diseases in a gene-specific manner. However, current 
clinical trials with both the antisense oligonucleotides and ribozymes have so far proven to 
be disappointing. RNAi is much more potent than these two strategies in terms of 
specificity, stability and efficacy, and RNAi may be more efficient in the clinical settings. 




PTGS was initially identified in plants as an ancient and effective mechanism to protect 
plant tissues from viral infection (Waterhouse et al., 2001). RNAi induces the most potent 
PTGS among a variety of species. Since the first description of RNAi in mammalian cells, 
there have been numerous studies aimed at using RNAi to treat human diseases. The 
potential therapeutic areas include: human viral infections, human cancers and other 
genetic diseases. 
 
Initial studies to test the potential applications of synthetic siRNAs to inhibit virus 
infection in vertebrates have been shown to be promising (McManus et al., 2002). HIV 
(human immunodeficiency virus) was the first infectious virus targeted by RNAi. It was 
possibly because the lifecycle and pattern of gene expression of HIV had been well 
understood. Synthetic siRNAs and expressed short hairpin RNAs (shRNAs) have been 
used to target several early and late HIV-encoded RNAs in cell lines and in primary 
haematopoietic cells including the TAR element, tat, rev, gag, env, vif, nef and reverse 
transcriptase (Jacque et al., 2002; Lee et al., 2002; Coburn et al., 2002; Surabhi et al., 
2002; Novina et al., 2002; Park et al., 2002). Because of the high mutation rate, targeting 
HIV encoded transcripts directly represents a substantial challenge for clinical 
applications. Therefore, siRNA mediated downregulation of the cellular cofactors required 
for HIV infection becomes an attractive alternative or complementary approach and has 
proven to be successful. These cofactors include NF-κB, the HIV receptor CD4, the 
coreceptors CXCR4 and CCR5 (Surabhi et al., 2002; Novina et al., 2002; Martinez et al., 
2002). It has also been reported that siRNAs can potently inhibit influenza virus 
production in both cell lines and embryonated chicken eggs (Ge et al., 2003). The same 
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research group also reported that siRNAs specific for conserved regions of influenza virus 
genes could prevent and treat influenza virus infection in mice (Ge et al., 2004). 
 
Because human hepatitis induced by HBV or HCV remains a major health problem, it is 
not surprising that RNAi technology was soon employed to inhibit the replication of HBV 
and HCV. HCV was first targeted. Studies have shown that siRNAs targeting the internal 
ribosome entry site (IRES) or mRNAs encoding the HCV non-structural proteins NS3 and 
NS5B strongly inhibited HCV replicon function in cell culture systems (Randall et al., 
2003; Wilson et al., 2003; Kapadia et al., 2003). McCaffrey and colleagues demonstrated 
that siRNAs or anti-HCV shRNAs delivered by hydrodynamic tail-vein injections 
efficiently cleaved HCV sequences in an HCV luciferase fusion construct in mouse 
hepatocytes in vivo (McCaffrey et al., 2003a), demonstrating the therapeutic potential of 
RNAi technique.  
 
During the course of my study on the effects of siRNAs on HBV, several papers were 
published describing inhibition of HBV gene expression and viral replication both in vitro 
and in vivo by using RNAi technology.  
 
The first study on HBV was carried out by Shlomai and Shaul in 2003. They showed that 
siRNA encoded by a siRNA-producing vector pSUPER significantly suppressed the 
expression of targeting HBV transcripts and proteins in cell cultures (Shlomai and Shaul, 
2003). Later on four papers were published, confirming the success of inhibition of HBV 
activity in vitro by RNAi (Hamasaki et al., 2003; Tang et al., 2003; Ying et al., 2003; 
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Konishi et al., 2003). Hamasaki and co-workers co-transfected human hepatoma cells with 
HBV DNA and a chemically synthesized siRNA against HBV-pregenome RNA. 
Transfection experiments demonstrated that the siRNA reduced the amount of 
HBV-pregenome RNA and resulted in the reduction of the levels of replicative 
intermediates and viral proteins. Tang and colleagues co-transfected HepG2 cells with a 
eukaryotic expression plasmid pHBV1.3 and a RNAi plasmid pSIHBV/C encoding a 
shRNA targeting the core ORF of HBV genome. They demonstrated that the expression of 
HBsAg and HBeAg in the cell culture medium and the expression of intracellular viral 
proteins were specifically inhibited. In the same year, Ying and colleagues published their 
studies on the effect of transfection of the HBV-inducible cell lines HepAD38 and 
HepAD79 with a chemically synthesized siRNA. It was shown that the siRNA specific for 
the core gene of the HBV genome resulted in a profound inhibition of viral replication. 
The inhibitory effect was corroborated by a marked reduction of HBV core protein. 
Konishi and co-workers’ work was the most similar to ours. They transfected 2.2.15 cells, 
a stable HBV-producing cell line, with HBV-specific siRNAs and observed the 
corresponding decrease of HBsAg expression, HBV pregenomic RNA levels and HBV 
core-associated DNA level.  
 
The most impressive in vivo study was carried out by McCaffrey and colleagues who first 
demonstrated RNAi efficacy against HBV virus in a mouse model. They showed that 
hydrodynamic co-delivery of an HBV replicon and an expression unit encoding an 
anti-HBV shRNA in mice resulted in a significant knockdown (99%) of the HBV core 
antigen in mouse liver hepatocytes, providing an important proof of principle for future 
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antiviral applications of RNAi in the liver (McCaffrey et al., 2003b). Similar results were 
achieved by Giladi and co-workers. HBV plasmid together with chemically synthesized 
siRNAs targeting the S ORF of HBV was delivered into mice using the hydrodynamic tail 
vein injection method. A significant inhibition in the level of viral transcripts, viral 
antigens, and viral DNA was detected in the livers and sera of the treated mice relative to 
control animals (Giladi et al., 2003). 
 
siRNAs have been used as an experimental tool to dissect the cellular pathways that lead 
to uncontrolled cell proliferation and to cancer. Moreover, RNAi has been proposed as a 
potential treatment for human cancer. The expression of major oncogenes and 
cancer-related genes can be repressed using the RNAi approach. For instance, it has been 
demonstrated that Bcr-Abl oncoprotein p210, one characteristic gene of chronic 
myelogenous leukaemia (CML), was selectively downregulated by both synthetic siRNAs 
and lentiviral-vector-transduced shRNAs in cell lines, and the downregulation was 
accompanied by strong induction of apoptotic cell death (Wilda et al., 2002; Scherr et al., 
2003). Another anti-apoptotic protein Bcl-2 was also shown to be a good target of RNAi 




1.3.3.3 Challenges for the applications of RNAi 
1.3.3.3.1 Design of siRNA 
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The most potent siRNAs can result in >90% reduction in target RNA and protein levels. 
However, the effectiveness of siRNAs varies. In order to achieve maximum specific 
inhibition, certain guidelines must be followed during selection of target sites and design 
of siRNAs. Generally speaking the most effective siRNAs are 21 nt dsRNAs with 2 nt 3' 
overhangs. In addition, if siRNAs can simultaneously satisfy all four of the following 
sequence conditions, chances are they are capable of inducing highly effective gene 
silencing in mammalian cells: (i) A/U at the 5' end of the antisense strand; (ii) G/C at the 5' 
end of the sense strand; (iii) at least five A/U residues in the 5' terminal one-third of the 
antisense strand; and (iv) the absence of any GC stretch of more than 9 nt in length (Ui-Tei 
et al., 2004). Qiagen provides a very simple and useful on-line siRNA design tool 
(URL:http://www1.qiagen.com/Products/GeneSilencing/CustomSiRna/SiRnaDesigner.as
px).The design tool incorporates standard Tuschl-based design, with additional parameters 
for differential melting temperature of the 5’ and 3’ ends, overall GC content, base 
preferences at specific sites, and avoidance of stretches of Gs or Cs. It is quite easy for 
researchers to search for potential siRNA target sites. Unfortunately, not all siRNAs 
meeting the rules described above or selected by siRNA design tools are effective. The 
reasons for this are unclear but may be a result of positional effects (Holen et al., 2002). 






Another key challenge in developing RNAi as a therapy is ensuring efficient delivery. 
Highly efficient mechanisms for the delivery of siRNA to the relevant cells will also be 
particularly important for successful treatment of human diseases. Synthetic siRNAs are 
double-stranded RNA molecules. Unlike single-stranded antisense agents which can bind 
to serum proteins and be taken up by cells and tissues in vivo, siRNAs cannot be taken up 
by cells spontaneously (Wang et al., 2003). Double-stranded siRNAs have to be packaged 
in liposome before they can enter cells. Although there are a few reports of functional 
RNAi being obtained in mammalian cells by systemic delivery of liposome-encapsulated 
siRNAs, the use of cationic or anionic lipids for in vivo delivery of siRNAs is still far away 
from being applicable in the treatment of human diseases. An alternative approach is the 
viral-vector-mediated delivery of therapeutic shRNA genes. The viral vector delivery may 
achieve very high efficiency and long-term effect. However, because of several associated 
safety concerns, systemic delivery of viral vectors is still a major hurdle. Fortunately, 
researchers have being dealing with this delivery issue and many approaches have been 
made to make RNAi therapy models more feasible. For example, several groups have 
developed chemical backbone modifications to synthetic siRNAs in order to provide them 
with resistance to serum nucleases and therefore improve their half-life. More importantly, 
these chemically modified siRNAs showed activity upon delivery by standard intravenous 
injection, which definitely shortens the distance to clinical applications (Chiu and Rana, 
2003; Czauderna et al., 2003; Morrissey et al., 2005).  
 
1.3.3.3.3 Specificity of RNAi 
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For RNAi to be a powerful gene knock down tool or useful therapeutics, it is crucial that it 
must not cause any effects other than those associated with the target gene. This issue is 
particularly important in its therapeutic applications where unwanted side-effects would 
be undesirable. As a result, in order to fully fulfill RNAi’s applications one key issue, the 
specificity of RNAi, needs to be addressed thoroughly.  
 
Unlike relatively simpler systems such as invertebrates and plants, mammalian cells have 
complicated immune systems which may cause unwanted adverse effects when activated 
by introduction of alien objects. For mammalian cells, both of RNAi’s initiator dsRNA 
and effector siRNA are “strangers”. Thus the specificity issue in mammalian systems 
becomes a more complicated problem.  
 
In 1994, Lee and his colleagues found that RNAi initiated by introduction of long dsRNA 
into mammalian cells was accompanied by the activation of the interferon pathway, which 
may lead to the global shutdown of gene expression, ultimately causing cell death (Lee 
and Esteban, 1994). This occurs through activation of RNaseL, which is a general 
ribonuclease that degrades cellular RNAs with no selectivity, and shutdown protein 
synthesis through the double-stranded RNA-dependent protein kinase (PKR) (Wang and 
Carmichael, 2004). However, only the specific inhibition of the target gene is wanted 
when RNAi is considered as a therapeutic approach. So the global effects caused by 
dsRNA make RNAi initiated by long dsRNA undesirable.  
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As described in section 1.3.2, in 2001, a breakthrough was achieved by Tuschl’s team. 
They found that by directly introducing the effectors synthetic siRNAs of 21 nucleotides 
into mammalian cells RNAi can be potently initiated without activation of the interferon 
pathway (Elbashir et al., 2001a). This study sent out a clear signal that short synthetic 
siRNAs can circumvent the undesirable off-target effects that may be caused by long 
dsRNAs. Tuschl’s findings strongly boosted researchers’ confidence in RNAi by 
suggesting that siRNAs may be promising as genomic tools and therapeutic agents, which 
led to further observations that consolidated the “safe siRNA” theory. To examine the 
specificity of siRNAs, global gene expression has been investigated using microarray 
technology (Chi et al., 2003). The results show that siRNA-induced gene silencing of 
transient or stably expressed mRNA is highly gene-specific and does not produce 
secondary effects detectible by genome-wide expression profiling. Semizarov and 
colleagues also investigated the overall cellular effects of siRNAs on transcription levels 
(Semizarov et al., 2003). Their results indicate that siRNA is a highly specific tool for 
targeted gene knockdown, establishing siRNA-mediated gene silencing as a reliable 
approach for large-scale screening of gene function and drug target validation. 
 
However, the specificity of RNAi induced by siRNA became uncertain again when reports 
emerged that RNAi mediated by siRNA is accompanied with off-target gene regulation 
and the introduction of the undesirable interferon pathways (Jackson et al., 2003; Sledz et 
al., 2003; Bridge et al., 2003; Persengiev et al., 2004; Kariko et al., 2004; Scacheri et al., 
2004). These findings put a question mark behind the already well-documented high 
specificity of siRNAs and raised safety concerns about the use of siRNAs for therapeutic 
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purposes. Because of these controversial reports, it is worthwhile to spend some effort in 
exploring the specificity issue of siRNA in more detail. The specificity issue is examined 
in this study and discussed again in chapter 4 of this thesis.  
 
One piece of exciting news is that recently, the company Sirna Therapeutics, Inc., 
announced interim results from Sirna-027 which is developed for the treatment of the 
wet-form of age related macular degeneration and is the first-ever chemically optimized 
siRNA that is undergoing human clinical trials. Despite considerable hurdles to be 
overcome, it seems likely that RNAi will revolutionize the treatment of human disease in 
the same way that it has revolutionized basic research into gene function. 
 
1.4 miRNA 
miRNAs represent a class of small (~22nt), endogenous, non-protein-coding RNA 
molecules which negatively regulate gene expression in a post-transcriptional manner. 
Thousands of miRNA genes have been identified in diverse organisms, and many of these 
are evolutionarily conserved. miRNAs have been found to be involved in many biological 
processes, including developmental timing, cell proliferation, apoptosis, haematopoiesis, 
patterning of the nervous system and fat metabolism (Krichevsky et al., 2003; Brennecke  
et al., 2003; Xu et al., 2003a; Lin et al., 2003; Chen et al., 2004a). Evidence is mounting 




1.4.1 Biogenesis of miRNA and Mechanisms of miRNA-mediated 
Gene Regulation 
Most miRNA genes are initially transcribed by RNA Polymerase II (Pol II) in the nucleus 
into long primary transcripts known as pri-miRNA transcripts (Kim, 2005). These primary 
transcripts are generally quite long (>1 kb) and contain a 5’ 7-methyl guanosine cap and a 
3’ poly (A) tail which are characteristics of RNA polymerase II transcripts. The finding 
that Pol II is responsible for miRNA transcription partially explains why miRNAs diverge 
in their expression levels in different tissues or in different developmental stages, because 
Pol II promoters are highly regulated and can vary greatly in strength. 
 
The pri-miRNA transcript must undergo a series of processing steps in order to generate 
the ~22 nt mature functional miRNA (Cullen, 2004; Du and Zamore, 2005). In the first 
step, the pri-miRNA is processed by the enzyme Drosha and its co-factor, Pasha, to 
generate the ~70-nucleotide hairpin looped transcript called the pre-miRNA or precursor 
miRNA. Drosha belongs to the class of RNaseIII type endonucleases. It produces duplex 
RNA products containing a 5’ phosphate and a 3’ -OH, with usually a 2 nt overhang at the 
3’ end (Lee et al., 2003). Subsequently, the pre-miRNA is transported by Exportin 5 (Exp5) 
and its Ran-guanosine triphosphate (GTP) cofactor into the cytoplasm (Yi et al., 2003; 
Bohnsack et al., 2004; Lund et al., 2004) where another RNase III enzyme, Dicer, cleaves 
the pre-miRNA to generate a transient ~22-nucleotide miRNA intermediate, 
miRNA:miRNA* duplex (Billy et al., 2001; Grishok et al., 2001; Ketting et al., 2001; 
Hutvagner and Zamore, 2002; Provost et al., 2002; Zhang et al., 2002). Dicer was first 
discovered in the RNAi pathway as described in section 1.3.2. Since siRNA and miRNA 
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share a lot in common, it was predicted and later shown that pre-miRNA is also processed 
by Dicer. Most Dicer proteins possess an approximately 130-amino-acid-long PAZ 
domain, which prefers to bind to single-stranded 3’ ends of double-stranded RNAs. As a 
pre-miRNA generated by Drosha already contains a 2 nt 3’ overhang, Dicer would 
recognize the 3’ overhang via its PAZ domain and cleave the double-stranded region 
approximately 20 nt away, with a single catalytic center formed intramolecularly by its 
two RNaseIII domains. Recently it has been reported that different Dicer isotypes often 
take on different roles. For example, in D. melanogaster, Dicer-1 is required for miRNA 
cleavage, whereas Dicer-2 is needed for siRNA processing (Lee et al., 2004b). The same 
dual-Dicer system was also suggested for Arabidopsis (Finnegan et al., 2003). 
 
Dicer produces a miRNA duplex intermediate, which is not very stable. Usually only one 
of the two strands can be retained in cells. The other strand degrades rapidly. The exact 
mechanism by which the asymmetry is achieved is still unclear. Some evidence suggests it 
likely involves differential binding to, and then differential retention of, the two individual 
RNA strands by Dicer and its associating proteins (Tomari et al., 2004). One possible rule 
is that relative thermodynamic stability of the 5’ end of the duplex determines which 
strand is chosen: the strand with relatively unstable 5’ end is selected and loaded into 
RISC (Schwarz et al., 2003; Khvorova et al., 2003). This property might explain partly 
why so many miRNAs have a U residue at their 5’ ends.  
 
Once it is selected, mature miRNA is loaded into the protein complex RISC, which was 
also first identified in the RNAi pathway, and facilitates post-transciptional inhibition of 
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gene expression. Recent studies show that miRNAs and siRNAs recruit different 
complexes as their effector assemblies: miRNAs are incorporated into the 
miRNA-associated multiprotein RNA-induced silencing complex (miRISC) (Hammond et 
al., 2000; Zamore et al., 2000), whereas, siRNAs into the siRNA-associated multiprotein 
RNA-induced silencing complex (siRISC) (Okamura et al., 2004; Tang, 2005). Generally, 
siRISCs direct mRNA cleavage, while miRISCs direct mRNA cleavage in plants but 
repression of translation in animals. Current evidence suggests that the type of Argonaute 
protein, an essential RISC component, determines whether a RISC is cleaving or 
non-cleaving. 
 
According to current knowledge, miRNA-directed post-transcriptional gene-regulation 
follows at least two distinct mechanisms based on the characteristics of the target 
recognition by miRNAs, either by inhibition of the translation of the target RNA or by 
cleavage of target RNA transcript at a fixed position relative to the miRNA 
complementary sequence (Hutvagner and Zamore, 2002) (Figure 1.7). The widely 
accepted principle is that the degree of miRNA–mRNA complementarity determines the 
type of PTGS. Therefore, in animal cells, normally the complementarity between miRNA 
and target RNA is not high and the miRNA only mediates translational inhibition, usually 
after the translation initiation step. In contrast, in plant cells, complementarity between 
miRNA and the target mRNA is high, just like the exact match between siRNA and its 
target mRNA. In such cases, there is cleavage of target transcript. Interestingly, there are 
exceptions for both animal and plant systems. For instance, in mouse embryos miR-196 
mediates direct cleavage of HOXB8 (Yekta et al., 2004). On the other hand, in 
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Arabidopsis miRNA172 regulates the expression of APETALA2, a floral homeotic gene, 
primarily through translational inhibition (Chen, 2004). It seems that the regulations 
mediated by of miRNAs are more complicated than previously suspected. 
 
In animals, instead of cleaving the target mRNAs, most miRNAs suppress translation of 
target genes. The mechanism of miRNA-mediated repression and the destiny of targets 
that do not have high complementarity have recently been unveiled. The answer lies in the 
processing bodies (PBs, or P-bodies) and stress granules (SGs). It has been shown that 
mRNA when bound to a small RNA–programmed Argonaute protein Ago2 can be moved 
from the cytosol to sites of mRNA destruction called P-bodies (Liu et al., 2005; Zamore 
and Haley, 2005). Some mRNAs are degraded slowly in the P-body, so the miRNAs 
appear only to repress translation. One the other hand, some mRNAs when moved to P- 
body are prone to be rapidly degraded by decapping enzyme Dcp1/2, and then by the 
5’-to-3’ exonuclease Xrn1. These mRNAs thus appear to be degraded. In 2006, Leung and 
co-workers proposed another model on the destiny of miRNA targeted mRNAs (Leung et 
al., 2006). By doing quantitative analysis of Argonaute protein they found that when 
translation initiation is specially inhibited by small RNAs, mRNAs together with miRNAs 
and Argonaute proteins are moved to newly assembled structures known as SGs in 
addition to PBs. SGs are known to be sites where nontranslating, 40S ribosome-associated 
poly(A)+ mRNAs accumulate when cells experience stresses. They also postulated that 
Argonaute-associated microribonucleoprotein complexes (miRNPs) are constantly 





Figure 1.7 miRNA biogenesis and miRNA-mediated regulation. miRNA genes are generally 
transcribed by RNA Polymerase II (Pol II) in the nucleus to form large pri-miRNA transcripts, which 
are capped (7MGpppG) and polyadenylated (AAAAA). These pri-miRNA transcripts are processed by 
Drosha and its co-factor, Pasha, to release the ~70-nucleotide hairpin-structured pre-miRNA precursor. 
RAN–GTP and exportin 5 transport the pre-miRNA into the cytoplasm. Subsequently, Dicer processes 
the pre-miRNA to generate a transient ~22- nucleotide miRNA:miRNA* duplex. This duplex is then 
loaded into the miRISC (light blue).The mature miRNA then binds to complementary sites in the 
mRNA target to negatively regulate gene expression in one of two ways that depend on the degree of 
complementarity between the miRNA and its target. miRNAs that bind to mRNA targets with 
imperfect complementarity block protein translation of target gene expression (lower 
left).Complementary sites for miRNAs using this mechanism are generally found in the 3’ UTRs of the 
target mRNA genes. miRNAs that bind to their mRNA targets with perfect (or nearly perfect) 
complementarity induce target-mRNA cleavage (lower right). miRNAs using this mechanism bind to 
miRNA complementary sites that are generally found in the coding sequence or open reading frame 




1.4.2 History of miRNA Study 
As shown in Figure 1.8, Lin-4 was the first miRNA discovered in 1993 by the groups of 
Ambros and Ruvkun, when they were studying development in the nematode 
Caenorhabditis elegans (Lee et al., 1993 Wightman et al., 1993). It was determined that 
lin-4 encodes a 22-nucleotide non-coding RNA which negatively regulates the translation 
of lin-14 by directly binding to the complementary sites within the 3’-untranslated region 
(3’UTR) of lin-4 transcript. Although the finding was published in a high impact journal, 
due to lack of homology in other species, this form of gene regulation was generally 
considered a bizarre phenomenon limited to C. elegans (Lee et al., 2004a; Ruvkun et al., 
2004). The situation did not change much until the second founding miRNA (let-7) was 
discovered by Reinhart and Ruvkun in 2000 (Reinhart et al., 2000). It was found that let-7 
was broadly conserved across a wide variety of species, including humans, suggesting a 
general role of this type of regulatory small RNA molecules. The broad significance of 
miRNAs was fully appreciated when hundreds of similar small RNAs were identified in C. 
elegans, Drosophila, and mammals by molecular cloning and bioinformatic analyses in 
2001 (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001). Since then, 
more than 4000 miRNAs have been identified in vertebrates, flies, worms and plants, and 
even in viruses. To date, 474 human miRNAs have been identified and deposited in 
Sanger miRBase (http://microrna.sanger.ac.uk/), and the estimated miRNA genes may be 
as many as 1000 (Berezikov et al., 2005; Griffiths-Jones et al., 2006).                
 
miRNAs play important roles in cell proliferation, cell death, and tumorgenesis and the 
miRNA expression pattern is regulated during development and is generally tissue specific 
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(Liu et al., 2004a). However, relatively little is known about their possible functions in 
mammals. Recently, researchers have linked miRNAs to many types of human diseases, 
including diabetes (Poy et al., 2004), Tourette’s- syndrome (Abelson et al., 2005) and 
cancers (Calin et al., 2002, 2005; Takamizawa et al., 2004; Iorio et al., 2005; Pallante et 
al., 2006; Murakami et al., 2006; Kutay et al., 2006). 
 
Figure 1.8 Timeline of miRNA study 
 
 
1.4.3 Identification of miRNA Genes 
miRNAs are small non-protein-coding RNAs. They cannot be found by conventional 
cDNA cloning, ORF searching or expressed sequence tag (EST) annotation. Although the 
two founding members lin-4 and let-7 were identified by standard positional cloning of 
genetic loci, on a large scale most miRNA genes are discovered either through cDNA 
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cloning of sequences from size-fractionated RNA samples or through computational 
approaches. 
 
Initially most known miRNAs were identified by direct biochemical cDNA cloning and 
sequencing. In 2001, three leading labs cloned hundreds of miRNAs from C.elegans, 
Drosophila and human cell lines (Lagos-Quintanal et al., 2001; Lau et al., 2001; Lee and 
Ambros, 2001). They published their findings in the same issue of Science, and thus 
triggered the explosion of miRNA study. This cDNA cloning strategy was first developed 
in Tuschl’s lab and initially used to isolate siRNAs after processing of long dsRNAs in 
Drosophila melanogaster embryo lysate. Briefly, the small RNA fraction is isolated by gel 
purification and 5’and 3’ adapter molecules are then ligated to the ends of the 
size-fractionated RNA population. This small RNA population is then amplified by 
reverse transcription followed by polymerase chain reaction (PCR). The PCR products are 
then concatamerized, cloned, and sequenced (Elbashir et al., 2001b). Currently, this 
cDNA cloning approach is still used for identification of miRNA genes. Most recently, it 
was reported that by constructing small-RNA cDNA libraries, 139 known miRNAs and 66 
new miRNAs were found for the zebrafish genome (Kloosterman et al., 2006). 
 
A large number of miRNAs were identified by miRNA cloning and sequencing, but this 
method alone cannot detect miRNAs with poor stability, very low expression or 
tissue-specific expression. Based on the understanding of the structure and processing 
procedures of existing miRNAs, computational biology tools have been developed to 
predict new miRNA sequences in various species, including C. elegans (Lim et al., 2003b; 
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Grad et al., 2003), D. melanogaster (Lai et al., 2003), human (Berezikov et al., 2005; Lim 
et al., 2003a; Legendre et al., 2005), Arabidopsis and other plants (Jones-Rhoades et al., 
2004; Billoud et al., 2005), and virus (Pfeffer et al., 2005; Couturier et al., 2005). Methods 
to find miRNA genes computationally usually utilize the following properties of known 
miRNAs: i) The pre-miRNAs can form stable extended folded structures (hairpin 
structures), with continuous helical pairing and a few internal bulges. ii) miRNAs genes 
are usually highly conserved among related species. iii) The evolutionary divergence 
between orthologous miRNAs shows a characteristic pattern: the terminal loops usually 
have more mutations than the arms of the stem-loops, and the miRNA-coding arms are 
more conserved than the non-coding ones (Kong and Han, 2005). Two programs that are 
commonly used for miRNA gene prediction are MiRseeker and MiRscan (Lai et al., 
2003). 
 
Although cDNA cloning and bioinformatics approaches are being used routinely, forward 
genetics remains one of the most fruitful approaches for identifying miRNA genes with 
critical roles in the regulation of development and physiology. Besides the canonical 
miRNA genes, lin-4 and let-7 of C. elegans, some miRNAs could only be identified by 
forward genetics. For example, miRNA lsy-6, the first microRNA discovered to have a 
role in nervous system development in vivo, was not detected either by cDNA cloning, or 
by computational predictions of worm miRNAs. This could be presumably attributed to its 
low abundance in total RNA and aberrant folding pattern. The lsy-6 miRNA was only 
found through forward genetics, namely genetic screens for mutations that caused a 
disruption in the asymmetrical expression of the gcy chemoreceptor genes (Johnston and 
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Hobert, 2003). Thus, the traditional forward genetic approach is still a useful tool. An 
alternative to forward genetics for identifying rare miRNAs with developmental roles is to 
start with computationally predicted miRNA genes and test for function by reverse 
genetics. The identification of miR-273 in the worm genome is a good example of this 
reverse genetics approach (Chang et al., 2004). 
 
1.4.4 Prediction of miRNA targets 
In plants, computational identification of miRNA targets is relatively easy. Because most 
miRNA:mRNA complementarity reaches almost 100%, the searching of putative targets 
can be performed by simple sequence homology search such as NCBI-BLAST. In contrast, 
in animals, most miRNAs are thought to recognize their mRNA targets by partial 
complementarity, which makes the prediction much more complicated. Commonly used 
programs for target prediction include miRanda (John-Rhoades et al., 2004), TargetScan 
(Lewis et al., 2003) and PicTar –VERT (Krek et al., 2005). The links can be found in the 
Sanger website: http://microrna.sanger.ac.uk. The common rules governing these 
programs are complementarity between miRNA and 3’ UTRs of its putative targets, low 
energy of RNA: RNA interaction, evolutionary conservation of both miRNA and its 
targets and cooperativity of binding of the same mRNA by different miRNAs. 
 
miRNA target prediction is a fast developing field and the accuracy of prediction will 
increase over time. Prediction alone, however, is insufficient. To derive a reliable picture 
of the likely miRNA pathways, it will be necessary to examine the interaction of miRNAs 
to their putative targets by reporter assay and furthermore to correlate the expression 
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profiles of miRNAs with those of their potential target genes. In addition to screening the 
3’UTR of transcripts for miRNA targets, Ambros also raised the issue of checking the 
5’UTR (Ambros, 2004).  
 
1.4.5 miRNAs and Human Cancers 
Because miRNAs potentially have a broad influence over diverse genetic pathways, the 
amplification, deletion or deregulation of these small RNAs is likely to contribute to 
human diseases, including human cancers. At present, there are several reports proposing 
that miRNAs represent a class of genes that are aberrantly expressed, deleted, amplified or 
mutated in human cancers. Deregulated expression of certain miRNAs has been linked to 
several types of human cancers. These miRNAs might function as tumor suppressors or 
oncogenes. 
 
miR-15a and miR-16-1 were first demonstrated to be implicated in human cancer by 
Croce and colleagues in 2002, just one year after miRNAs were widely recognized as 
regulatory molecules (Calin et al., 2002). B cell chronic lymphocytic leukemia (CLL) is 
the most common adult leukemia in the western world. CLL is highly associated with loss 
of chromosomal region 13q14 (Dohner et al., 2000). Although this abnormality had been 
recognized for many years, no identifiable gene within this region was clearly linked to 
CLL. Within chromosomal 13q14 region, Croce’s group identified a 30-kb critical region 
of deletion by exploiting somatic cell hybrids of B-CLL patients. They also recognized 
that two small noncoding RNAs, miR-15a and miR-16-1 were localized in this 30kb 
minimally deleted region. Subsequently, they demonstrated that miR-15a and miR-16-1 
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were deleted or downregulated in 68% of CLL cases. These data clearly demonstrate that 
downregulation of miR-15a and miR-16-1 expression in CLL correlates with allelic loss at 
13q14, and point to a role for miR-15a and miR-16-1 in CLL pathogenesis. They initially 
proposed that the Arginyl-tRNA Synthetase Gene (RARS) might be a putative target of 
miR-16-1 (Calin et al., 2002), although later on they identified BCL2 as the real target of 
miR-15a and miR-16-1 (Cimmino et al., 2005). The expression of miR-15a and miR-16-1 
is inversely correlated to the expression of B-cell leukemia/lymphoma protein 2 (BCL2) 
and miR-15a and miR-16-1 may induce apoptosis by targeting BCL2 (Cimmino et al., 
2005). Besides miRNA-15a and miR-16-1, other miRNAs were also found to be 
downregulated. These include let-7 family in lung cancer (Takamizawa et al., 2004; 
Yanaihara et al., 2006), miR-125b, miR-145, miR-21 and miR-155 in breast cancer (Iorio 
et al., 2005) as well as miR-143 and miR-145 in colorectal neoplasia (Michael et al., 2003). 
Given that loss-of-function of these miRNAs contributes to tumorgenesis of certain types 
of human cancers, these miRNAs are likely to be tumor suppressor genes. 
 
In contrast to those downregulated miRNAs that may function as tumor suppressors, some 
miRNAs were found to be upregulated in certain types of human cancers. They are likely 
to function as oncogenes. Among these onco-miRs, the miR-17-92 cluster is the best 
known oncogene cluster. This polycistronic miRNA cluster resides in intron 3 of the 
C13orf25 gene (chromosome 13 open reading frame 25). The C13orf25 gene is located 
within chromosomal 13q31–32 region which is known to undergo amplification in large 
B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and primary cutaneous 
B-cell lymphoma (Ota et al., 2004). As expected, He and coworkers identified the 
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mir-17-92 polycistron as a potential human oncogene in human B-cell lymphomas (He et 
al., 2005b). They found that the levels of the primary or mature miRNAs derived from the 
mir-17-92 locus are often substantially increased in these cancers by comparing B-cell 
lymphoma samples and cell lines to normal tissues. They also extended their work to a 
mouse B-cell lymphoma model, showing that enforced expression of the mir-17-92 cluster 
accelerated tumor development. At about the same time, Hayashita and co-workers 
reported for the first time that the miR-17-92 cluster, which comprises seven miRNAs, 
was also markedly overexpressed in lung cancers, especially with small-cell lung cancer 
histology (Hayashita et al., 2005). They observed the presence of increased gene copy 
numbers of the miRNA cluster in a fraction of lung cancer cell lines with overexpression 
by southern blotting analysis, which may partly explain their overexpression. In addition 
they confirmed that it was the miR-17-92 cluster NOT the putative ORF of C13orf25 gene 
that could enhance lung cancer cell growth. These data, coupled with the widespread 
overexpression of this miRNA cluster in cancer, strongly implicate the miR-17-92 cluster 
as an oncogene. Besides miR-17-92 cluster, several other miRNAs have been shown to be 
upregulated in cancers and to contribute to tumorgenesis, such as miR-21 in glioblastoma 
and breast cancer (Chan et al., 2005; Si et al., 2006), miR-221, miR-222 and miR-146 in 
thyroid papillary carcinomas (Pallante et al., 2006) and miR-143 and miR-145 in 
colorectal neoplasia (Michael et al., 2003). 
 
Besides trying to identify deregulated miRNAs in human cancers, a lot of effort has been 
put into uncovering the mechanisms that contribute to miRNA deregulation in cancer. One 
possible reason of miRNA deregulation in human cancers is that the alteration of miRNA 
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gene copy numbers in genomes. By using high-resolution array-based comparative 
genomic hybridization, Zhang and colleagues showed that a high proportion of genomic 
loci containing miRNA genes exhibited DNA copy number alterations in ovarian cancer 
(37.1%), breast cancer (72.8%), and melanoma (85.9%) (Zhang et al., 2006). The other 
possible reason is the deregulation of genes that regulate the transcription of miRNA genes. 
For example, O'Donnell and colleagues demonstrated that transcription of the miR-17-92 
cluster is directly activated by c-myc which is generally upregulated in human cancer 
(O’Donnell et al., 2005). Despite these important findings, we have to admit that the exact 
mechanisms that govern miRNA deregulation remain poorly understood. 
 
1.4.6 miRNAs deregulated in HCC 
HCC remains a global health problem. The relationship between miRNAs and 
development of HCC is under investigation. Most recently, it has been reported that 
certain miRNAs (miR-18, miR-224, miR-199, miR-195, miR-200, miR-125) are 
significantly deregulated in human hepatocellular carcinoma (Murakami et al., 2006), and 
miR-122, a liver-specific miRNA, is downregulated in rodent and human HCCs (Kutay et 
al., 2006). In both studies the microRNA profilings were done by microarray analysis. 
These findings indicate that miRNAs are deregulated in HCC and these deregulated 
miRNAs might be involved in HCC development. However, little has been done to 
identify the possible functional roles of these deregulated miRNAs. Thus it is worthwhile 




















The main objective of this study is to examine the therapeutic and diagnostic potential of 
small RNA molecules in hepatic diseases. The focus of the study was on hepatitis B which 
is prevalent in Asia and on HCC of which chronic hepatitis B infection is a risk factor.  
 
This study can be divided into two parts. The first part of this study examines the use of 
the RNAi approach for inhibition of HBV gene expression. The aims of this part of study 
are: 
i)    To investigate the efficiency of synthetic siRNAs as effector molecules in inhibiting 
HBV S antigen expression and the effect on virion production. 
ii)    To investigate the specificity of siRNAs and to determine if off-target effects are 
triggered by siRNA treatments. 
 
The second part of this study involves the investigation of the role of miRNAs in human 
HCC. The aims here are: 
i) To identify miRNAs that are deregulated in HCC. This will be carried out by 
comparing the expressions of miRNAs in pair matched tumor (HCC)/ non-tmor 
samples. 
ii) To identify miRNAs that are differently expressed in cirrhotic livers. This will be 
achieved by comparing the expressions of miRNAs in cirrhotic and non-cirrhotic 
liver tissues. 
iii) To examine the expression of miRNAs in human hepatoma cell lines and in 
primary hepatocytes.  
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iv) To examine the function of miRNAs that are differentially expressed in HCC. 
The objectives and significances are further discussed in the next part of this chapter. 
 
2.1 The RNAi Approach for Inhibition of Hepatitis B Viral 
Gene Expression 
When this study was initiated at the start of 2003, the RNAi approach showed great 
potential in down-regulating gene expression and this approach had not been used for 
inhibition of hepatitis B viral gene expression. The first part of this study was thus aimed 
to examine the use of this approach to inhibit hepatitis B viral gene expression and to 
determine if this can eventually lead to reduced viral replication. In order to achieve this, 
siRNAs that target HBsAg transcripts were designed and chemically synthesized and the 
effects of siRNAs on the HBsAg producing cell line, PLC/PRF/5 and the HBV-producing 
cell line 2.2.15 were studied. The flow of the part of the study is summarized in Figure 2.1. 
A key aspect of this part of the study was to examine if the RNAi approach using siRNAs 
was specific and if any undesirable or off-target effects accompanied the treatments with 
siRNAs. Knowledge gained from this study would provide us with a better understanding 
of the effects of siRNAs on inhibition of HBV gene expression and viral replication, and 







































Figure 2.1 Flow chart of the study on inhibition of HBV gene expression by siRNAs. 
RT: reverse transcription
Design and synthesis of siRNAs oligos against HBV 
Transfection of PLC/PRF/5 and 2.2.15 cells with siRNAs  
 
Selection of transfection reagents and examination of transfection 
efficiency 




Collection of media at 24-hour 
intervals 








RNAi by cDNA 
microarray 
Quantification of 
HBV DNA by 





(only for 2.2.15 
cells)  
Quantification of 












2.2 miRNAs and HCC 
As mentioned in the earlier sections, there are many patients with HCC and current 
diagnosis and treatment for HCC are far from satisfactory. In addition, the mechanism of 
HCC development is not well understood, although the risk factors are well defined. Given 
the relatedness in the mechanism of the siRNA and miRNA pathways as well as recent 
studies showing changes in miRNA expression in cancers (Calin et al., 2002, 2005; 
Takamizawa et al., 2004; Iorio et al., 2005; Pallante et al., 2006; Murakami et al., 2006; 
Kutay et al., 2006), the second part of this study was aimed at evaluating the role of 
miRNAs in human HCC. To achieve this, miRNA expression profiling using reverse 
transcription-PCR was carried out in paired HCC tumor and non-tumor samples. miRNAs 
that were differentially expressed were then identified and for a subset of these, the effects 
of deregulated expression on cell growth and anchorage-independent growth were 
examined. The flow of this part of the study is summarized in Figure 2.2. Data obtained 
would aid in determining if certain miRNAs could serve as putative therapeutic or 






































Figure 2.2 Flow chart of the study of miRNAs and HCC. 
RT: reverse transcription 
 
Selection of Clinical Samples (tumor and non-tumor) and extraction of 
total RNA 
Expression profiling of 157 miRNAs by Taqman RT-real-time PCR in 
10 paired clinical samples and identification of miRNAs that are 
deregulated in HCC 
Effects of miRNAs on 
anchorage-independent growth by soft 
agar assay (only for miR-106b, miR-93 
and miR-25)
Further examination of the a subset of the upregulated miRNAs in 56 
pairs of clinical samples (tumor vs. non-tumor), in HCC cell lines and 
primary hepatocytes (including all members of the miR-106b-25 
cluster) 
Effects of miRNAs on cell growth 
and proliferation by MTS/PES 
assay 
 
Examination of the 
expressions of mature 
miRNAs by RT-real-time 
PCR  
Examination of the 
expressions of pri- and pre- 
miRNAs by RT-real-time 
PCR (only for miR-106b, 
miR-93 and miR-25) 
Examination 
of the 











Materials and Methods 
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3.1 Materials 
3.1.1 Cell Cultures 
3.1.1.1 Human tumor cell lines  
Human tumor cell lines HepG2, PLC/PRF/5 and HeLa were obtained from ATCC. 2.2.15 
was kindly provided by Dr. A Batholomeusz and Prof. S Locarnini of the Victorian 
Infectious Disease Reference Laboratory. Huh7 was obtained from Riken Cell Bank. 
 
3.1.1.2 Primary hepatocytes  
Human hepatocytes were purchased from BD Biosciences (San Jose CA, U.S.A). After 
Percoll purification, the viability of the cells was >90% as determined by Trypan blue 
exclusion. 
 
3.1.2 Surgical Tissue Specimens (tumor vs. non-tumor) 
Surgical samples were obtained from National University Hospital. NUS-IRB and 
NHG-DSRB ethics approval was obtained prior to collection and experimentation. 
 
3.1.3 Preparation of Media for Cell Culture  
The media used for culturing human cells lines are shown in Table 3.1 
Table 3.1 Media used in this study.    
Medium Ingredients Preparation 
DMEM(10% 
FBS) 
10% fetal bovine serum, 100 U/ml penicillin, 100 
µg/ml streptomycin, 2 mM glutamine, 1 mM sodium 
pyruvate and 0.1 mM MEM nonessential amino acids 
0.22 μm filtered 
DMEM(25% 
FBS) 
25% fetal bovine serum, 100 U/ml penicillin, 100 
µg/ml streptomycin, 2 mM glutamine, 1 mM sodium 
pyruvate and 0.1 mM MEM nonessential amino acids 
0.22 μm filtered 
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3.1.4 Oligos, Reagents and Special Chemicals 
All siRNAs used in this study were synthesized by Qiagen-Xeragon (Germantown, MD, 
U.S.A). QIAamp DNA Blood Mini kit, RNeasy Mini kit, LabelStar Array kit and HiLight 
Dual Color Kit were purchased from Qiagen (Hilden, Germany). Dulbeccco’s modified 
Eagle medium (DMEM) and G418 were purchased from Sigma (St. Louis, MO, U.S.A). 
All other cell culture reagents including Opti-MEM
 
I Reduced Serum Medium were 
obtained from Gibco (Grandisland, NY, U.S.A). TRIzol and Lipofectamine2000 were 
obtained from Invitrogen (Carlsbad, CA, U.S.A), while TransIT TKO Transfection 
Reagent was from Mirus (Madison, WI, U.S.A). 3,(4,5-Dimethylthiazol-2-yl)-5- 
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium/phenazine ethosulfate 
(MTS/PES) reagent (supplied as Cell Titer 96 Aqueous One Solution Cell Proliferation 
Assay) , Access reverse transcription (RT)-PCR system and AMV reverse transcriptase 
were purchased from Promega (Madison, WI, U.S.A). Vectashield mounting medium was 
obtained from Vector Laboratories, Inc. (Burlingame, CA, U.S.A). The Murex HBsAg 
Version 3 Kit was obtained from Murex Biotech Limited (Dartford, UK). 
Affinity-purified HBsAg was from Chemicon International (Temecula, CA, U.S.A). 
TaqMan Universal PCR Master Mix was obtained from Applied Biosystems (Foster City, 
CA, U.S.A). Biotin-16-dUTP and fluorescein-12-dUTP were purchased from Roche 
(Mannheim, Germany). Primers and probes for real-time PCR were synthesized by 
Proligo (Singapore). PeliCheck HBV-DNA-99 reference panel was purchased from VQC 
International (Alkmaar, The Netherlands). 
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TaqMan® MicroRNA Assays Human Panel - Early Access Kit, TaqMan® MicroRNA 
Assays for individual miRNA, TaqMan® MicroRNA Reverse Transcription Kit, 
TaqMan® 2X Universal PCR Master Mix, No AmpErase® UNG and SYBR® Green 
PCR Master Mix were purchased from Applied Biosystems (Foster City, CA, U.S.A). 5S 
rRNA mirVanaTM qRT PCR Primer Set was obtained from Ambion (Austin TX, U.S.A). 
RNase-free DNase I was purchased from Invitrogen (Carlsbad, CA, U.S.A). Anti-miR™ 
miRNA Inhibitors were obtained from Ambion (Austin TX, U.S.A). 
 
3.2 Methods  
3.2.1 Inhibition of HBV Gene Expression by siRNAs 
3.2.1.1 Cell culture  
The HepG2, PLC/PRF/5, 2.2.15 human liver cell lines and the HeLa cell lines were 
maintained in DMEM, supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 
100 µg/ml streptomycin, 2 mM glutamine, 1 mM sodium pyruvate and 0.1 mM MEM 
non-essential amino acids at 37oC under 5% CO2. For the 2.2.15 cell line, 150 µg/ml G418 
was added to the medium. PLC/PRF/5 cells produce HBsAg, but no intact virus, while 
2.2.15 cells produce both HBsAg and intact Dane particle.  
 
3.2.1.2 Synthesis of siRNA 
Three 21nt-siRNA duplexes with 2-nt dTdT 3’ overhangs were synthesized by 
Qiagen-Xeragon (Figure 3.1). Two of the three siRNAs (S1 and S2) were designed to 
target regions on the viral genome that are conserved in all the different HBV serotypes. 
S1 and S2 target regions within HBV S ORF and within HBV P ORF, while the last 
  60
duplex Scr was a control scrambled sequence with the same base composition as S2 
(Figure 3.1). Fluorescein-labeled S2 siRNA was also synthesized by Qiagen-Xeragon. 
The label was on the 3’ end of the sense strand. 











 5'-CUCAACCUACCAACUCCACdTdT-3'   
3'-dTdTGAGUUGGAUGGUUGAGGUG-5' 
 
Figure 3.1 Sequences of siRNAs used in experiments: S1 and S2 target sites within the HBV S ORF. 
Scr serves as a scrambled control and has the same base composition as S2. 
 
3.2.1.3 Transfection with siRNAs 
PLC/PRF/5 cells (5x104 cells) were seeded into each well of a 24-well plate and allowed 
to recover for 24 hours. Before transfection, the appropriate amount of siRNA was diluted 
in 150 µl of Opti-MEM
 
I Reduced Serum Medium in one tube. In another tube 3 µl of 
Lipofectamine2000 was also diluted in 150 µl of Opti-MEM
 
I Reduced Serum Medium. 
Both of these two solutions were mixed gently by pipetting up and down. After incubation 
at 23 for 5 minutes, these two solutions were mixed gently, and incubated for 20 
minutes at 23 to allow the siRNA:Lipofectamine2000 complexes to form. Cells were 
then rinsed with Opti-MEM
 
I Reduced Serum Medium once. 300 µl of 
siRNA:Lipofectamine2000 complexes was then added to each well and mixed gently by 
rocking the plate back and forth.  
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2.2.15 cells (2 x 105 cells) were seeded into each well of a 24-well plate and allowed to 
recover for 24 hours. 4 µl of TransIT TKO Transfection Reagent (Mirus) was diluted in 50 
µl of Opti-MEM
 
I Reduced Serum Medium and mixed thoroughly by vortexing. After 
incubation at 20-23 for 10 minutes, the appropriate amount of siRNA was added and 
mixed gently by pipetting up and down. The solution was incubated for 20 minutes at 23 
to allow the siRNA:TransIT TKO Transfection Reagent complexes to form. Cells were 
washed with Opti-MEM
 
I Reduced Serum Medium once and overlaid with 250 µl 
Opti-MEM
 
I Reduced Serum Medium. 50 µl of siRNA:TransIT TKO Transfection 
Reagent complexes was added to each well and mixed gently by rocking the plate back 
and forth.  
 
After introducing the siRNA:transfection reagent complexes, the cells were incubated at 
37 °C in a CO2 incubator for 4 hours for transfection to take place. Following the 
transfection process, the transfection reagent was removed and replaced with the complete 
DMEM medium for the PLC/ PRF/5 cells or DMEM medium containing 150 µg/ml G418 
for the 2.2.15 cells. 
 
Mock transfections were carried out for both cell lines as described above but with the 
omission of the siRNA. For treatments of durations longer than 24 hours, the medium was 
collected every 24 hours and fresh medium was added to each well. At the end of the 
treatment period, the medium was collected for detection of HBsAg or viral DNA and the 
cells were used for isolation of total RNA. 
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3.2.1.4 Estimation of transfection efficiency 
To estimate transfection efficiency, cells were grown on glass coverslips and transfected 
with fluorescein-labeled siRNA as described in section 3.2.1.3. 24 hours after transfection, 
cells were washed twice with ice-cold phosphate-buffered saline (PBS), and fixed with 
chilled methanol (-20°C) for 10 minutes. The cells were then washed again with PBS and 
a drop of Vectashield mounting media containing propidium iodide was then added. The 
cells were observed using the Leica DMLB fluorescent microscope. The percentage of 
fluorescein-labeled cells in five randomly selected fields from two independent 
experiments was determined. 
 
3.2.1.5 Cell viability assay 
PLC/PRF/5 cells (5.0 x 103 or 3 x 104 for 2.2.15 cells) were seeded in each well of a 
96-well plate and allowed to recover for 24 hours. Transfection and treatment of cells were 
performed as described in section 3.2.1.3. At 2, 5 and 7 days post-transfection, MTS/PES 
reagent (20 µl) was added to each well. After incubation at 37 °C for 1 hour, the 
absorbance at 490 nm was measured. All assays were performed in triplicate and as two 
independent experiments. 
 
3.2.1.6 Quantitative assay of HBsAg 
The amount of HBsAg secreted into the culture medium was determined using the Murex 
HBsAg Version 3 Kit with the protocol described in the manufacturer’s manual. Briefly, 
25 µl of Sample Diluent was added to each well. Sample was diluted appropriately. 75 µl 
of diluted sample were added to the wells. The plate was covered with a lid and incubated 
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for 60 minutes at 37 °C. 50 µl of Conjugate was added to the wells. The plate was shaken 
for 10 seconds by gently tapping the sides, covered with a lid and then incubated for 
another 30 minutes at 37 °C. At then end of the incubation, the plated was washed 5 times 
with Wash Fluid as described under Wash Procedure in the manufacturer’s protocol. 
Immediately after washing, 100 µl of Substrate Solution was added to each well. The plate 
was then covered with a lid and incubated at least for 30 minutes at 37 °C for the color to 
develop. In the last step, 50 µl of Stop Solution was added to each well and the absorbance 
of each well was then read at 450 nm using 650 nm as the reference wavelength. The 
standard curve was generated using affinity-purified HBsAg. Results were expressed as 
percent of mock transfection which was considered as 100%. 
 
3.2.1.7 HBV viral DNA quantification 
Extraction of HBV DNA from the medium of 2.2.15 cell cultures was performed using the 
QIAamp DNA Blood Mini Kit. HBV DNA was extracted from 200 µl of medium 
following the protocol described by the manufacturer. Briefly, 20 μl of QIAGEN Protease 
was pipetted into the bottom of a 1.5 ml microcentrifuge tube. 200 μl of culture medium 
and 200 μl of buffer AL were then added to the microcentrifuge tube.  The solution was 
mixed by pulse-vortexing for 15 seconds. The tube was incubated at 56 °C for 10 min to 
allow QIAGEN Protease to function. After brief centrifugation, 200 μl of ethanol 
(96–100%) was then added to the sample, and mixed again by pulse-vortexing for 15 
seconds. After a short centrifugation to collect drops from inside of the lid, the mixture 
was carefully applied from to the QIAamp Spin Column (in a 2 ml collection tube) 
without wetting the rim. After centrifugation at 6000 x g (8000 rpm) for 1 minute, the 
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QIAamp Spin Column was placed in a clean 2 ml collection tube. The QIAamp Spin 
Column was washed with 500 μl Buffer AW1 and 500 μl Buffer AW2. The Spin Column 
was then placed in a new 2 ml microcentrifuge tube and any chance of possible Buffer 
AW2 carryover was eliminated by centrifuging at 20,000 x g (14,000 rpm) for 1 minute. 
The DNA was then eluted with 50 µl of nuclease-free water. 5 µl of HBV DNA was mixed 
with the HBV genome specific primers, the probe and the TaqMan Universal PCR Master 
Mix (Table 3.2; Loeb et al., 2000). The reaction mixture was first incubated at 50 °C for 2 
minutes and 95 °C for 10 minutes. Following this, the PCR reaction was performed at 95 
°C for 15 seconds and 58 °C for 1 minute for 45 cycles. The levels of PCR products were 
examined with an ABI PRISM 7000 sequencing detection system and analyzed with ABI 
PRISM 7000SDS software (Applied Biosystems, Foster City, CA, U.S.A). Cycle times 
were determined at a reading of 0.2 fluorescence unit. To determine the absolute quantity 
of viral DNA numbers, the PeliCheck HBV-DNA-99 reference panel with known copy 
numbers of HBV DNA was used to generate the standard curve. Sequences of the primers 
and probes are described in Table 3.2. 
 
Table 3.2 Sequences of PCR primers and probes for real-time PCR quantification of HBV DNA. 
Target sequence  Primer Sequence (5’-3’) 
HBV DNA  HBV Forward   CCGTCTGTGCCTTCTCATCTG 
(Loeb et al., 2000) HBV Reverse AGTCCAAGAGT(C/T)CTCTTATG(C/T)AAGACCTT 





3.2.1.8 RNA extraction using RNeasy mini kit and quantification 
Following treatment with siRNA, total RNA was extracted from the cells using the 
RNeasy mini kit. The extraction was carried out according to the manufacturer’s 
instructions.  In short, cells were trypsinized and washed once with PBS. Cells were then 
disrupted by the addition of the appropriate amount of buffer RLT. Cells were mixed 
thoroughly with RLT by vortexing. The resulting samples were homogenized by passing 
through a 20-gauge needle (0.9 mm diameter) fitted to an RNase-free syringe at least 5 
times. One volume of 70% ethanol was added to the homogenized lysate and mixed 
thoroughly by pipetting up and down. The sample (up to 700 µl) was then applied to an 
RNeasy mini column placed in a 2 ml collection tube and centrifuged for 15 seconds at 
≥8000 x g (≥10,000 rpm). The RNeasy column was washed with 700 µl Buffer RW1 and 
500 µl Buffer RPE subsequently. Another 500 µl Buffer RPE was applied to wash the 
RNeasy column. To eliminate any chance of Buffer RPE carryover, the RNeasy column 
was placed in a new 2 ml microcentrifuge tube and centrifuged in a microcentrifuge at full 
speed for 1 minute. In the final step, RNA was eluted with 100 µl RNase-free water. The 
concentration of RNA was quantified by the absorbance at 260 nm. 
 
3.2.1.9 RNA extraction using TRIzol and quantification 
Tissues or cells grown in monolayer were homogenized using a power homogenizer or by 
applying TRIzol reagent directly in a culture dish or flask. Total RNA was extracted 
following manufacturer’s instruction. In brief, homogenized sample was incubated for 5 
minutes at 23 to permit the complete dissociation of nucleoprotein complex. 0.2 ml of 
chloroform per ml of TRIzol reagent was added to the sample. The tube was shaken 
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vigorously by hand for 15 seconds and incubated for 3 minutes at 23. The tube was then 
centrifuged at 10,000 x g for 20 minutes at 4 °C. Following centrifugation, the mixture 
was separated into a lower red, phenol-chloroform phase, an interphase, and a colorless 
upper aqueous phase. The aqueous phase was then transferred to a fresh tube. Total RNA 
was precipitated by mixing with 0.5 ml of isopropyl alcohol per ml of TRIzol reagent. The 
sample was incubated for 10 minutes at 23 and then centrifuged at 10,000 x g for 15 
minutes at 4 °C. The supernatant was then removed and RNA pellet was washed once with 
75% ethanol, adding 1 ml of 75% ethanol per ml TRIzol reagent. The sample was mixed 
by vortexing and centrifuged at 7,500 g for 5 minutes at 4 °C. In the last step, the RNA 
pellet was briefly dried and dissolved in the appropriate amount of RNase-free water. The 
concentration of RNA was quantified by the absorbance at 260 nm. 
 
3.2.1.10 Denaturing agarose gel electrophoresis of RNA 
The overall quality of an RNA preparation was assessed by electrophoresis on a 
denaturing agarose gel. 1.2 g agarose was added in 87 ml DEPC-H2O and then boiled. 
After the solution had cooled down to 60°C, 10 ml 10X MOPS running buffer and 3 ml 
37% formaldehyde (12.3 M) were added into the gel solution. The gel was poured using a 
comb that will form wells large enough to accommodate at least 25 µl. The gel was 
assembled in the tank, and enough 1X MOPS running buffer was then added to cover the 
gel by a few millimeters. Then the comb was removed. The gel was pre-run for 10 minutes 
at 80V. Ethidium bromide was added to the 0.5 X RNA loading dye at a final 
concentration of 10 µg/ml. 0.5-1 µg RNA sample was mixed with 2X volumes of RNA 
Loading dye. RNA sample was denatured at 70°C for 5 minutes and then loaded into the 
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wells of the gel. After incubation for 5 minutes, electrophoresis was carried out at 5-6 
V/cm until the bromophenol blue (the faster-migrating dye) has migrated at least 2-3 cm 
into the gel, or as far as 2/3 the length of the gel. The bands were visualized on a UV 
transilluminator and the image was captured.  
 
3.2.1.11 Reverse Transcription and PCR 
Four sets of primers were used for reverse transcription followed by PCR. The HBpc 
primers were 5’ACTGTTCAAGCCTCCAAGCT3’ (forward) and 
5’AGGAAAGAAGTCAGAAGGCAAA3’ (reverse). This pair of primers was designed 
to reverse transcribe and amplify the 3.5kb precore and pregenomic transcripts. The HBps 
primers were 5’CAAGGTAGGAGCTGGAGCATTC3’ (forward) and 
5’GCAGGAGGCGGATTTGC3’ (reverse) and were designed to reverse transcribe and 
amplify the 3.5kb as well as the 2.4kb transcripts. The Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH, Meyer et al., 2000) and HBs primers are shown in Table 3.3. 
The GAPDH primers are specific for the human GAPDH ORF while the HBs primers are 
specific for the HBV S ORF and will amplify the 3.5kb, the 2.4kb and the 2.1kb 
transcripts.  
 
The isolated RNA was first subjected to reverse transcription-PCR using the one-step 
Access RT-PCR system (Promega, U.S.A). A typical 25 µl reverse transcription-PCR 
reaction contained 0.5 µg of RNA, 0.1 mM dNTPs, 0.5 µM of the forward and 
corresponding reverse primers, 0.5 mM of MgSO4, 0.05 u/µl of Avian Myeloblastosis 
Virus (AMV) reverse transcriptase and 0.05 u/µl of Tfl DNA polymerase. The reverse 
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transcription was carried out at 48 oC for 45 minutes followed by denaturation at 94 oC for 
2 minutes. Following reverse transcription, the cDNA was subjected directly to PCR. 
Each cycle consisted of denaturation at 94 oC for 30 seconds, annealing at 55 oC for 1 
minute and extension at 68 oC for 1 minute. The product was separated by agarose-gel 
electrophoresis and visualized by ethidium bromide staining. The number of PCR cycles 
used was the lowest needed to produce a product which could be visualized on the gel. 
 
In order to quantify the changes in transcript levels, reverse transciption followed by 
real-time PCR was also carried out. Reverse transcription was carried out in a 50 µl 
reaction mixture, containing 1 µg of total RNA and HBs reverse PCR primer (Table 3.3), 
at 42 °C for 90 minutes with AMV reverse transcriptase. 5 µl of reverse transcription 
product was then mixed with the HBs PCR primers, the HBs probe and the TaqMan 
Universal PCR Master Mix. The real-time PCR process was as described in section 3.2.1.7. 
The expressions of HBs transcripts were normalized to that of GAPDH. Sequences of the 
primers and probes are shown in Table 3.3. 
 
Table 3.3 Sequences of PCR primers and probes for real-time PCR quantification of HBs transcripts. 
Target sequence  Primer Sequence (5’-3’) 
HBs HBs Forward   TGTTGACAAGAATCCTCACAATACC 
 HBs Reverse GGTTGGTGAGTGATTGGAGGTT 
 HBs Probe CAGAGTCTAGACTCGTGGTGGACTTCTCTCAATT 
GAPDH  GAPDH Forward GAAGGTGAAGGTCGGAGTC 
(Meyer et al., 2000) GAPDH Reverse GAAGATGGTGATGGGATTTC 
 GAPDH Probe CAAGCTTCCCGTTCTCAGCC 
 
  69
3.2.1.12 Microarray procedures and data analysis 
Global gene expression patterns were analyzed using the Stanford Human cDNA 
Microarrays (SFGF001) containing approximately 43,000 elements representing the 
human genome printed on Corning UltraGAPS coated slides (Corning, Acton, MA, 
U.S.A). The following combinations of RNA were used on 2 slides each: 
1. 2.2.15 cells: mock transfection (reference) versus S2 treatment (test) 
2. 2.2.15 cells: mock transfection (reference) versus Scr treatment (test) 
3. PLC/PRF/5 cells: mock transfection (reference) versus S2 treatment (test) 
4. PLC/PRF/5 cells: mock transfection (reference) versus Scr treatment (test) 
One µg of each reference RNA was labeled with biotin-16-dUTP and 1 µg of each test 
sample with fluorescein-12-dUTP. The resultant labeled cDNAs were purified using the 
LabelStar Array kit as per manufacturer’s instructions. The microarray slides were 
hybridized with the paired samples overnight at 42oC in Corning hybridization chambers 
(Corning, Acton, MA, U.S.A). Post-hybridization washing, blocking and detection were 
carried out using the HiLight Dual Color Kit. Detection of the signals on a HiLight Reader 
GSD-501 (Qiagen, Hilden, Germany) was by Resonance Light Scattering (RLS), a 
technology based on the optical light-scattering properties of nano-sized metal colloidal 
particles (Yguerabide and Yguerabide. 1998a; Yguerabide and Yguerabide. 1998b; 
Francois et al., 2003). The biotinylated reference cDNAs were detected with gold particles 
coated with anti-biotin antibodies and the fluorescein-labeled test cDNAs were detected 
with silver particles coated with anti-fluorescein antibodies.  
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The slides were scanned on the HiLight Reader. The scanned slides were saved as .tiff 
files, imported into and analyzed using GenePix Pro4.1 software (Axon Instruments, 
Union City, CA, U.S.A), and loaded onto the Stanford Microarray Database for further 
analysis (Gollub et al., 2003). The data filters for the GenePix result sets were: regression 
correlation > 0.6; hybridization signals at least 5-fold greater than the local background 
fluorescence; genes and arrays for which technically adequate data were obtained in at 
least 80% of experiments; and a cutoff of genes whose R/G Normalized Ratio is < 0.66 or 
> 1.5 fold for at least one of the comparisons. These filtered genes were then clustered by 
Pearson Correlation (non-centered metric) and organized by hierarchical clustering (Eisen 
et al., 1998).  
 
The RNA samples were prepared by the author. The microarray experiments and data 
analysis were carried out mainly by our collaborator, Dr. Shanthi Wasser. 
 
3.2.2 Analysis of miRNA Expression and Function in HCC  
3.2.2.1 Cell culture  
The HepG2, Huh7, 2.2.15 human liver cell lines and HeLa human cervical carcinoma cell 
line were maintained in DMEM, supplemented with 10% fetal bovine serum, 100 U/ml 
penicillin, 100 g/ml streptomycin, 2 mM glutamine, 1 mM sodium pyruvate and 0.1 mM 
MEM nonessential amino acids at 37oC under 5% CO2.  
 
Human hepatocytes were purchased from BD Biosciences (San Jose, CA, U.S.A). Viable 
human hepatocytes were purified and cultured following the manufacturer’s protocols.  
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3.2.2.2 RNA extraction and quantification 
Tissues were homogenized in TRIzol using a power homogenizer while cells grown in 
monolayers were lysed or by applying TRIzol reagent directly in a culture dish or flask. 
Total RNA extraction was carried out following manufacturer’s instruction as described in 
section 3.3.1.9. The concentration of RNA was quantified by the absorbance at 260 nm. 
 
3.2.2.3 Mature miRNA expression profiling  
TaqMan® MicroRNA Assays Human Panel - Early Access Kit purchased from Applied 
Biosystems (Foster City, CA, U.S.A) was used for mature miRNA expression profiling in 
paired HCC tissues (tumor vs. non-tumor) in this study. The panel contains 157 of the 
known human miRNAs.  
 
Quantification of mature miRNAs using the Early Acess Kit was done using two-step 





















Figure 3.2 The principle of two-step RT- PCR. 1. In the reverse transcription (RT) step, cDNA is 
reverse transcribed from total RNA samples using specific miRNA primers from the TaqMan 
MicroRNA Assays Human Panel and reagents from the High-Capacity cDNA Archive Kit. 2. In the 
PCR step, PCR products are synthesized from cDNA samples using primers from the TaqMan 
MicroRNA Assays Human Panel together with TaqMan Universal PCR Master Mix. 
 
These miRNAs were quantified as described in the manufacturer’s protocol. cDNA was 
first reverse transcribed from 10 ng of total RNA sample extracted by TRIzol using 
specific miRNA RT primers from the TaqMan® MicroRNA Assays Human Panel and 
reagents from the TaqMan® MicroRNA Reverse Transcription Kit with the exception of 
the primer for the control 5S rRNA that was obtained in a mirVanaTM qRT PCR Primer Set 
(Ambion, Austin TX, U.S.A). In brief, all the reagents were thawed on ice. RT master mix 
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was prepared as described in Table 3.4. 1 μL of RT primer from the appropriate wells of 
the RT Primer Plates was transferred into the wells of the RT reaction plate. 9 μL of RT 
master mix was then added into each well of the RT reaction plate. The plate was then 
sealed using MicroAmp Adhesive Film (PN 4306311). Samples were mixed gently and 
centrifuged to bring the solutions to the bottom of the plate. The plate was incubated on ice 
for 5 minutes and kept on ice until loading the plate on the thermal cycler. The reaction 
mixture was incubated for 30 minutes at 16 oC. The reverse transcription was then carried 
out at 42 oC for 30 minutes followed by denaturation at 85 oC for 5 minutes.  
 
Table 3.4 Components of RT reaction for quantification of mature miRNA. 
 
1.5 µl of the cDNA product from the RT step was then mixed with miRNA-specific 
primers and probes from the TaqMan® MicroRNA Assays Human Panel and TaqMan® 
Universal PCR Master Mix without AmpErase® UNG. For the control 5S rRNA, the 
primers were obtained from the Ambion mirVanaTM qRT PCR Primer Set, and the SYBR® 
Green PCR Master Mix was used instead. The reaction mixture was incubated at 95 °C for 
10 minutes. Following this, the PCR reaction was performed at 95 °C for 15 seconds and 





Volume for 100 
reactions 
100 mM dNTPs (with dTTP) 0.1 μL 10 μL 
MultiScribe™ Reverse Transcriptase, 50 U/μL 0.2 μL 20 μL 
10 X Reverse Transcription Buffer 1 μL 100 μL 
RNase Inhibitor, 20U/μL 0.03 μL 3 μL 
Nuclease-free water 2.67 μL 267 μL 
Reverse Primer 1 μL 1 μL each 
Total RNA sample ( 1 mg/ml) 10 ng (0.01 μL) 1000 ng 
Total 10 μL 1000 μL 
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PRISM 7000 sequencing detection system and analyzed with ABI PRISM 7000SDS 
software (Applied Biosystems, Foster City, CA, U.S.A). Cycle numbers were determined 
at a reading of 0.2 fluorescence unit. To determine the relative quantity of mature miRNAs, 
ΔCt method was used with 5S rRNA as an internal control. The cycle number at which the 
reaction crossed an arbitrarily placed threshold (CT) was determined for each gene, and 
the relative amount of each miRNA to 5S rRNA was calculated using the equation 2-ΔCT 
where ΔCT = (CTmiRNA -CT5S rRNA) (Livak and Schmittgen, 2001). In order to facilitate data 
presentation, relative gene expression was multiplied by 106. 
 
3.2.2.4 TaqMan® microRNA individual assay 
miRNAs of interest were quantified in 56 pairs of surgical samples (tumor vs. non-tumor) 
using TaqMan® MicroRNA Individual Assay. The reverse transcription and real-time 
PCR steps were carried out as described in section 3.2.2.3. 
 
3.2.2.5 Quantification of miRNA precursors  
The quantification of miRNA precursors were carried out as previously described 
(Thomas et al 2004). Total RNA was briefly digested with DNase I, Amp Grade 
purchased from Invitrogen (Carlsbad, CA, U.S.A) according to manufacturer’s 
instructions. In short, 1 µg RNA was mixed with 1 µl 10 X DNase I Reaction Buffer, 1µl 
DNase I, Amp Grade, 1U/µl in one RNase-free microcentrifuge tube on ice. RNase-free 
water was added to the tube to 10 µl. The tube was incubated for 15 minutes at 23 and 
then DNase I was deactivated by the addition of 1 µl of 25 mM EDTA to the reaction 
mixture. The mixture was heated for 10 minutes at 65 °C. 
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DNase I treated total RNA was then reverse transcribed to cDNA using gene-specific 
primers and AMV reverse transcriptase (Promega). A 1 µg aliquot of DNase-treated total 
RNA (10 µl) was heated for 10 minutes at 70 °C and then placed on ice after pulse 
centrifugation. The reverse transcription reaction mixture was then assembled on ice. 1.5 
µl of a cocktail reverse primer mixture containing 10 µM of each of the antisense primers 
was mixed with DNase I treated total RNA together with the remaining reagents as 
specified in the Access RT-PCR protocol. The reaction mixture was incubated for 10 
minutes at 23 and the reaction proceeded for 15 min at 42 °C. Finally, the reverse 
transcriptase was inactivated by incubation at 95 °C for 5 minutes. 5 µl of appropriately 
diluted cDNA was mixed with the gene specific primers and the SYBR Green PCR Master 
Mix. The procedure of real-time PCR reaction and determination of the relative amounts 
of miRNA precursors was as described in section 3.2.1.11. The 5S rRNA was used as an 
internal control. In order to facilitate data presentation, relative gene expression was 
multiplied by 106. 
 
All primers were designed using Primer Express version 2.0 (Applied Biosystems, Foster 
City, CA). Both forward and reverse primers were designed to be located within the 










Table 3.5 Sequences of PCR primers for RT-real-time PCR detection of pri- and pre-miRNAs. 
 







pri- and pre-miR-106b Pre-miR-106b Forward  GCTGACAGTGCAGATAGTGGTCCT 
 Pre-miR-106b Reverse TGGAGCAGCAAGTACCCACAGT 
pri- and pre-miR-93 Pre-miR-93 Forward   AAGTGCTGTTCGTGCAGG 
 Pre-miR-93 Reverse   CTCGGGAAGTGCTAGCTCA 
pri- and pre-miR-25 Pre-miR-25 Forward   GTGTTGAGAGGGCGGAGACTT 
 Pre-miR-25 Reverse   TCAGACCGAGACAAGTGCAA 
5S rRNA 5S rRNA Forward TACGGCCATACCACCCTGAA 
 5S rRNA Reverse TAACCAGGCCCGACCCTGCT 
 
3.2.2.6 Transfection of cell lines with miRNA inhibitors 
HepG2 or HeLa cells (3x103 cells) were seeded into each well of a 96-well plate (5x104 
cells for each well of a 6-well plate) and allowed to recover for 24 hours. Before 
transfection, the appropriate amount of Anti-miR™ miRNA Inhibitors (Ambion, Austin 
TX, U.S.A) was diluted in 50 µl of Opti-MEM
 
I Reduced Serum Medium in one tube. In 
another tube 0.5 µl of Lipofectamine2000 was also diluted in 50 µl of Opti-MEM
 
I 
Reduced Serum Medium. Both of these two solutions were mixed gently by pipetting up 
and down. After incubation at 23 for 5 minutes, these two solutions were mixed gently, 
and incubated for 20 minutes at 23 to allow the miRNA Inhibitors:Lipofectamine2000 
complexes to form. Cells were then rinsed with Opti-MEM
 
I Reduced Serum Medium 
once. 100 µl of miRNA Inhibitors: Lipofectamine2000 complexes was then added to each 
well and mixed gently by rocking the plate back and forth.  
 
After introducing the miRNA Inhibitors:transfection reagent complexes, the cells were 
incubated at 37 °C in a CO2 incubator for 4 hours for transfection to take place. Following 
the transfection process, the transfection reagent was removed and replaced with the 
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complete DMEM medium. Mock transfections were carried out for both cell lines as 
described above but with the omission of the miRNA Inhibitors.  
 
3.2.2.7 Cell viability assay 
HepG2 or HeLa cells (3.0 x 103 cells) were seeded in each well of a 96-well plate and 
allowed to recover for 24 hours. Transfection and treatment of cells were performed 
following the methods described above. At 2 days post-transfection, MTS/PES reagent 
(20 µl) was added to each well. After incubation at 37 °C for 1 hour, the absorbance at 490 
nm was measured. All assays were performed in triplicate and as two independent 
experiments. 
 
3.2.2.8 Soft agar assay for colony formation 
Malignantly transformed cells can differ from their normal counterparts in a number of 
ways. The most significant differences include the loss of contact-inhibited growth, the 
acquisition of an infinite life span, and the ability to form tumors in animal hosts. In 1974 
Freedman and Shin found that there was a general correlation between the carcinogenetic 
potential of transformed cells in vivo and their ability to form colonies in an 
anchorage-independent manner in vitro. Thus, growth in soft agar can serve as a surrogate 
in vitro assay to evaluate transformation and tumorgenesis. The advantages of this assay 
are it is relatively easier; takes much less time than an in vivo tumorgenesis assay, and 




The soft agar assay was performed as follows:  
The base agar was poured and allowed to set. The cells were then mixed with aliquots of 
the top agar solution and poured onto the base agar. When the agar had set, the 6-well 
plate was incubated at 37 °C in a humid atmosphere of 5% CO2. The numbers of colonies 
were counted about 3 weeks after the initial plating or until colonies were big enough to be 
counted (larger than 1 mm in diameter). The preparation of reagents and the treatment of 
cells were carried out as follows: 
 
Reagents: DMEM (25% FBS) was prepared from DMEM (D1152) powder 
(Sigma-Aldrich, St. Louis MO, U.S.A). The resulting solution was filtered through a 
sterile venting filter (0.22µm). 2% Agar (DNA grade) was also prepared and sterilized by 
autoclaving.  
 
Base agar: To form the base agar, 2 % agar was melted and then cooled to 45°C in a water 
bath. DMEM (25% FBS) was also warmed to 45°C in a water bath. Both solutions were 
allowed to equilibrate for 30 minutes. 1 ml 2% agar was then mixed with 3 ml DMEM 
(25%FBS) (final concentration of agar: 0.5%) and then poured into one well of a 6-well 
plate. The agar was then allowed to set. 
 
Top Agar:  2 % Agar was melted, and then cooled to 45°C in a water bath. DMEM (25% 
FBS) was also warmed to 45°C in a water bath. Both were allowed to equilibrate for 30 
minutes. 0.75 ml 2% Agar was mixed with 3.25 ml DMEM (containing 25% FBS) and 1 
ml of diluted cells. The mixture was then quickly poured on the top of the base agar in one 
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well of a 6-well plate (final concentration of agar: 0.375%). Treatments of cells are 
described in the next paragraph. 
 
Treatment of cells: HepG2 or HeLa cells (5x104 cells) were seeded into each well of a 
6-well plate and allowed to recover for 24 hours. Cells were transfected with Anti-miR™ 
miRNA Inhibitors using Lipofectamine2000 as described in section 3.2.2.6. One hour 
after transfection, cells were trypsinized, counted, and diluted to a concentration of 100 
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4.1 Introduction 
Hepatitis B virus is a member of the hepadnaviridae family. The human hepatitis B virus 
(HBV) is a small-enveloped DNA virus which can cause acute and chronic infection of the 
liver (Robinson, 1994). Chronic hepatitis B infection is a major health problem, especially 
in Asia, and patients with chronic hepatitis are at increased risk of developing HCC 
(Beasley et al., 1981). Sequence-specific strategies such as the antisense approach and the 
use of ribozymes have been explored as research tools to examine the roles of viral protein 
and as inhibitors of viral replication with potential therapeutic applications (Goodarzi et 
al., 1990; Yao et al., 1996; Feng et al., 2001; Tan et al., 2002). Another promising 
sequence-specific strategy is that of RNAi which is mediated by siRNA molecules.  
 
In this study, we first examine if siRNA can be used to inhibit hepatitis B viral gene 
expression and replication. In addition, work was also carried out to examine if siRNA can 
mediate downregulation of viral gene expression without causing off-target effects. 








4.2 Selection and Transfection of HBV Specific siRNAs 
4.2.1 Selection of HBV Specific siRNAs 
In order to determine whether RNAi could be used to downregulate HBV gene expression 
effectively, siRNAs were designed and synthesized as described in section 3.2.1.2.  
 
Selection of the target sites was carried out as described by Harborth et al (Harborth et al., 
2001). Compared to current prevailing siRNA design algorithm, the algorithm we used 
was relatively simple. In brief, target sites should begin with AA; both the sense and 
antisense siRNA strands should have 3' overhangs; G/C content should be around 50%.  
 
As a result, all target sites were preceded by 5’AA nucleotides and the target sites were 
conserved in all HBV serotypes. Blast-search (NCBI database) was performed on the 
selected siRNAs sequence against EST libraries to ensure that no human genes are 
targeted. Among the siRNAs designed, two siRNAs (S1 and S2) showed the best 
inhibiting effect and were thus used in subsequent experiments. A 21-nt duplex with 
scrambled sequence (Scr) was also included as the negative control. As shown in Figure 
4.1, both S1 and S2 siRNAs target the HBV S ORF. HBsAg is not only a component of the 
viral envelope but is also present in spherical and tubular particles. These particles do not 
contain viral DNA but are secreted from cells harboring HBV DNA. HBV produces four 
transcripts of different lengths (Figure 4.1). Theoretically both S1 and S2 are capable of 
cleaving 3.5kb, 2.4kb and 2.1kb transcripts because the complementary sites can be found 









Figure 4.1 Illustration of HBV transcripts and the targeting sites of S1 and S2 siRNAs. HBV produce 4 
transcripts in its life cycles. They are 3.5kb, 2.4kb, 2.1kb and 0.7 kb transcripts. It has four partially 
overlapping open reading frames (ORFs). The four ORFs are named S, C, X and P respectively. ORF P 
overlaps with all other ORFs. S1 and S2 siRNAs target S ORF. 
 
4.2.2 Selection of Transfection Reagents 
Transfection efficiency is one of the key factors that determine the efficiency of RNAi. 
Different types of cells may respond differently to different transfection reagents. In order 
to get the best effect of HBV-specific gene knockdown by RNAi, five commercially 
available transfection reagents were tested in this study (Table 4.1). My preliminary data 
showed that S2 siRNA could effectively downregulate the expression level of HBsAg in 
both PLC/PRF/5 and 2.2.15 cells, so the two cell lines were transfected with S2 siRNA 
using different transfection reagents following the manufacturer’s protocols. Decrease in 







Table 4.1 Transfection reagents. 




QIAGEN Lipid-based reagent and is used in conjunction  with a specific RNA-condensing reagent (Enhancer R) 
RNAiFect QIAGEN Cationic-liposome-based reagent  
Oligofectamine  Invitrogen Cationic-liposome-based reagent  
Lipofectamine2000  Invitrogen Lipid-based reagent  
Trans-IT TKO  Mirus Non-cationic-liposome-based reagent,  enhanced polymer/lipid formulation 
 
For PLC/PRF/5 cells, S2 siRNA delivered by Lipofectamine2000 and Trans-IT TKO 
showed the best inhibitory effect on HBsAg expression (Table 4.2). Maximal reduction of 
HBsAg secretion was observed at 2 days following siRNA transfection. The decrease was 
90.3 + 1.6% and 74.7 + 1.4 % for S2 siRNA delivered by Lipofectamine2000 and 
Trans-IT TKO respectively. However, compared to untreated cells, Trans-IT TKO mock 
transfection showed significant inhibitory effect on HBsAg expression. The non-specific 
inhibitory effect is not desirable for RNAi study. In contrast, Lipofectamine2000 alone did 
not show significant effect on HBsAg expression of PLC/PRF/5 cells. Thus, in subsequent 
experiments, Lipofectamine2000 was used to transfect PLC/PRF/5. 
 
For 2.2.15 cells, S2 siRNA delivered by Trans-IT TKO showed the best inhibitory effect 
on HBsAg expression (Table 4.2). Maximal reduction of HBsAg secretion was observed 2 
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days after initial siRNA transfection. The decrease was 73.6 + 2.7% and Trans-IT TKO 
mock transfection did not show significant inhibitory effect on HBsAg expression. Thus, 
in subsequent experiments, Trans-IT TKO was used to transfect 2.2.15 cells. 
Table 4.2 Inhibition of HBsAg production by transfection of S2 siRNA with different transfection 
reagents in PLC/PRF/5 and 2.2.15 cells. 
 
 
The effect of different transfection reagents on PLC/PRF/5 cells and 2.2.15 cells were examined using 
S2 siRNA. Cells were left untreated (U), or mock transfected with the transfection agent (M), or 
transfected with 0.2 µM S2 siRNA. HBsAg concentrations in the culture media were determined 48 
hours after transfection. The HBsAg concentrations in untreated samples were set as 100%. Data 
shown represent mean ±SD (n=3). *p<0.05, ANOVA analysis, for comparison between Untreated and 




PLC/PRF/5 cells Treatment 
Transfection reagents Untreated Mock transfection 0.2 μM S2 
Transmessenger 
Transfection Reagent 
100 + 6.3 95.1 + 3.6 26.9 + 7.4 * 
RNAiFect 100 + 10.7 74.7 + 4.5 * 23.6 + 2.4 * 
Oligofectamine 100 + 4.2 91.9 + 1.0 51.4 + 5.5 * 
Lipofectamine2000 100 + 4.2 88.5 + 12.8 8.6 + 1.4 * 
Trans-IT TKO 100 + 1.6 37.3 + 0.3 * 9.2 + 0.5 * 
2.2.15 cells Treatment 
Transfection reagents Untreated Mock transfection 0.2 μM S2 
Transmessenger 
Transfection Reagent 
100 + 6.0 107.7 + 7.3 95.9 + 6.7 
RNAiFect 100 + 8.8 101.5 + 11.8 70.4 + 3.8 * 
Oligofectamine 100 + 5.3 96.0 + 11.4 70.7 + 1.7 * 
Lipofectamine2000 100 + 3.5 92.0 + 1.7 52.2 + 2.2 * 
Trans-IT TKO 100 + 3.1 90.5 + 2.7 23.9 + 2.4 * 
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4.2.3 Transfection Efficiency of HBV Specific siRNA 
Fluorescein-labeled S2 duplexes were used to examine the transfection efficiency of 
siRNA into the cell lines used in this study. At 1 hour post-transfection with 0.2 µM of 
labeled-S2, the percentage of fluorescein-labeled PLC/PRF/5 cells was > 95% while that 
for 2.2.15 cells was 74 + 9%. The fluorescein signal was localized mainly outside of the 
nucleus (Figure 4.2). Similar percentages of fluorescein-labeled cells were also observed 
at 24 hours post-transfection (data not shown). 
 
 A                   B 
 
C                   D 
 
Figure 4.2 Transfection with fluorescein-labeled siRNA (green) in PLC/PRF/5 and 2.2.15 cells. (A) 
Bright field and (B) fluorescence image of PLC/PRF/5 cells. (C) Bright field and (D) fluorescence 




4.3 Inhibition of HBsAg Expression and Reduction in Virion 
Production 
4.3.1 Concentration Dependent Inhibition of HBsAg Expression 
Two cell lines PLC/PRF/5 and 2.2.15 were used to assess the effectiveness of the S1 and 
S2 siRNAs. The PLC/PRF/5 cells produce only the spherical and tubular particles while 
the 2.2.15 cells produce the particles and viruses.  
 
The inhibitory effects of S1 and S2 siRNA treatments on HBsAg expression in both cell 
lines were evident at 48 hours after treatment. Both S1 and S2 siRNAs showed significant 
inhibitory effect on HBsAg expression in PLC/PRF/5 and 2.2.15 cells at a very low 
concentration of 0.01 µM. In PLC/PRF/5 cells, the inhibition was 72.6±2.6% for S1 and 
78.0±1.0% for S2. In 2.2.15 cells, the inhibition was 18.8±4.5% for S1 and 46.2±1.4% for 
S2 (Figure 4.3). Inhibition of HBsAg expression was dependent on the concentration of 
siRNA used and increased inhibition was observed as the concentration of siRNA was 
increased from 0.01 μM to 0.4 μM. Maximum inhibition was achieved at the highest 
concentration of 0.4 µM. In PLC/PRF/5 cells, the inhibition was 95.7±0.8 % for S1 and 
96.5±0.3 for S2. In 2.2.15 cells, the inhibition was 67.7±2.6% for S1 and 74.5±0.8% for 
S2 respectively (Figure 4.3).  
As shown in Figure 4.3, the mock transfection had no significant effect on HBsAg 
expression. In addition to the mock transfection, the Scr siRNA (which has a scrambled 
sequence with the same base composition as S2) was included as a control. At 
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concentrations up to 0.2 μM, Scr siRNA had no effect on HBsAg expression, but 
decreased HBsAg expression was observed at 0.4 µM (Figure 4.3). Thus, in subsequent 






































































Figure 4.3 Dose-dependent effects of siRNA on HBsAg expression in (A) PLC/PRF/5 cells and (B) 
2.2.15 cells. Cells were left untreated (U), or mock transfected with the transfection agent (M), or 
transfected with 0.2 µM or 0.4 µM Scr, or transfected with 0.01 µM –0.4 µM S1, or transfected with 
0.01 µM – 0.4 µM S2. HBsAg concentrations in the culture media were determined 48 hours after 
transfection. The HBsAg concentration in mock transfected samples is 27.2 + 3.0 ng/ml for PLC/PRF/5 
cells and 14.0 + 0.8 ng/ml for 2.2.15 cells. These were set as 100% for the data in (A) and in (B) 
respectively. Data shown represent mean + SD (n=3). * p<0.01, ANOVA analysis, for comparison 
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4.3.2 Effect of siRNA on HBsAg Transcripts in PLC/PRF/5 and 
2.2.15 Cells 
At 48 hours following the treatment of PLC/PRF/5 with 0.2 µM of S1 or S2, there was a 
significant decrease in HBsAg secretion into the culture medium. To address the question 
whether HBsAg was specifically knocked-down in the two cell lines by siRNAs specially 
designed to target HBV S ORF, the levels of HBV transcripts encoding HBsAg were 
determined by reverse transcription-real time PCR analysis in untreated cells, mock 
transfected cells, Scr siRNA treated cells, and S1 and S2 siRNA treated cells.  
 
As expected, a corresponding decrease in transcripts encoding HBsAg was observed for 
RNA isolated from the PLC/PRF/5 cells treated with 0.2 μM of S1 or S2 siRNA (Figure 
4.4A). The inhibition was 91.6 + 3.3% for cells treated with S2 siRNA. For mock 
transfected cells and cells transfected with 0.2μM Scr siRNA, the levels of HBsAg 
transcripts were not altered significantly compared to untreated cells. 
 
Reduced HBsAg secretion was similarly observed for the 2.2.15 cells treated with 0.2 μM 
S1 or S2 siRNA. RT-real-time PCR analysis showed a decrease of 54.9 + 9.0% and 74.8 + 
4.2% in transcripts encoding HBsAg following transfection by S1 and S2 respectively 
(Figure 4.4B). Similar to that observed for the PLC/PRF5 cells, the levels of HBsAg 


















































Figure 4.4 Effect of siRNA on HBsAg RNA in (A) PLC/PRF/5 cells and (B) 2.2.15 cells. Cells were 
left untreated (U), or mock transfected with the transfection agent (M), or transfected with 0.2 µM Scr, 
0.2 µM S1 or 0.2 µM S2. Total RNA was isolated 48h after transfection. Following 
reverse-transcription, real-time PCR with primers to the S ORF was carried out. Results were 
normalized with GAPDH. The value for the mock transfected cells was set as 100%. Data shown 
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4.3.3 Effect of siRNA on HBV Transcripts in 2.2.15 Cells 
Four viral transcripts with the HBV S ORF are present in the 2.2.15 cells. These include 
the 3.5kb precore RNA, the 3.5kb pregenomic RNA, the 2.4kb pre-S RNA and the 2.1kb 
HBs RNA (Figure 4.1). In order to analyze the effect of siRNA on these HBV transcripts 
individually, specific primers were designed and quantitative RT-PCR was performed for 
the untreated cells, mock transfected cells, Scr siRNA treated cells, and S1 and S2 siRNA 
treated cells 48 hours after initial transfection. Treatment with S1 and S2 resulted in 
decreased levels of the 2.4kb and 2.1kb transcripts but had little effect on the 3.5kb 
transcripts (Figure 4.5). Mock transfection and Scr siRNA transfection did not cause any 
















 U     M    Scr    S1   S2 
 
Figure 4.5 Reverse transcription-PCR analysis of HBV transcripts in 2.2.15 cells. The RT-PCR 
products for (A) the 3.5kb pre-core/pre-genomic transcripts, (B) both the 2.4kb pre-S1 and the 3.5kb 
transcripts, (C) the 3.5kb, 2.4kb and 2.1kb transcripts and (D) the GAPDH RNA are shown for 
untreated cells (U), cells treated with transfection agent only (M), cells treated with 0.2 µM Scr siRNA, 
0.2 µM S1 siRNA and 0.2 µM S2 siRNA. 
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4.3.4 Effect of siRNA on Virion Production in 2.2.15 Cells 
As HBsAg is an essential component of the viral envelope, we next addressed the question 
of whether S1 and S2 siRNAs affected virion production. 48 hours after the initial 
treatment, viral DNA content in the medium of treated 2.2.15 cells was analyzed by 
real-time PCR. Treatment with S1 resulted in 56.7+2.8% decrease in viral DNA while 
treatment with S2 led to 68.0+1.9% reduction (Figure 4.6). As expected, treatment with 





















Figure 4.6 Analysis of HBV DNA levels in culture medium of 2.2.15 cells. Cells were left untreated 
(U), or mock transfected with the transfection agent (M), or transfected with 0.2 μM Scr, 0.2 μM S1 or 
0.2 μM S2. HBV DNA levels were determined 48h after transfection. 1.0 x 106 + 4.6 x 104 copies/ml 
was present in the mock transfected medium and this was set as 100%. Data shown represent mean + 
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4.3.5 The Time Course of HBsAg Inhibition by siRNA 
It has been reported that siRNA might be amplified by RNA-dependent RNA polymerase 
(RdRP) in plants, fungi and worms (Zamore et al., 2000; Nishikura K, 2001). This 
amplifying mechanism could make RNAi mediated by siRNA extremely efficient and 
lasting in these species. However, the mechanism has not been found in mammalian 
system as there are no such RdRP analogues in mammalian genomes. Therefore, in 
mammalian cells, siRNA acquired by transfection would diminish due to degradation by 
RNases or dilution during cell division making the effects of siRNAs transient in 
mammalian systems. To address the question of how fast siRNAs might take effect after 
initial transfection and how stable these siRNAs could be in mammalian cells, the 
time-course of siRNA inhibitory effect was also examined in this study.  
 
Culture medium was collected and replaced with fresh medium at 24 hour intervals after 
initial treatment. HBsAg secreted in the culture medium was quantified by ELISA assay as 
described in section 3.2.1.6. Significant reduction in HBsAg secretion from PLC/PRF/5 
cells was observed one day after siRNA transfection with maximal inhibition of 95.7 + 
0.8% for S1 and 96.3 + 0.3% for S2 at 2 days. At 7 days post-transfection, significant 
inhibition was still observed (Figure 4.7A). Similar observations were also obtained for 
the 2.2.15 cells (Figure 4.7B). Maximal reduction of HBsAg secretion was observed at 2 
days following siRNA transfection. The decrease was 59.6 + 7.1% and 71.8 + 3.3% for S1 
and S2 transfected cells respectively. For both cell lines, mock transfected cells and Scr 
transfected cells did not show any inhibition of HBsAg expression during the whole 










































Figure 4.7 The time course of HBsAg inhibition by siRNA in (A) PLC/PRF/5 cells and (B) 2.2.15 cells. 
Cells were left untreated (round symbols), or mock transfected with the transfection agent (square 
symbols), or transfect with 0.2 μM Scr (x symbols), or 0.2 μM S1 (triangle symbols) or 0.2 μM S2 
(diamond-shaped symbols). Culture media were collect every 24 hours and fresh media was introduced. 
HBsAg levels in the culture are presented as percent of that in mock transfected controls. Data shown 
represent mean + SD (n=3). All data points for S1 and S2 were significantly different from untreated, 




4.3.6 Reversal of RNAi  
 
The liver has a great ability to regenerate. The chronic HBV patients always suffer from 
long-term liver damage accompanied by continuous liver cell proliferation. As described 
in section 4.3.5, siRNA introduced to mammalian cells will be diluted gradually during 
cell division. In order to assess the potential of siRNA as a therapeutic tool to treat HBV 
infection one important issue that has to be addressed is how long can the effect of siRNA 
could last in growing liver cells. To address the question, the following experiments were 
designed and carried out using 2.2.15 cells. 
 
For this time course study, 2.2.15 cells were seeded at a high density to achieve the 
optimal inhibition effects. Cells were confluent 2-3 days after initial treatment and cell 
proliferation would slow down considerably. Therefore, siRNA introduced by lipofection 
would not be diluted further during cell division. In order to provide cells more space to 
proliferate, 2.2.15 cells were trypsinized and counted 2 days after the initial transfection 
with 0.2 µM S2 siRNA. 2 x 105 cells were then seeded into each well of a 24-well plate 
and allowed to grow for another 7 days. The medium was collected every 24 hours and 
fresh medium was replaced. HBsAg secreted in the culture medium was quantified by 
ELISA assay. 
 
As shown in Figure 4.8, the expression of HBsAg mediated by S1 and S2 siRNAs 
decreased significantly after cell splitting. However, at the 7th day after splitting, 



















mock transfected cells and Scr transfected cells didn’t show any inhibition of HBsAg 
expression during the whole course of 7 days. 
 
Figure 4.8 The time course of HBsAg inhibition by siRNAs in 2.2.15 cells. Cells were left untreated 
(round symbols), or mock transfected with the transfection agent (square symbols), or transfect with 
0.2 μM Scr (x symbols), or 0.2 μM S1 (triangle symbols) or 0.2 μM S2 (diamond-shaped symbols). 
Cells were trypsinized, counted and reseeded 2 days after the initial treatment with siRNAs. Culture 
media were collect every 24 hours and fresh media was introduced. HBsAg levels in the culture are 
presented as percent of that in mock transfected controls. Data shown represent mean + SD (n=3).  
 
 
4.4 Specificity of the Effects of siRNA 
4.4.1 Effects of siRNA on Cell Viability 
For siRNA to be a potential therapeutic tool, siRNA should specifically inhibit the 
expression of its target gene and should not cause any severe off-target effects. In order to 
address the specificity of siRNAs designed to knockdown HBV gene expression, the 
effect of siRNA on cell viability was examined.  
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The viability of the cells was determined at 2, 5 and 7 days following transfection with 
siRNAs. This was achieved using the MTS/PES assay. The S1 and S2 siRNAs as well as 
the scrambled duplex, Scr did not affect the cell growth and viability of both PLC/PRF/5 
and 2.2.15 cell lines as shown in Table 4.3. 
 
Table 4.3 Effects of siRNAs on the viability of PLC/PRF/5 and 2.2.15 cells.  
 
Treatment Viability of PLC/PRF/5 cells at: 
 Day 2 Day 5 Day 7 
Mock transfection 100 + 4.2 100 + 3.6 100 + 1.9 
Untreated 102.9 + 4.4 98.2 + 4.8 101.5 + 1.9 
0.2 μM Scr ND 105.4 + 3.0 109.7 + 5.3 
0.2 μM S1 103.0 + 7.7 100.4 + 4.8 108.7 + 4.2 
0.2 μM S2 113.5 + 12.8 97.6 + 5.4 108.5 + 1.6 
Treatment Viability of 2.2.15 cells at: 
 Day 2 Day 5 Day 7 
Mock transfection 100 + 10.3 100 + 9.6 100 + 6.6 
Untreated 113.3 + 9.3 114.0 + 4.9 109.0 + 11.6 
0.2 μM Scr ND 97.0 + 6.3 102.0 + 15.0 
0.2 μM S1 100.2 + 10.7 91.7 + 8.5 97.9 + 4.5 
0.2 μM S2 113.5 + 12.0 101.0 + 16.8 96.8 + 5.0 
 
4.4.2 Expression Profiling 
Microarray analysis is one of the most powerful approaches to examine gene expression 
on a global scale. To evaluate the specificity of the siRNAs used in this study, human 
cDNA microarrays containing approximately 43,000 elements were used to examine the 
global gene expression patterns of cells after transfection with siRNAs. Gene expression 
profiling comparisons between mock transfected and cells transfected with 0.2 µM S2 
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siRNA or 0.2 µM Scr siRNA were carried out in duplicates. The profiling was carried out 
with both PLC/PRF/5 cells and 2.2.15 cells. The magnitude of the changes in expression 
of all gene examined was small. Most changes were less than 2 fold.  
 
A total of 49 genes were either up- or down-regulated by at least 1.5 fold for both cell lines 
(Table 4.4). Of these, treatment of 2.2.15 cells with S2 siRNA and Scr siRNA resulted in 9 
and 12 genes being differentially regulated respectively. The magnitude of change was at 
least 2 fold but not more than 3. Only 2 of the genes (cytochrome P450 2A6 and a 
mitochondria EST of unknown function) were common for both treatments. Treatment of 
PLC/PRF5 cells with S2 siRNA and Scr siRNA resulted in 3 and 7 genes being 
differentially regulated by at least 2 fold, respectively and only one gene 
(ubiquitin-activating enzyme E1-domain containing 1 protein) was common for both 
treatments. In addition, a comparison of the differentially regulated genes in both cell lines 
showed that there were only 3 common genes (of unknown functions). None of the genes 
that were differentially regulated in this study coincides with the 14 genes that were 
commonly regulated by a series of siRNAs targeted against Rb1, AKT1 and Plk1 
(Semizarov et al., 2003). These results indicate that there were no significant off-target 
gene regulation and similar to that previously observed by Chi et al (Chi et al., 2003), 




Table 4.4 Gene expression in 2.2.15 and PLC/PRF5 cells following treatment with siRNAs. 
 
   
 
 2.2.15 cells   PLC/PRF/5 cells   
SUID NAME GenBank No M-vs-S2 M-vs-SCR M-vs-S2 M-vs-SCR 
  
 
Lipid, fatty acid and steroid metabolism           
307401 CYP4F3 || cytochrome P450, family 4, subfamily F, polypeptide 3 AI249090 1.60 1.43 1.54 1.92 
330264 CYP2A6 || cytochrome P450, family 2, subfamily A, polypeptide 6  AI343237 0.42 0.43 0.59 0.55 
112881 PCCA || propionyl Coenzyme A carboxylase, alpha polypeptide  AA983154 0.62 0.62 0.45 0.72 
              
  Protein metabolism and modification           
104159 RPL14 || ribosomal protein L14 AI053558 1.13 0.61 0.67 0.97 
102992 EEF1A1 || eukaryotic translation elongation factor 1 alpha 1  T89301 0.98 1.36 0.67 0.56 
              
  Intracellular protein traffic           
311822 VPS35 || vacuolar protein sorting 35 (yeast)  AA916752 0.50 0.73 0.64 0.52 
              
  Nucleoside, nucleotide and nucleic acid metabolism           
98713 APOBEC1 || apolipoprotein B mRNA editing enzyme AA587939 1.00 0.58 0.57 0.73 
117045 SIX3 || sine oculis homeobox homolog 3 (Drosophila) N41052 0.60 0.31 0.55 0.52 
106655 SOX12 || SRY (sex determining region Y)-box 12  AA866160 0.54 0.56 0.65 0.57 
              
  Unclassified/new ESTs/Unknown function           
318884 NDUFV3 || NADH dehydrogenase (ubiquinone) flavoprotein 3, 10kDa  AI291172 1.44 1.28 1.95 1.80 
104774 UBE1DC1 || ubiquitin-activating enzyme E1-domain containing 1  R32014 0.66 0.56 0.49 0.48 
120543 MTMR9 || myotubularin related protein 9 AA418387 2.17 0.85 0.75 0.83 
102654 C10orf45 || chromosome 10 open reading frame 45  AA431133 0.71 0.47 0.51 0.40 
104661 C21orf91 || chromosome 21 open reading frame 91 AA400378 0.50 0.68 0.64 0.58 
99690 DKFZp761I2123 || **hypothetical protein DKFZp761I2123  AA405740 0.57 0.42 0.63 0.45 
117850 DKFZp313M0720 || hypothetical protein DKFZp313M0720  AI054231 1.19 0.62 0.60 0.84 
105201 FLJ40919 || hypothetical protein FLJ40919 T92157 0.78 0.74 0.62 0.57 
98367 KIAA0114 || KIAA0114 gene product  AI053704 1.14 0.55 0.76 0.54 
310463 LOC159090 || similar to hypothetical protein MGC17347  N74901 0.68 0.42 0.52 0.62 
225970 Homo sapiens cDNA FLJ11366 fis, clone HEMBA1000282.  AA704270 1.49 1.16 1.44 1.98 
112373 Homo sapiens clone 252 mRNA sequence  AA190764 0.76 0.61 0.68 0.58 
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Table 4.4: …cont. 
 
 
    2.2.15 cells   PLC/PRF/5 cells   
SUID NAME GenBank No M-vs-S2 M-vs-SCR M-vs-S2 M-vs-SCR 
 
313320 Homo sapiens transcribed sequences AI245660 0.63 0.71 0.52 0.93 
223940 Homo sapiens cDNA FLJ32525 fis, clone SMINT2000060. AA705015 0.47 0.71 0.82 0.67 
317836 Homo sapiens transcribed sequences  AI241280 0.86 0.47 0.57 0.61 
314256 Homo sapiens transcribed sequences AI371327 0.75 0.47 0.53 0.53 
312421 Homo sapiens cDNA: FLJ22133 fis, clone HEP20529  AI344687 0.93 0.51 0.60 0.69 
104905 Homo sapiens transcribed sequences  AI053487 0.74 0.57 0.55 0.52 
184956 Homo sapiens transcribed sequences Unknown  UG Hs.87530  ESTs  AA281926 0.62 0.56 1.00 0.66 
317076 Homo sapiens transcribed sequences AI271427 0.96 1.92 0.69 0.78 
331189 Homo sapiens similar to Gamma-glutamyltranspeptidase 1 precursor AI344264 0.42 0.62 0.58 0.64 
433347 mitoch. cont. ESTs  nil 2.04 2.25 1.47 1.49 
433310 mitoch. cont. EST  nil 1.33 1.55 1.87 1.60 
433351 mitoch. cont. ESTs  nil 1.69 1.52 1.71 1.46 
433300 mitoch. cont. ESTs  nil 2.14 1.32 1.64 1.52 
433311 mitoch. cont.  nil 1.57 1.40 1.54 1.70 
433303 mitoch. cont.  nil 1.06 1.10 1.53 2.59 
115821 nil AI054041 0.81 0.71 0.56 0.86 
316453 nil AI333424 0.47 0.74 0.68 0.51 
308324 nil AI335863 0.62 0.64 0.52 0.61 
106302 nil AI053735 0.66 0.52 0.57 1.16 
110818 nil AI053443 0.95 0.54 0.80 0.64 
116683 nil AA411391 0.90 0.48 0.61 0.83 
103556 nil AI053440 0.60 0.48 0.73 0.47 
102516 nil N38990 0.91 0.46 0.54 0.64 
472864 nil nil 1.86 2.14 1.53 1.78 
472867 nil nil 1.26 1.45 2.22 1.83 
472868 nil nil 1.50 1.52 1.69 1.62 
472862 nil nil 1.69 1.29 1.13 2.54 
472866 nil nil 1.32 1.42 1.40 2.81 
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Comparisons between mock transfection (M) and cells treated with 0.2 µM S2 siRNA or 0.2 µM Scr 
siRNA at 48 hours after transfection with siRNAs were carried out in duplicate. Genes with expression 
changes that demonstrated coordinate induction or repression by siRNA in the cell lines 2.2.15 or 
PLC/PRF/5 are shown, grouped together according to their biological functions. Each value is the fold 
induction in an average of 2 microarray experiments, with a value <1 indicating gene repression and a 
value > 1 representing gene induction. Values in bold fonts indicate at least a 2 fold change in gene 
expression. The Stanford Unique Identification (SUID) numbers are unique identifying numbers within 
the Stanford Microarray Database which are specific for arrayed clones or PCR-amplified regions of 






The uniqueness of viral genomes has been continually exploited for the development of 
antiviral agents. These approaches include the use of antisense oligonucleotides, 
ribozymes (Xu et al., 2003b; Karayiannis et al., 2003; Hilleman, 2003) and more recently 
RNAi. The RNAi approach has been used to inhibit expression of viral proteins and to 
reduce viral titer (Stevenson, 2003; Saksela, 2003).  
 
Synthetic siRNA duplexes and plasmid-derived short hairpin RNA (shRNA) are 
commonly used to mediate the RNAi effect in mammalian cells. Plasmid-derived shRNA 
is dependent on cellular transcription and it is difficult to regulate the level of expression. 
In addition, shRNA contain additional sequences which may contribute to potential 
non-specific effects. Indeed, shRNA have been shown to trigger an interferon response 
while the corresponding synthetic siRNA did not (Bridge, 2003). Thus in this study, we 
chose to use chemically synthesized siRNAs.  
 
4.5.1 Inhibition of HBV Gene Expression by siRNAs 
Synthetic siRNAs targeted at two different sites within the HBV S ORF can specifically 
inhibit the expression of HBsAg in PLC/PRF/5 cells. This together with a reduction in the 
corresponding mRNA indicates that this is a true RNAi effect. The siRNA-induced RNA 
interference also effectively reduced HBsAg expression in 2.2.15 cells. Reduction in 
virion production was also observed. This is probably a consequence of reduced HBsAg 
expression as both S1 and S2 siRNAs had little effect on the 3.5kb pregenomic and 
precore RNA but could effectively reduce the levels of the 2.1kb / 2.4kb transcripts 
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leading to reduced HBsAg for incorporation into the viral envelope. Although the 3.5kb 
RNA has the HBV S ORF, it is possible that there are secondary structures within the 
RNA that prevent siRNA-induced cleavage. 
 
The siRNAs were more effective in inhibiting HBsAg production in PLC/PFR/5 cells than 
in 2.2.15 cells. This is similar to previous observations with minimized ribozymes (Tan et 
al., 2002). The difference in the inhibitory effect is probably due to differences in the 
uptake of the siRNAs. Transfection of siRNA was more efficient in PLC/PRF/5 cells and 
this resulted in > 95% reduction in production of HBsAg. In contrast, the transfection 
efficiency in 2.2.15 cells was only ~74% and this correlated with smaller reductions in 
HBsAg production.  
 
During the course of this study, two other reports also made similar observations using the 
same cell line, 2.2.15 (Giladi et al., 2003; Konishi et al., 2003). Collectively, our study and 
these reports indicate that there are multiple sites within the HBV transcripts that can be 
used as targets for the action of siRNA. It is encouraging to note that in the 2.2.15 system 
which constitutively produces hepatitis B antigens and virus particles, siRNA can 
effectively reduce viral gene expression and virion production. siRNA specific for the core 
gene has also been shown to induce mark reduction of HBV replication of both wild-type 
and lamivudine-resistant YMDD variant (Klein et al., 2003). Another point of interest is 
the fact that siRNA appears to be effective at a much lower concentration than antisense 
oligomers with the former being active at nM while the latter at μM concentrations (Tan 
and Ting, 1995; Li et al, 2004). To date, there have been many studies showing efficient 
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siRNA mediated inhibition of HBV gene expression and viral replication in cell cultures 
(Shlomai and Shaul, 2003; Hamasaki et al., 2003; Tang et al., 2003; Ying et al., 2003; 
Konishi et al., 2003). In addition, it has also been demonstrated that it is possible to use the 
RNAi approach to inhibit HBV replication in mice (McCaffrey et al., 2003b; Giladi et al., 
2003; Morrissey et al., 2005). All these augur well for the potential use of siRNA as 
therapeutic agents, although many issues including the mode of delivery, the stability of 
the siRNA, and the possibility of non-specific off target effects need to be addressed. It is 
unclear from the reported studies if the siRNAs targeting the viral mRNA had resulted in 
any non-specific off-target effects.  
 
4.5.2 Microarray Analysis of HBV-induced Changes in Gene 
Expression 
cDNA microarray analysis had also been previously employed to examine HBV-induced 
changes in cellular gene expression. The majority of the genes investigated differed only 
slightly in HBV producing cells. However, there were several genes which showed 
changes of up to ~4-5 fold as shown in Table 4.5 (Honda et al., 2001; Otsuka et al., 2003). 
In this study, attempts were made to examine if siRNA-treatment would lead to the 
reversal of the previously described changes of certain HBV regulated genes (Table 4.4). 
However, from our microarray analysis, no reversal was observed. This may be due to the 
fact that the siRNA treatment of 2.2.15 cells could not result in complete inhibition and 
many of the previously documented changes were small in magnitude, thus the reversal in 
expression was not detected. In addition, the expression of viral genes in 2.2.15 cells is 
generally low several days after confluence (Sells et al., 1998). For certain cellular genes, 
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there is an inverse correlation with HBV RNA levels (Norton et al., 2003). Thus, the lack 
of reversal in cellular gene expression may also be due to the use of pre-confluence cells in 
this study. 
 
Table 4.5 HBV-induced gene changes. 
Gene 
 
Up- or Down-regulated 
due to HBV infection Fold change References: 
Insulin-like growth 
factor 2 Upregulated 4.8 Otsuka et al., 2003 
Interferon-a Upregulated 4.95 Honda et al., 2001 
Metallothionein I Upregulated 4.56 Honda et al., 2001 
Endoglin Upregulated 4.12 Honda et al., 2001 
Interferon regulatory 
factor 7 Upregulated 4.68 Honda et al., 2001 
Nuclear factor 
NF-IL6 Upregulated 6.05 Honda et al., 2001 
 
4.5.3 Specificity of the Effects of siRNA 
In this study, cell growth and viability were first examined as a parameter to determine if 
there were any non-specific effects. The 2.2.15 cell line used in this study permitted this as 
there is no lytic process following HBV replication. Cell growth and viability was not 
affected by treatment with the HBV specific as well as with the scrambled siRNAs. 
Similar observations were also made using another cell line, PLC/PRF/5. These results 
show that siRNA treatment did not cause any non-specific effects on cell growth and 
viability and provide implications that it may be possible to design and synthesize 
non-toxic siRNAs for therapeutic purposes. 
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Further analysis using cDNA microarrays demonstrated that siRNA-mediated gene 
silencing was highly specific and there were little non-specific effects, similar to that 
observed in two previous studies (Semizarov et al., 2003; Chi et al, 2003). During the 
course of this study, there had also been a series of studies reporting off-target effects 
caused by introduction of shRNA or siRNAs (Jackson et al., 2003; Bridge et al., 2003; 
Persengiev et al., 2003; Kariko et al., 2004; Scacheri et al., 2004). These off-target effects 
include the induction of global shut down of protein synthesis by stimulating interferon 
pathway and the non-specific inhibition of non-target genes. However, it was obvious 
from these studies (Semizarov et al., 2003; Chi et al., 2003; Jackson et al., 2003; 
Persengiev et al., 2003; Scacheri et al., 2004) and our study that the presence of 21- to 
23-nucleotide duplexes did not lead to a single consistent response pattern of gene 
expression and any observed changes in cellular gene expression may be purely 
sequence-dependent. Hence, unlike the general interferon response to long dsRNA 
molecules, there is no single siRNA-induced response to siRNA duplexes in mammalian 
cells.  
 
Taken together, these observations indicate that it is possible to design siRNAs which 
have little off-target effects. However, care should always be taken to verify that this is 
indeed so. In addition to demonstrating that there is a reduction in the expression at the 
mRNA and protein level, other validations such as genome-wide expression profiling may 
indeed be necessary to confirm that there are indeed no off-target effects.  
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4.5.4 Comparison of Studies on siRNA’s effect on HBV  
Table 4.6 Summary of studies of siRNA’s effect on HBV 
No. Model Target gene Target sequence Efficacy Reference 
1 HuH-7 cells X or Core X siRNA GGTCTTACATAAGAGGACT(1649 to 1667) 
Core siRNA  
GATCAGGCAACTATTGTGG (2191 to 2209)  
Core-2 siRNA  
GCCATTCTCTGCTGGGGGG(2075 to 2093)  
HBcAg: 89% reduction for X siRNA,63% for Core siRNA and 80% for Core-2 siRNA;  
HBsAg: 60% reduction for X siRNA and no change for Core siRNA;  
HBV mRNA: 68% reduction for X siRNA and 13% reduction in the 3.5kb transcript for Core siRNA,  
50% in the 3.5kb transcript for Core-2 siRNA 
Shlomai and Shaul, 
2003 Apr 
2 HuH-7 cells  
and HepG2 cells 
Core Core siRNA  
AACATTGTTCACCTCACCATA (2137-2157) 
HBeAg: 4.6-fold decrease in HuH-7 cells and 4.9-fold in HepG2 cells;  
HBV mRNA: 2.4/2.1-kb mRNA of HBV was not suppressed by siHBV,  
whereas the level of 3.5-kb mRNA was reduced by 70%;  
the level of open circular and single-stranded HBV-DNA was clearly suppressed by siHBV.  
On the other hand, the level of doublestranded HBV-DNA, which is mostly derived from  
the transfected DNA, was slightly diminished. 
Hamasaki et al., 2003 
May  
3 NMRI mouse 
model 
S or Core S siRNA: TTTGTTCAGTGGTTCGTAG(2096-2114)  
Core siRNA GCCTTAGAGTCTCCTGAGC(207-227) 
S siRNA inhibition of HBeAg and HBsAg serum expression.HBsAg: 70% reduction.  
Core siRNA inhibited HBeAg, but not HBsAg expression.HBeAg: 60% reduction.  
In contrast to the S siRNA, the effect of the Core siRNA on HBeAg was transient, and, 5 days after 
injection, HBeAg expression in the treated animals was approximately 70% of controls.  
Klein et al., 2003 Jul 
4 HepG2 cells Core NIL HBsAg: 92% reduction; HBeAg: 85% reduction  Tang et al., 2003 Aug 
5 HepAD38  
and HepAD79 
Core Core GACCTAGTCAGTTATG (2149-2168) Viral replication: 1.6 or 4 microg/ml siRNA caused 72% and 98% reduction for HepAD38, respectively;  
1.6 or 4 microg/ml siRNA caused 75% and 89% of viral replication for HepAD79 cells, respectively.  
HBV core protein synthesis was remarkably reduced. 
Ying et al., 2003 Sep 
6 HepG2.2.15 cells  P, Pre-C or S HBVPA siRNA ACCCTTATAAAGAATTTCC  
HBVPreC siRNA GCTGTGCCTTGGGTGGCTT  
HBVS siRNA TACCGCAGAGTCTAGACTC 
HBsAg: 78%, 67%, and 42% reduction for HBVPA, HBVPreC and HBVS treatment respectively;  
HBV mRNA: 86% reduction for HBVPA siRNA treatment;  
HBV core-associated DNA level: 71% reduction for HBVPA siRNA treatment 
Konishi et al., 2003 Oct 
7 HepG2 cells P, DR, S,  
Core or X 
PreS and P siRNA  
GACTACTGCCTCACCCATA (99-117)  
GACTTCAACCCCAACAAGG (2979-2997)  
S and P siRNA 
CATGGAGAGCACAACATCA(157-175)  
GACTACCAAGGTATGTTGC (451-469)  
CGTTTCTCCTGGCTCAGTT (660-678) 
GTTATATGGATGATGTGGT (736-754)  
X and the DR2 and DR1 
siRNA TTCACCTCTGCACGTCGCA (1592-1610)  
TTCACCTCTGCCTAATCAT (1826-1844)  
X siRNA GACCTTGAGGCATACTTCA (1694-1712)  
Core and P siRNA   
ATGCCCCTATCTTATCAAC (2310-2328) 
HBV mRNA: reduction up to 90%;  
HBV replication: drop by 90-97% by S and P siRNA, X siRNA, Core siRNA or  
DR siRNA  treatment 
Chen et al., 2003 Nov 
8 HepG2 cells,  
2.2.15 cells  
and a mouse 
model 
S siRNA-1 CATCACATCAGGATTCCT (9-27)  
siRNA-2 CCTCCAATCACTCACCAAC (168-186) 
siRNA-3 CCAGTACGGGACCATGCAA (346-364)  
siRNA-4 TACCTATGGGAGTGGGCCT (479-497)  
siRNA-5 GTCTGTACAGCATCGTGAG (610-628) 
siRNA-1 gave best inhibition. HBsAg and HBeAg: >80% drop in 2.2.15 cells for siRNA-1treatment;  
Co-injection of pHBV with siRNA-1 caused a strong reduction in all HBV DNA species to undetectable  
levels in a mice model 
Giladi et al., 2003 Nov 
9 HepG2.2.15 cells  not clearly  
stated 
not clearly stated HBsAg: 44% reduction Liu et al., 2004c Jul 
10  HuH-7 cells  S ,P, or Core si-HBV1(310-328), si-HBV2 (1868-1886)  
and si-HBV3 (2373-2391) 
pSi-HBV1 was most potent. HbsAg:86% reduction;  
HBeAg: 83% reduction;pSi-HBV1 and pSi-HBV2 were much more efficient  
Zhang et al., 2004 Oct 
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with over 90% reduction in viral RNAs. 
11 AD293 cells  S NIL HBs-EGFP: reduction by 69.8%; HBs-EGFP mRNA: reduction by 74.6% Yang et al., 2004 Sep 
12 HepG2.2.15 cells  Core NIL HBsAg: no inhibition; HBeAg: no inhibition Cai et al., 2004 Sep 
13 HepG2.2.15 cells  Core NIL HBV replication: effectively inhibited in a dose-dependent manner Zhu et al., 2004 Sep 
14 HBV transgenic 
mouse model 
S or Core  HBV225(225-243) HBV546(546-564)  
HBV765(765-783) HBV1036(1036-1064)  
HBV1681(1681-199) 
HBsAg:5- to 6-fold less in serum after shHBV546- or the 
shHBV765-expressing adenovirus treatment 
Uprichard et al., 2005 
Jan 
15 HepG2.2.15 cells  S, P or Pre-C NIL HBsAg and HBeAg and the replication of HBV: specifically inhibited in a dose-dependent manner;  
combination of siRNAs targeting various regions could inhibit HBV replication and antigen expression  
in a more efficient way 
Chen et al., 2005 Apr 
16 293T.HBs cells  
and HepG2.2.15 
cells 
S pSuper1 GGTATGTTGCCCGTTTGTC (460-478) 
pSuper4 TGTCAACGACCGACCTTGA (1683-1701) 
pSuper5 CATCACATCAGGATTCCTA (165-183)  
pSuper6 GAATCCTCACAATACCGCA (227-245) 
pSuper7 TCCTCACAATACCGCAGAG (230-248)  
pSuper8 TACCGCAGAGTCTAGACTC (239-257) 
pSuper9 CTACCGTGTGTCTTGGCCA (290-308)  
pSuper10 TCACTCACCAACCTCCTGT (333-351) 
pSuper11 CCTCCTGTCCTCCAACTTG (344-362)  
pSuper16 TTCCTATGGGAGTGGGCCT (637-655) 
pSuper17 GTCTGTACAGCATCTTGAG (767-785)  
pSuper27 TATACATCGTTTCCATGGC (1362-1380)
pSuper30 TCATCTCTTGTTCATGTCC (1841-1859) 
HBsAg: knockdown by approximately 90%, Moore et al., 2005 Jul 
17 HuH-7 cells  
and mouse model 
S or X pSuper/HBVS1 
GGTATGTTGCCCGTTTCTC(456-476) 
pSuper/HBVX1 (1396-1406) 
HBsAg:>90% reduction;  
HBeAg:>50% in cell system.  
Serum HBsAg in mice: reduction by over 99% with pSuper/HBVS1 treatment 
Wu et al.,  2005a Mar 
18 HeLa cells  
and HepG2.2.15  
cells 
S  NIL HBs-EGFP: reduction by 63.3%;  
HBs mRNA: reduction by 75.6% 
Zhou et al., 2005 May 
19 mouse model large S or P large S and P GGACTTCTCTCAATTTTCT(263-281) HBV DNA and HbsAg in serum: >3 log(10) decrease in levels of serum; 
liver HBV RNA:>3 log(10) decrease 
Morrissey et al., 2005 
Jun 
20 mouse model Core  NIL HBsAg: negative in the interference group  
HBcAg expression in liver: negative in the interference group 
Wu et al., 2005c Mar 
21 HepG2.2.15 cells Different  
regions of  
HBV genome 
NIL HBsAg: inhibited by 80% and 90% with 80 nmol/L single siRNA treatment and 
20 nmol/L combined siRNAs treatment, respectively;  
HBeAg: inhibited by about 60% with single siRNA treatment, and the inhibition didn’t increase much in the 
case of combined siRNAs treatment;  
HBV replication: inhibited by 90% with 80 nmol/L single siRNA treatment or 20 nmol/L combined siRNAs 
treatment.  
Ye et al., 2005 Apr 
22 Bel-7402 cells  
and HepG2.2.15  
cells 
S or X S1 GCTCCCGCGTGTCTTGGCC  
S2 GGTGGACTTCTCTCAATTT  
S3 GCCAAAATTCGCAGTCCC  
S4 GTTGCTGTACCAAACCTT  
S5 GCTCAGTTTACTAGTGCCA  
X1 GCACTTCGCTTCACCTCTG  
X2 GCAATGTCAACGACCGACC  
X3GTTTAAAGACTGGGAGGAG 
HBsAg: reduction by 83.7% by dual siRNA treatment;  
HBx: reduction by 87.5% by dual siRNA treatment;  
HBV core associated DNA: significantly reduced  
Wu et al., 2005b Sep 
23 mouse model  S,P or X S and P GGACTTCTCTCAATTTTCT (263-281)  
X GCACTTCGCTTCACCTCTC (1583-1601) 
serum HBV DNA: reduction by >1.0 log(10) Morrissey et al., 2005b 
Aug 
  110
24 HepG2.2.15 cells P or X P1 AACCTCAATGTTAGTATTCCT(p133) 
P2 AACATGGAGAACATCACATCA(p1028)  
P3 AACATCACATCAGGATTCCTA(p1037)  
X1 –AATGTTGCCCAAGGTCTTACA(x261)  
X2 AAGAGGACTCTTGGACTCTCT(x283)  
X3 AACGACCGACCTTGAGGCATA(x312) 
HBsAg: inhibited by 86%;  
HBeAg: inhibited by 91%;  
HBV DNA: restrained by 3.28-fold 
Ren et al., 2005 Oct 
25 HuH-7 cells  
and mouse model 
S HBsAg-1 CCTGCACGACTCCTGCTCATT(524-542)  
HBsAg-2 TACCTATCCCAGTGGGCCTTT(637-655)  








HBsAg-8 GTCCTCTAATTCCAGGATCTT(476-494)  
HBsAg-9 GCCTCATCTTCTTATTGGTTT(425-443)  
HBsAg-10 CCTCCAATCACTCACCAACTT(326-344) 
HBsAg: strong inhibition in HuH-7 cells by HBsAg-3, 7, 9, and 10 shRNAs;  
serum HBsAg: completely inhibited by HBsAg-3 shRNA in the mouse model 
Chen et al.,2005b Oct 
26 mouse model Core NIL HBcAg: reduced to 0.9% +/- 0.1%, compared with 5.4% +/- 1.2% of positive hepatocytes in infecting 
group;  
HBV C mRNA: reduced by 84.7% 
Wu et al., 2005d Oct 
27 HepG2.2.15  Core, P or S Not clearly stated siRNA-1 and siRNA-7 altered the expression of 54 and 499 genes, respectively. 
18 of these genes were suppressed by both siRNA-1 and siRNA-7.  
7 of these genes were originally activated by HBV. 
Guo et al., 2005 Nov 
28 HepG2.2.15 cells  
and animal model 
S S1 siRNA 324–344; S2 siRNA 542–562; S3 siRNA 
591–611  
HBsAg, transcription of HBV and viral DNA copy numbers: reduction by 50-70% in 2.2.15 cells by Ts2 
siRNA treatment.  
Efficiency of inhibition by Methyl-modified small interfering RNA was lower but could last longer.In the 
mouse model, inhibition rates were approximately 80-90 %.  
Peng et al., 2005 Dec 
29 HepG2.2.15 cells S  NIL HBsAg:decreased by 75%, 82%, 89%;  
HBeAg: decreased by 32%, 38%, 43%; 
HBV DNA production: decreased by 30%, 43%, 49%;  
The HBV mRNA: reduced by 30%, 70%, 90% when transfected with 1 microg, 2 microg, 4 microg HBV 
S-siRNA, respectively.  
Zhu et al., 2005 Sep 
30 HepG2.2.15 cells P NIL Transfection efficiency:30% to 40%;  
HBsAg: reduction by up to 32.28%; 
HBeAg: reduction by up to 38.33%  
Normalized against transfection efficiency: the actual inhibitory rate of HBV antigen secretion  
might reach 80% and over. 
Liu et al., 2005b Nov  
31 Bel-7402 cells NIL NIL HBV pre-c/c gene expression: decreased by 81.9% and 87.3%, respectively  
when Bel-7402 cells were treated by two SECs that expressed siRNAs;  
HBV DNA; decreased by 83.5% and 85.2% in HepG2.2.15 cells, respectively.  
Wu et al., 2005e 
32 mouse model Core NIL In the mice model, the siRNA effectively inhibited HBV replication and expression.  
The inhibitive effect of siRNA on HBV lasted at least 3 days 
Ying et al., 2006 Jan 
33 PLC/PRF/5 cells X X1 CGCCCACCGAATGTTGCCC (X255-274)  
X2 GAGGACTCTTGGACTCTCT(X285-294) 
HBx mRNA and protein levels: reduction by 50-95%;  
RNAi targeting HBx in PLC/PRF/5 cells demonstrated significant reduction in cell proliferation, cell 
growth, anchorage-independent growth in soft agar, and tumour development in nude mice. 
Chan et al., 2006 Feb 
34 Cells and animal 
model 
esiRNAs 
targeting all of 
the four ORFs of 
HBV genome  
dsRNA digested by E. coli Rnase III In vitro experiment showed that esiHBVP suppressed HBsAg expression most effectively. 
A single dose of 1 microg esiHBVP was able to reduce HbsAg and HbeAg level in the mouse  
serum by 90% and 89% one day after injection, while the same amount of chemically synthesized  
siRNA only reduced that by 33 and 45%. 
A single dose of 1 microg esiHBVP was able to reduce HbsAg and HbeAg level in the mouse serum  
by 90 and 89% one day after injection, while the same amount of chemically synthesized siRNA  
only reduced that by 33% and 45%.  
Xuan et al., 2006 Jun 
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35 HuH-7 cells and 
animal model 
X HBx-1 GAGGACTCTTGGACTCTCA (1655-1674)  
HBx-2 TGTCAACGTCCGACCTTGA (1678-1697)  
HBx-3 GTCCGACCTTGAGGCATA (1684-1703)  
HBx-4 TGATCTTTGTACTAGGAGG (1759-1778)  
HBx-5 ATTGGTCTGTTCACCAGCA (1790-1809)  
HBsAg: decreased by 97% and 94% by pRNAiDu-HBx1 and pRNAiDu-HBx3 transfection, respectively.  
Viral antigen expression: in vivo, inhibited by over 90%. 
Shin et al., 2006 Aug 
36 HepG2.2.15 cells siRNA targeting 
all 4 transcrips 
close to the polyadenylation HBsAg: reduced by up to 96.1%;  
HBeAg: reduced by up to 88.3%;  
HBV 3.5 and 2.4/2.1-kb mRNA: reduced by 78 and 89%, respectively;  
viral replication: reduced by up to 12.8-fold;  
Most importantly, this suppression effect persists after 30 passages. 
Ren et al., 2006a Apr 
37 HepG2.2.15 cells Core Core siRNA (492) The expressed shRNA targeting HBV C mRNA in 492i, has most efficient RNAi effect. 
tRNAval Pol III-shRNA expression cassettes produced by one-step overlapping extension  
PCR strategy is useful for identification of optimal siRNA 
Pan et al., 2006 Mar 
38 HBV-producing 
human liver cells  
X NIL HBx mRNA: reduced by up to 80-90% in HBx-transformed and HBV-producing human liver cells Kim et al., 2006 Jul 
39 HepG2.2.15 cells X X (1649 to 1667) HBsAg: inhibited by 28.5% and 38.67% at 48h and 72h after pGenesil-HBV X transfection, respectively; 
HBeAg: inhibited by 32.2% and 42.86% at 48 h and 72 h after pGenesil-HBV X transfection, respectively 
Zhao et al., 2006 Oct 
40 HepG2-N10  S, X or Core NIL HBsAg: reduced by 53% by pS, 70% by pX , and 75% by pC; 
HBeAg: reduced by 43% by pX and 34% by pC;  
HBV mRNAs: effectively degraded by pS and pC;  
HBV DNA: inhibited by pS, pX and pC  
Ren et al., 2006b 
41 HBV transgenic 
mouse model 
Core, S or  
Pre-C 
Core siRNA GCCTTAGAGTCTCCTGAGCTT  
S siRNA GGTATGTTGCCCGTTTGTCTT  
Pre-C siRNA TCATGTCCTACTGTTCAAGTT 
HBV load in mouse circulation: up to 2-3log(10) decrease for at least 120 days  
by shRNA delivered by double-stranded adeno-associated virus 8-pseudotyped vector (dsAAV2/8)  
Chen et al., 2007 Jan 
42 HepG2.2.15 ells 
and a mouse 
model 
S or Core S siRNA CATCACATCAGGATTCCTAAA (S9-S27)  
Core siRNA  
CTAATGACTCTAGCTACCTAA (C193-C211) 
HBsAg: reduced by >80% in cell culture and >90% in mouse serum; 
HBeAg: significantly inhibited.  
Intracellular HBcAg: reduced by 76%.  
HBsAg-positive cells in the liver tissues by immunohistochemical detection: not detected.  
HBcAg-positive cells: >70% reduction for shRNA-1 and substantial reduction for shRNA-2;  
Viral mRNA: significantly inhibited;  
HBV DNA:reduced by >40% for shRNA-1 and >60% for shRNA-2 
Ying et al., 2007 Jan 
43 PLC/PRF/5 and 
HepG2.2.15 cells 
S S1 siRNA GGUAUGUUGCCCGUUUGUC(458-476)  
S2 siRNA CCUCCAAUCACUCACCAAC(324-342) 
C  siRNA GATCTCAATCTCGGGAATC 
(2432-2450) 
X  siRNA ATTGGTCTGCGCACCAGCA  
(1795-1813) 
Transfection efficiency: > 95% for PLC/PRF/5 cells and 74±9% for 2.2.15 cells;  
HBsAg: for PLC/PRF/5 cells, inhibition of 95.7±0.8% for S1 and 96.3±0.3% for S2, respectively.  
For 2.2.15 cells, decrease of 59.6±7.1% and 71.8±3.3% for S1 and S2;  
HBV mRNA: for PLC/PRF/5 cells, decrease of 74.3±5.3% and 91.5±3.3% by S1 and S2 respectively 
and for 2.2.15 cells, decrease of 54.9±9.0% and 74.8±4.2% by S1 and S2 respectively   
Viral DNA: decreased by 56.7±2.8% with S1 and by 68.0±1.9% with S2;  
Specificity of siRNA treatment: only 3 common genes (of unknown functions) were identified as  
differently expressed genes in both PLC/PRF/5 and 2.2.15 cells following siRNA treatment 
HBsAg: for 2.2.15 cell, decrease by 15% by C siRNA, decrease by 30% by X siRNA 
Li et al., 2004 Aug 
 
S: HBsAg; Core: HBcAg; X: HBxAg; P: Polymerase 
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All the 4 ORFs of HBV genome have been targeted by either chemically synthesized 
siRNAs or siRNAs expressed by vectors in both cells and mouse models. The efficacy 
ranged from about 30% to 95% in terms of inhibition of HBV gene expression or HBV 
viral replication (Table. 4.5). S-ORF is one of the most effective targets of siRNA as 
shown by us and by other researchers. siRNAs targeting S-ORF could lead to almost 
complete shutdown of HBV gene expression and strong suppression of viral replication.  
 
We were among the first groups who researched on siRNA’s effect on HBV. At the 
beginning of the project, besides siRNAs targeting S-ORF, we also designed siRNAs 
targeting Core-ORF or X-ORF. But they were not as effective as siRNAs targeting S-ORF 
in terms of inhibition of HBsAg expression (as shown in Table. 4.5). For siRNAs targeting 
Core-ORF, some other researchers observed similar results. They found that siRNAs 
targeting Core-ORF might not be able to suppress HBsAg expression (Shlomai and Shaul, 
2003; Klein et al., 2003; Cai et al., 2004). One possible reason is that siRNAs targeting 
Core-ORF can only interfere with the 3.5kb HBV transcript and HBsAg could be 
expressed by other HBV transcripts (2.1kb/2.4kb). Theoretically, siRNAs targeting 
X-ORF can interfere with all the HBV transcripts. Thus X-ORF holds the potential as an 
optimal targeting site. From Table 4.5, we found that the effects of this group of siRNAs 
varied from 28.7% to 97%. The difference in efficacy could be due to design of siRNA. In 
this study, both S1 and S2 siRNAs targeting S-ORF showed very good inhibition of HBV 
gene expression and viral replication. Together with other researcher’s findings, we 
conclude that S-ORF may hold the potential as a therapeutic target for HBV infection.
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4.6 Conclusion 
In summary, siRNAs can potently inhibit the expressions of HBV genes and viral 
replication both in vitro and in vivo as shown by us and the other groups (Shlomai and 
Shaul, 2003; Hamasaki et al., 2003; Tang et al., 2003; Ying et al., 2003; Konishi et al., 
2003; McCaffrey et al., 2003b; Giladi et al., 2003; Morrissey et al., 2005). In addition, as 
shown in our study, siRNAs targeting HBV S ORF did not cause any off-target gene 
regulation nor did it affect cell growth and proliferation. All the observations indicate that 
the inhibition of HBV gene expression and viral replication induced by siRNAs is potent 
and specific. However, in order to develop siRNA-based therapeutics some issues, such as 


















Chapter V  











As the sixth most common cancer, HCC is a global health problem (Parkin et al., 2005). 
Although HCC has well-defined risk factors, the development of HCC is poorly 
understood. Current diagnostic and therapeutic approaches are far from satisfactory. 
miRNAs have been shown to be implicated in several types of human cancers, including 
CLL (Calin et al., 2002, 2005), colorectal neoplasia (Michael et al., 2003), lung cancer 
(Hayashita et al., 2005), breast cancer (Iorio et al., 2005), glioblastoma (Chan et al., 2005) 
and thyroid papillary carcinomas (Pallante et al., 2006).  
 
In this part of our study, we aim to identify miRNAs that are deregulated in HCC and 
cirrhotic liver. 10 pairs of clinical liver samples (tumor vs. non-tumor) were used for 
mature miRNA profiling based on RT-real-time PCR. The most frequently upregulated 
miRNAs were then screened in a larger number of samples (sample size = 56). The 
miRNA-106b-25 cluster was selected for more detailed investigation and this includes the 
examination of the expression of pri- and pre- forms and the examination of the expression 
of this cluster in cell lines. In addition, work was also carried out to examine the possible 
functions of some of these deregulated miRNAs, including their possible roles in cell 






5.2 miRNA Expression in Livers 
miRNA expression profiling was carried out in paired clinical samples (tumor vs. 
non-tumor) and miRNAs that are deregulated in HCC were identified. 
 
5.2.1 Choice of Patient Samples and Validation of RT-real-time 
PCR Approach 
5.2.1.1 Selection of patient RNA samples  
Surgical liver tumor tissues and the surrounding non-tumor tissues were obtained from 56 
HCC patients. In order to minimize the difference caused by gender and race, 10 pairs of 
clinical samples from Chinese male patients with HBV infection were chosen for miRNA 















Table 5.1 Clinical information of patients. 
NO Diagnosis Aetiology Cirrhosis TNM Age sex Race 
126 Poorly differentiated HCC HBV + T3 N0 M0 stage IIIA 53 M Chinese 
127 Moderately differentiated HCC HBV - T4 N0 M0 stage IVA 52 M Chinese 
155 Poorly differentiated HCC HBV + T4 N0 M0 stage IVA 63 M Chinese 
156 Moderately differentiated HCC HBV - T3 N0 M0 stage IIIA 53 M Chinese 
160 Poorly differentiated HCC HBV + T3 N0 M0 stage IIIA 56 M Chinese 
187 Poorly differentiated HCC HBV + T3N0M0 61 M Chinese 
193 Moderately differentiated HCC HBV - T4N0M0 38 M Chinese 
196 Moderately differentiated HCC HBV + T3N0M0 40 M Chinese 
233 Poorly differentiated HCC HBV - T1NXMX 53 M Chinese 
246 well differentiated HCC HBV - T2NXMX 54 M Chinese 
TNM: Tumor, Node, Metastases staging system. 
 
5.2.1.2. Quality of RNA preparations 
High quality RNA is essential for obtaining good real-time PCR results. The most 
important prerequisite for any gene expression analysis experiment is consistent, 
high-quality RNA from every experimental sample. Therefore, the sample handling and 
RNA isolation procedures are critical to the success of the experiment. Total RNAs were 
isolated using TRIzol following the protocol described in the manufacturer’s manual. The 
quality of the RNAs was evaluated by two criteria:  
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1) RNA purity by UV Spectrophotometry. Good quality RNA will have an OD 260/280 
ratio of 1.8 to 2. This is because nucleic acid is detected at 260 nm, whereas protein, salt 
and solvents are detected at 230 and 280 nm. A high OD 260/280 ratio therefore indicates 
that the extracted RNA is devoid of any of these contaminants. Because the spectral 
properties of nucleic acids are highly dependent on pH, OD 260/280 ratio should be 
measured in 10 mM Tris-Cl buffer with a pH of 7.5. As shown in Table 5.2, for all the 




Table 5.2 Ratios of absorbance 260/280 for the 10 pairs of HCC samples. 
Sample 126NT 127NT 155NT 156NT 160NT 187NT 193NT 196NT 233NT 246NT 
260/280 1.95 1.96 1.93 1.89 1.94 1.94 1.92 1.83 1.86 1.81 
Sample 126T 127T 155T 156T 160T 187T 193T 196T 233T 246T 
260/280 1.89 1.96 1.95 1.94 1.92 1.92 1.91 1.86 1.90 1.89 
N: non-tumor; T: tumor 
 
2) Ribosomal RNA band integrity. The overall quality of an RNA preparation may be 
assessed by electrophoresis on a denaturing agarose gel. Intact total RNA ran on a 
denaturing gel will have sharp 28S and 18S rRNA bands (for eukaryotic samples). The 
28S rRNA band should be approximately twice as intense as the 18S rRNA band. This 2:1 
ratio (28S:18S) is a good indication that the RNA is intact. Partially degraded RNA will 
have a smeared appearance, or will not exhibit a 2:1 ratio. Figure 5.1 shows the RNA 
samples that were separated on formaldehyde denaturing agarose gel. Two major sharp 
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bands with a nearly 2:1 ratio (28S:18S) were seen for all the samples, indicating the 
integrity of RNA samples. 
 
 
5.2.1.3 Validation of RT-real-time PCR approach to quantify the 
expression of pri- and pre-miRNAs 
As described in section 3.2.2.5, the expressions of pri- and pre-miRNAs were examined 
by SYBR Green-based RT-real-time PCR as previously described by Thomas and 
coworkers (Thomas et al., 2004). This RT-real-time PCR method would amplify both 
precursors (the pre-miRNA and the pri-miRNA) in one assay. SYBR Green specifically 
binds double-stranded DNA by intercalating between base pairs, and fluoresces only when 
bound to dsDNA. Detection of the fluorescent signal occurs during the PCR cycle at the 
end of either the annealing or extension steps when the greatest amount of double-stranded 
DNA product is present. However, SYBR Green detects any double-stranded DNA 
126NT  126T  127NT 127T  156NT  156T  160NT  160T 
187NT  187T  193NT 193T  196NT  196T  233NT  233T 
155NT  155T  246NT  246T 
Figure 5.1 Separation of RNA on 1.2% formaldehyde denaturing agarose gel. 1μg total RNA 
was loaded per lane. High quality RNA preparation was demonstrated by the sharp bands for the 








non-specifically. Therefore, PCR reactions using this detection method must generate 
single, gene-specific amplicons without the co-amplification of non-specific secondary 
products. SYBR Green detection allows for checking the specificity of the PCR using 
dissociation curves (also known as melting curves). After 40 reaction cycles, a 
temperature ramp is performed. At low temperature, the PCR DNA product is double 
stranded, and it binds SYBR Green, which fluoresces. With increasing temperature, the 
DNA product melts or dissociates becoming single stranded, releasing SYBR Green and 
decreasing the fluorescent signal. Most real-time instruments usually plot melting curves 
as a first derivative. The inflection point in the melting curve then becomes a peak. A 
single peak indicates that there is a single product, while multiple peaks usually indicate 
multiple products. These other products may be primer dimers, genomic DNA 
contamination, or amplification of splice variants. As shown in Figure 5.2 A, each of the 
four dissociation curves displayed one single sharp peak, showing that only one single 
PCR product was generated during one real-time PCR reaction. 
 
In addition, the SYBR Green-based RT-real-time PCR approach was further verified 
through characterization of the product by agarose gel electrophoresis. PCR products were 
separated by 2% agarose gel electrophoresis and visualized under UV light by ethidium 
bromide staining. As shown in Figure 5.2B, only one single sharp band was seen for each 
RT-real-time PCR reaction, demonstrating that only one PCR product was generated 
during PCR amplification. The sizes of PCR products for the 5S rRNA, the precursors of 
miR-106b, the precursors of miR-93 and the precursors of miR-25 are 71 bp, 60 bp, 61 bp 
and 68 bp respectively. The sizes were consistent with what was predicted, indicating that 
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Figure 5.2 Examination of the specificity of reactions for the SYBR Green based RT-PCR method. 
The SYBR Green based detection method uniquely permits a check of the reactions’ specificity. A. 
Dissociation curves generated during the SYBR Green based detection method. Dissociation curves: 1. 
5S rRNA 2. pri-and pre- miR-106b 3. pri-and pre- miR-93 4. pri-and pre- miR-25. In each case, the 
curve contains only one peak indicating that the reaction generates only one specific PCR product. B. 
2% Agarose gel electrophoresis. It confirms the results of the melting curve by demonstrating that each 




5.2.2 Deregulation of miRNAs Expressions in HCC 
5.2.2.1 Mature miRNA expression profile 
In order to identify miRNAs which are differently expressed in HCC, RT-real-time PCR 
was performed to examine miRNA expression profiles of 10 paired tumor and non-tumor 
samples using TaqMan MicroRNA Assays Human Panel - Early Access Kit. 
 
The relative quantity of the mature form of each miRNA was calculated as described in 
materials and methods section 3.2.2.3. For the non-tumor tissues, 5 were cirrhotic and the 
other 5 were not cirrhotic. Thus, the profiling enabled us to search for miRNAs that may 
be differently expressed in tumor vs non-tumor tissues and in cirrhotic vs non-cirrhotic 
tissues. In order to facilitate data presentation, the relative quantities of miRNAs in 10 
pairs of HCC samples (tumor vs. non-tumor) were median-centered and hieratically 
clustered in both dimensions and then plotted in a heatmap by Cluster 2.0 and TreeView 
1.6 (Figure 5.3).  
 
As shown in Figure 5.3, most of the tumor samples (T) are clustered into one group while 
most of the non-tumor samples (NT) are clustered into another group. Thus, our results 


























Figure 5.3 Heatmap of miRNA expression profiling of tumor (T) and paired non-tumor (NT) samples. 
Data obtained by RT-real-time PCR were median-centered and hierarchically clustered in both 
dimensions and then plotted in a heatmap by Cluster 2.0 and TreeView 1.6. Red represents high 




5.2.2.1.1 Identification of miRNAs that are deregulated in HCC 
miRNAs that were upregulated >= 2 fold or downregulated >=50% in at least 5 out of 10 
tumors were selected. The expression profiles of the tumor samples showed that of the 157 
miRNAs examined, 28 were upregulated while 14 were down regulated (Table 5.3).  
 
Table 5.3 miRNAs that were deregulated in HCC. 
miRNA Number 
(out of 10) 
miRNA Number 
(out of 10) 
miRNA Number 
(out of 10) 
Upregulated   Upregulated  Downregulated  
miR-17-3p 5 miR-132 5 miR-23a 5 
miR-17-5p 6 miR-135a 7 miR-99a 6 
miR-19a 6 miR-141 5 miR-100 5 
miR-20a 6 miR-151 5 miR-122a 6 
miR-92 6 miR-155 6 miR-125b 5 
miR-25 5 miR-182 9 miR-130a 5 
miR-9 5 miR-187 6 miR-134 6 
miR-15a 5 miR-221 7 miR-199a 5 
miR-15b 7 miR-222 6 miR-199a* 5 
miR-21 6 miR-224 10 miR-199-s 5 
miR-34a 6 miR-301 5 miR-200a 7 
miR-106a 7 miR-324-5p 5 miR-200b 6 
miR-107 5 miR-330 5 miR-214 7 
miR-130b 5 miR-339 5 miR-223 5 
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5.2.2.1.2 miRNA expression in cirrhotic liver samples 
The non-tumor tissues used for miRNA expression profiling can be grouped into two 
categories: cirrhotic and non-cirrhotic. A comparison of the expressions of 157 miRNAs 
in cirrhotic livers to their expressions in non-cirrhotic livers was carried out in this study. 
However, independent t test did not identify any miRNA of which the expression level in 
cirrhotic livers is significantly different from its expression level in non-cirrhotic livers. In 
order to examine if miRNA profiling can differentiate cirrhotic samples and non-cirrhotic 
samples, only the data obtained from 10 non-tumor tissues were used for clustering. The 
heatmap was drawn as described in section 5.2.2.1 (Figure 5.4). The heatmap showed that 
samples were not clustered nicely into two clusters. The cirrhotic samples interspersed 
with the non-cirrhotic samples. Our result suggests that miRNA expression profiling 
might not be able to differentiate cirrhotic samples from non-cirrhotic samples. However, 
the number of samples used is small and not all the known miRNAs are included in the 




















Figure 5.4 Heatmap of miRNA expression profiling of cirrhotic (C) and non-cirrhotic (NC) samples. 
Data obtained by RT-real-time PCR were median-centered and hieratically clustered in both 
dimensions and then plotted in a heatmap by Cluster 2.0 and TreeView 1.6. Red represents high 
miRNA expression, while Green represents low miRNA expression. NT: non-tumor. NC: non-cirrhotic. 
C: cirrhotic.  
 
  127
5.2.2.2 Confirmation of the deregulation of miRNAs in 56 pairs of HCC 
samples 
The profiling is based on miRNA expressions in 10 pairs of HCC samples. For most of the 
deregulated miRNAs, their expressions are enhanced. Thus, we focused our attention on 
the upregulated group. A series of the upregulated miRNAs was selected and screened in 
more paired HCC samples (sample size = 56). They are miR-15b, miR-25, miR-135a, 
miR-182, miR-221, miR-222 and miR-224. We noted that miR-25 is a member of the 
miR-106b-25 cluster (Fig 5.5). The other two members are miR-106b and mir-93. Thus, 
these two miRNAs together with the other most frequently upregulated miRNAs were also 
analyzed in 56 pairs of samples. The percentages of HCC tumors among which miRNAs 
were upregulated >= 2 fold are summarized in Table 5.4. For miR-15b, the upregulation 
was detected in 46% of HCC samples. For all the other screened miRNAs, the significant 
upregulation was found in more than 50% of HCC samples. Further paired t-test 
confirmed the upregulation of the expression of these 9 miRNAs in HCC. We considered 






Figure 5.5 Schematic illustration of the miR-106b-25 cluster. This cluster is located on chromosome 7. 
Three miRNAs are encoded by this polycistronic miRNA cluster. They are miR-106b, miR-93 and 
miR-25 respectively. Blue boxes represent the locations of the sequences that encode pre-miRs and red 






miR-106b miR-93 miR-25 
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Table 5.4 Upregulation of the mature forms of miRNAs.  
miRNAs Percentage p-value 
miR-15b 46 <0.01 
miR-106b 52 <0.01 
miR-93 55 <0.01 
miR-25 52 <0.01 
miR-135a 64 <0.01 
miR-182 68 <0.01 
miR-221 66 <0.01 
miR-222 66 <0.01 
miR-224 66 <0.01 
 
Upregulation of the mature forms of 9 miRNA in 56 pairs of surgical liver tissues (tumor 
vs. non-tumor). The percentages of the samples with greater than 2 fold upregulation of 
the miRNAs are shown. None of these miRNAs were downregulated. 
 
We detected the upregulation of miR-17-3p, miR-17-5p, miR-19a, miR-20a, and miR-92 
by doing miRNA expression profiling in 10 paired surgical liver tissues. These miRNAs 
are encoded by the miR-17-92 cluster, a well characterized polycistronic microRNA 
cluster which has been shown to be upregulated in lung cancer and several types of 
lymphoma (Hayashita et al., 2005; He et al., 2005a; O’Donnell et al., 2005). As shown in 
Table 5.3 and Table 5.4, we also detected the upregulation of miR-25 as well as the other 
two members of the miR-106b-25 cluster. The miR-106b-25 cluster is homologous to the 
miR-17-92 cluster (Tanzer and Stadler, 2004). It’s possible that, like the miR-17-92 
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cluster, the miR-106b-25 cluster might also play an important role in cell growth and 
proliferation. Therefore, the miR-106b-25 cluster was selected for further investigation. 
 
5.2.2.3 Upregulation of the expression of the miRNA-106b-25 cluster in 
HCC   
RT-real-time PCR was performed to examine the expressions of both the mature forms 
and pri- and pre- forms of the three members of the miRNA-106b-25 cluster in 56 paired 
tumor and non-tumor samples. The relative quantity of each miRNA was calculated as 
described in section 3.2.2.5. The percentages of HCC tumors among which miRNAs were 
upregulated >= 2 fold were calculated (Table 5.5). For the mature forms, all the three 
miRNAs were upregulated by at least 2 fold in more than 50 percent of tumor samples. 
Similarly, for the pri- and pre-forms, the upregulation of all the three miRNAs was 
significant. The percentages were 61%, 46% and 48% for the precursors of miR-106b, 
miR-93 and miR-25 respectively. Further paired t-test confirmed the upregulation of the 


















Table 5.5 Upregulation of the pri-and pre- forms and the mature forms of the mir-106b-25 cluster.  
miRNAs Percentage p-value 
pri- and pre- miR-106b 61 <0.01 
pri- and pre- miR-93 46 <0.01 
pri- and pre- miR-25 48 <0.01 
mature miR-106b 52 <0.01 
mature miR-93 55 <0.01 
mature miR-25 52 <0.01 
 
Comparison of the pri-and pre- forms and the mature forms of the mir-106b-25 cluster in 
56 pairs of surgical liver tissues (tumor vs. non-tumor). 
 
5.2.2.4 Upregulation of the expression of the miRNA-106b-25 cluster in 
HCC cell lines   
We also extended the analysis of the miRNA-106b-25 cluster to cell lines and primary 
hepatocytes. Total RNAs were extracted using TRIzol according to the manufacturer’s 
protocol. The expression of this cluster in primary human hepatocytes, HCC cell lines and 
HeLa cells were examined using RT-real-time PCR and the relative quantities of the 
miRNAs were calculated as described in section 3.2.2.4 and 3.2.2.5. 
 
For the mature forms, all the three miRNAs were upregulated by ~ 4-13 fold in all the 
HCC cell lines (HepG2, Huh7 and 2.2.15) compared to their expressions in cultured 
human primary hepatocytes (Figure 5.6B). As expected, for the pri- and pre-forms, the 
upregulation of all the three miRNAs was also significant in all three HCC cell lines. The 
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upregulation was about 2-10 fold as shown in Figure 5.6A. One-way ANOVA analysis 
confirmed the upregulation of the expression of the miRNA-106b-25 cluster in HCC cell 
lines compared to in primary hepatocytes. We considered p-value <0.05 as significant. 
 
The 2.2.15 cell line was derived from the HepG2 cell line. These cells simulate the 
condition where liver cells are infected with Hepatitis B virus. Interestingly, compared to 
HepG2 cells, the expression of this miRNA-106b-25 cluster in 2.2.15 cells did not change 
very much (Figure 5.6A-B). It suggests that this miRNA cluster is not implicated in HBV 
replication and the expression of HBV-related genes.  
 
In addition, this miRNA cluster was also highly expressed in the cervical carcinoma cell 
line, HeLa. The expression levels of the three miRNAs in this cluster were comparable to 
their expressions in the HCC cell lines (Figure 5.6A-B). Therefore, HeLa cells were also 

























































































Figure 5.6 The expressions of the miRNA-106b-25 cluster in primary human hepatocytes, HCC cell 
lines and HeLa cells. (A) RT-real-time PCR analysis of the expressions of pri- and pre-miRNAs of the 
miRNA-106b-25 cluster. (B) RT-real-time PCR analysis of the expressions of mature forms of the 
miRNA-106b-25 cluster. Data shown are mean±SD based on three independent experiments.  




















5.3 Functions of Deregulated miRNAs 
5.3.1 Effects of the Deregulated miRNAs on Cell Growth 
As shown in Table 5.4, miR-182, miR-221, miR-222 and miR-224 and all the three 
members of the miR-106b-25 cluster are significantly upregulated in HCC. In this study, 
the effects of these miRNAs on cell growth and viability were first examined. The 
expressions of these were blocked by the introduction of the corresponding antisense 
2’-O-methyl- oligoribonucleotides (Anti-miR miRNA Inhibitors) as described in section 
3.2.2.6. A randomized Anti-miR molecule, Anti-miR Negative Control #1 was used as 
negative control in this study. Cell growth and proliferation were examined by MTS/PES 
assay. Because the miRNA-106b-25 cluster will be discussed in the next section, in this 
section we will only describe the results of other 4 miRNAs. 
 
Inhibition of most of the upregulated miRNAs led to decreased cell growth in both HepG2 
and HeLa cells. Treatment of HepG2 cells with Anti-miR-221 miRNA inhibitor or 
Anti-miR-224 miRNA inhibitors resulted in significant inhibition of cell growth and 
proliferation. The inhibition was 16.5±6.2% and 26.1±3.0% respectively (Figure 5.7A). 
Similarly, treatment of HeLa cells with Anti-miR-182 miRNA inhibitor, Anti-miR-221 
miRNA inhibitor, Anti-miR-222 miRNA inhibitors or Anti-miR-224 miRNA inhibitors 
resulted in significant decrease in cell growth and proliferation. The inhibition was 
19.4±2.8%, 39.3±4.8%, 21.3±2.0% and 29.7±4.8% respectively (Figure 5.7B). As 
expected, treatment of HepG2 and HeLa cells with the Anti-miR Negative Control #1 did 
not result in any inhibition. The inhibition was confirmed by one-way ANOVA analysis 






















































Figure 5.7 Effects of knockdown of some of the deregulated miRNAs by corresponding Anti-miR 
miRNA Inhibitors on cell growth and proliferation in (A) HepG2 cells and (B) HeLa cells. Cells were 
left untreated (U), or mock transfected with the transfection agent (M), or transfected with 50 nM 
Anti-miR Negative Control #1 (Neg 50), or 50 nM Anti-miR-182 miRNA Inhibitor (182), or 50 nM 
Anti-miR-221 miRNA Inhibitor (221), or 50 nM Anti-miR-222 miRNA Inhibitor (222), or 50 nM 
Anti-miR-224 miRNA Inhibitor (224). Examination of cell growth and proliferation was achieved 
using the MTS/PES assay. Cell growth and proliferation is proportional to the absorbance at 490nm. 
The A490 of mock transfected cells was set as 100%. Data shown represent mean ± SD (n=3).  
* p<0.05, ANOVA analysis, for comparison between M and the other treatments. 
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5.3.2 Effect of the miR-106b-25 Cluster on Cell Growth 
The expressions of miRNA-106b, miRNA-93 and miRNA-25 were blocked by the 
introduction of the corresponding antisense 2’-O-methyl- oligoribonucleotides (Anti-miR 
miRNA Inhibitors) individually or simultaneously as described in section 3.3.2.6. A 
randomized Anti-miR molecule, Anti-miR Negative Control #1 was used as a negative 
control. 
 
Inhibition of the miRNA-106b-25 cluster led to decreased cell growth in both HepG2 and 
HeLa cells. Treatment of HepG2 cells with Anti-miR-106b miRNA inhibitor alone or a 
mixture of all three Anti-miR miRNA inhibitors targeted against the miR-106b-25 cluster 
resulted in the significant inhibition of cell growth and proliferation. The inhibition was 
12.9±2.4% and 36.1±1.3%, respectively (Figure 5.8A). Similarly, treatment of HeLa cells 
with Anti-miR-106b miRNA inhibitor alone or a mixture of all three Anti-miR miRNA 
inhibitors resulted in significant decrease of cell growth and proliferation. The inhibition 
was 13.8±4.1% and 33.7±3.4% respectively (Figure 5.8B). As expected, treatment of 
HepG2 and HeLa cells with the Anti-miR Negative Control #1 did not result in any 
inhibition. The inhibition was confirmed by one-way ANOVA analysis and p-value <0.05 












































Figure 5.8 Effects of knockdown of the miR-106b-25 cluster by the corresponding Anti-miR miRNA 
Inhibitors on cell growth and proliferation in (A) HepG2 cells and (B) HeLa cells. Cells were left 
untreated (U), or mock transfected with the transfection agent (M), or transfected with 50 nM Anti-miR 
Negative Control #1 (Neg 50), or 150 nM Anti-miR Negative Control #1 (Neg 150), or 50 nM 
Anti-miR-106b miRNA Inhibitor (106b), or 50 nM Anti-miR-93 miRNA Inhibitor (93), or 50 nM 
Anti-miR-25 miRNA Inhibitor (25), or a mixture of 50 nM Anti-miR-106b miRNA, Anti-miR-93 and 
Anti-miR-25 miRNA Inhibitor (Mix). Examination of cell growth and proliferation was achieved using 
the MTS/PES assay. Cell growth and proliferation is proportional to the absorbance at 490nm. The 
A490 of mock transfected cells was set as 100%. Data shown represent mean ± SD (n=3).  




5.3.3 Effect of the miR-106b-25 Cluster on Anchorage-independent 
Growth  
Malignantly transformed cells will lose contact-inhibition during growth. There is a 
general correlation between the oncogenic potential of transformed cells in vivo and their 
ability to form colonies in an anchorage-independent manner in vitro. Therefore, HepG2 
and HeLa cells were treated with a mixture of Anti-miR miRNA Inhibitors targeted at the 
three members of the miR-106b-25 cluster and the tumorgenic potential was evaluated by 
colony formation assay in soft agar. Cells treated with Anti-miR Negative Control #1 were 
used as negative control. 
 
As determined by trypan blue staining, treatment of HepG2 cells and HeLa cells with 
Anti-miR miRNA Inhibitors for 4 hours did not affect cell viability (data not shown). For 
all the treatments, 100 viable cells were counted and seeded in soft agar. Colony formation 
assay showed that fewer colonies were formed for HepG2 cells treated with miRNA 
inhibitors compared to HepG2 cells treated with the same concentration of negative 
control miRNA inhibitor (Figure 5.9A). HepG2 cells treated with negative control miRNA 
inhibitor formed 42±2 colonies, while HepG2 cells treated with Anti-miR miRNA 
Inhibitors formed only 29±3 colonies. Compared to cells left untreated, cells treated with 
the miRNA inhibitor negative control did not significantly change anchorage-independent 
growth. The same pattern was also observed in HeLa cells (Figure 5.9B). HeLa cells 
treated with negative control miRNA inhibitor formed 22±3 colonies, while HeLa cells 
treated with Anti-miR miRNA Inhibitors formed only 5±2 colonies. The inhibition was 
confirmed by one-way ANOVA analysis and p-values <0.05 were considered significant. 
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A                                       B  
 
Figure 5.9 Anchorage-independent growth examined by colony formation assay (miRNA-106b-25 
cluster). (A) HepG2 cells and (B) HeLa cells were left untreated (U), or transfected with 150 nM 
Anti-miR Negative Control #1 (Neg 150), or a mixture of 50 nM of Anti-miR-106b, Anti-miR-93 and 
Anti-miR-25 miRNA Inhibitors (Mix). Data shown represent mean ± SD (n=3). * p<0.05, ANOVA 
analysis, for comparison between Neg 150 and the other treatments. 
 
5.3.4 Effect of the Deregulated miRNAs on Anchorage-independent 
Growth 
The anchorage independent assay was also performed to examine the oncogenic potential 
of the 4 other downregulated miRNAs which were miR-182, miR-221, miR-222 and 
miR-224. As shown in Figure 5.10A, HepG2 cells treated with negative control miRNA 
inhibitor formed 39±4 colonies, while HepG2 cells treated with Anti-miR-182, 
Anti-miR-221, Anti-miR-222, Anti-miR-224 miRNA Inhibitors formed only 24±2, 29±3, 
25±2, 20±3 colonies respectively. The same pattern was also observed in HeLa cells 
















































































Figure 5.10 Anchorage-independent growth examined by colony formation assay (miRNA-182, 
miR-221, miR-222 and miR-224). (A) HepG2 cells and (B) HeLa cells were left untreated (U), or 
transfected with 150 nM Anti-miR Negative Control #1 (Neg 150), or 150 nM of Anti-miR-182, 
Anti-miR-221, Anti-miR-222, Anti-miR-224 miRNA Inhibitors respectively. Data shown represent 
mean ± SD (n=3). * p<0.05, ANOVA analysis, for comparison between Neg 150 and the other 
treatments. 
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5.4 Prediction of the Putative Targets of the miR-106b-25 
Cluster 
In mammalian cells, miRNA generally inhibits the expression of its target gene by binding 
to the 3’UTR of the transcript of target gene. By searching two major databases, miRanda 
and PicTar, several putative targets of the miR-106b-25 cluster were selected based on 
their scores assigned by miRanda and their physiological functions that would coincide 
with our hypothesis that members of this cluster may function as oncogenes when 
overexpressed. Based on these considerations, the E2F transcription factor 5 (E2F5) was 
selected as the putative target of miR-106b, while the caspase 6 (CASP6) was selected as 
the putative target of miR-93, and the transcription factor 2 (TCF2) was selected as the 
putative target of miR-25 (Table 5.6). The predicated binding of the miRNAs to the 
corresponding putative targets are shown in Table 5.6. 
 
Table 5.6 Putative target genes of the miR-106b-25 cluster and the possible binding format. 
RFAM ID: ID number in Rfam database (http://www.sanger.ac.uk/Software/Rfam/) 
Energy: the change of energy when miRNA binds to its target in the proposed format. 
 
Gene Rfam ID Score by MIRBASE Energy Start End Alignment 
E2F5 hsa-miR-106b 17.3208 -17.95 495 515 
uaGACGUGACAGUCGUGAAAU
  || |  | |:||||||||| 
gcCTTCTGTTTTAGCACTTTA 
CASP6 hsa-miR-93 17.7561 -24.35 68 89 
gaUGGACGUGCUUGUCGUGA
AA 
  |||||:|    ||||||||| 
acACCTGTAATCCCAGCACTTT 
TCF2 hsa-miR-25 15.699 -16.43 500 522 
agucUGGC-UCUGUUCACGUU
Ac 




Besides siRNAs, miRNAs are another group of small RNA molecules that plays important 
roles in PTGS. miRNAs are tiny molecules, about 22 nucleotides in length, which 
posttranscriptionally regulate the expression of genes. They do not encode proteins, but 
they control the mRNAs that do and thus are key players in many physiological and 
developmental processes. Discovered a little more than a decade ago, miRNAs have 
rapidly become the focus of considerable scientific scrutiny. However, exactly what they 
do and how they work remain to be determined. Deregulated expression of certain 
miRNAs has been linked to several types of human cancers (Calin et al., 2002, 2005; 
Michael et al., 2003; Cimmino et al., 2005; Chan et al., 2005; Hayashita et al., 2005; He et 
al., 2005a; Pallante et al., 2006; Si et al., 2006). Both over-expression as well as 
downregulation of miRNA expression have been described and it has been proposed that 
miRNAs might function either as oncogenes or tumor suppressors (Kent and Mendell, 
2006).  
 
5.5.1 Deregulation of miRNAs in HCC 
In this study, the changes in the expression of miRNAs in HCC were examined. In order to 
quantify the expression of miRNAs, the RT-real-time PCR approach was adopted. 
Analysis of miRNA precursors was carried as described by Thomas and co-workers 
(Thomas et al., 2004), while analysis of the mature miRNAs was carried out with a 
commercially available TaqMan MiRNA Assays Human Panel-Early Access Kit. Both 
were found to be robust for the quantification of mature or precursor miRNA molecules by 
our group as well as by other groups (Si et al., 2006; Bandres et al., 2006). The advantage 
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of using the RT-real-time PCR approach over that of miRNA arrays for profiling is that 
the former is more sensitive and quantitative and by using the former, there is no need for 
additional confirmation of the data obtained. This is important as the amount of RNA 
available for analysis can be limiting. 
 
The miRNA expression profiles based on 157 miRNAs in this study led to the 
identification of 28 upregulated and 14 downregulated miRNAs in HCC. Volinia and 
co-workers had shown in an earlier study that in six different types of solid tumors, the 
trend is generally for more miRNAs to be upregulated rather than downregulated in tumor 
(Volinia et al., 2006). Our results for the HCC samples are consistent with this observation 
with more miRNAs being upregulated. By comparing the deregulated miRNAs in various 
cancers (breast, colon, lung, pancreas, prostate and stomach), 21 miRNAs were found to 
be commonly upregulated in at least 3 or more of these solid tumors (Volinia et al., 2006). 
Our data indicates that some of these miRNAs are also upregulated in HCC which is also a 
solid tumor. These miRNAs include miR-17-5p, miR-20a, miR-21, miR-25, miR-92, 
miR-106a, miR-107, miR-155 and miR-221. Of interest to note is that miR-17-5p, 
miR-20a and miR-92 are members of the miR17-92 cluster while miR-25 is a member of 
the miR-106b-25 cluster. 
 
Among the 42 deregulated miRNAs we identified in our samples, some have been 
demonstrated to be oncogenic miRNAs or tumor suppressors. These miRNAs and their 
functions and targets are shown in Table 5.7. We observed the upregulation of miR-17-5p, 
miR-20a, miR-21, miR-92, miR-155, miR-221 and miR-222 in HCC, and these miRNAs 
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have been shown to be oncogenes by various other investigators (Table 5.7). We also 
observed the downregulation of miR-122, miR-199a, miR-199a* and miR-200a in HCC. 
This is consistent to the previous findings (Murakami et al., 2006; Kutay et al., 2006). 
Interestingly, the only exception is miR-15a. miR-15a has been shown to be 
downregulated in several types of cancers (prostate cancer, CLL and pituitary adenomas) 
(Dong et al, 2001; Calin et al., 2002, 2005; Cimmino et al.,2005; Bottoni et al., 2005.), 
while in our study miR-15a is upregulated in HCC. The difference in these findings 
suggests that one miRNA may play distinct roles in different types of cancers. This is 
possibly because the genes that are functional targets for certain miRNAs in certain types 
of cancers may not be expressed in other types of cancers. In addition, our functional study 
on the effects of miRNAs on cell growth and proliferation confirmed the possible 
oncogenic roles of miR-221and miR-222 which have been shown to be upregulated in 
papillary thyroid carcinoma and may function by inhibiting the expression of its target 
gene KIT (Table 5.7).  
 
As shown in Table 5.7, phosphatase and tensin homolog (PTEN) was identified as one of 
the targets of the miR-17-92 cluster. PTEN is a tumor suppressor. It has been reported that 
PTEN expression is generally reduced in HCC and decreased PTEN expression is 
correlated with HCC progression (Hu et al., 2003; Ma et al., 2005a). This observation is 
certainly congruent with the observation of the upregulation of the miR-17-92 cluster in 
HCC (our data and that of Murakami et al and Kutay et al) (Murakami et al., 2006; Kutay 
et al., 2006). Since PTEN is a target of this cluster, overexpression of this cluster would 
lead to reduced PTEN expression. 
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Table 5.7 miRNAs that are commonly deregulated in cancers and their functions.   
miRNA:  
 
Function / Targets: References: 




/E2F1, PTEN, TGFBR2 
Lewis et al., 2003; Ota et al., 2004; He et 
al., 2005b; O’Donnell et al., 2005; 




Tumor suppressor  
/ BCL2 
Dong et al., 2001; Calin et al., 2002, 2005; 
Cimmino et al.,2005. Bottoni et al., 2005. 
miR-21 Anti-apoptotic factor 
/ Unknown 
Chan et al., 2005; Volinia et al., 2006 ; Si 
et al., 2006. 
miR-155 Oncogenic  
/ AT1R 
Eis et al., 2005; He et al., 2005a; Martin et 






He et al., 2005a; Pallante et al.,2006. 
E2F1: E2F transcription factor 1; PTEN: phosphatase and tensin homolog; TGFBR2: transforming 
growth factor, beta receptor II; BCL2: B-cell leukemia/lymphoma protein 2; AT1R: angiotensin II 
receptor, type 1 ; KIT : v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog. 
 
During the course of this study, two other groups published data showing changes in the 
expression of miRNAs in HCC based on miRNA profiling using miRNA arrays. 
(Murakami et al., 2006; Kutay et al., 2006). Despite the difference in techniques, the 
differences in the miRNAs that are represented in each study and the differences in species, 
it is interesting to note that these two studies and ours did yield some results that overlap 
and this will be discussed. 
 
By an array-based miRNA profiling approach, Murakami and co-workers observed that 
miR-18, the precursor of miR-18 and miR-224 were significantly upregulated in HCC 
while miR-125a, miR-195, miR-199a, miR-199a* and miR-200a were significantly 
downregulated (Murakami et al., 2006). By employing the RT-real-time PCR approach, 
we also observed similar changes: miR-224 was significant upregulated in HCC, while 
miR-199a, miR-199a* and miR-200a were downregulated. miR-18 is a member of the 
  145
miR-17-92 cluster. We did not have any data on miR-18 as this was not included in the 
human panel early access kit. Since all the members of the cluster are co-expressed from 
one single pri-miRNA transcript, it is not surprising that we detected the upregulation of 
miR-17-5p, miR-20a and miR-92 which are also members of this cluster.  
 
Kutay and co-workers’ work was mainly on a rat HCC model (Kutay et al., 2006). They 
identified 23 upregulated and only three downregulated miRNA genes using an 
array-based approach. The primary principle they followed to identify miRNAs that are 
deregulated in HCC is that miRNAs that showed twofold or higher expression in at least 
two out of three tumors analyzed compared to the controls were considered significantly 
upregulated miRNAs in HCC, while miRNAs that are underexpressed (ratio<=50%) in at 
least two tumors were identified as significantly downregulated. We used a similar 
approach in our study to identify miRNAs that are deregulated in HCC. We had a much 
larger sample size (sample size = 10) compared to theirs (sample size = 3), and we selected 
miRNAs that were upregulated >= 2 fold or downregulated >=50% in at least 5 out of 10 
tumors as significantly deregulated miRNAs. Comparison of our profiling data to theirs 
shows that among 23 upregulated miRNAs only miR-17, miR-20, miR-21 and miR-93 are 
commonly observed in both studies. Although miR-93 was not included in the early access 
kit, we detected the upregulation of miR-25 by miRNA profiling. Both of them are 
members of the miR-106b-25 cluster (Figure 5.5), and we confirmed the enhanced 
expressions of all the three members. Among the 3 downregulated miRNAs, only 
miR-122 was identified in both studies. 
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Among the commonly deregulated miRNAs in rat HCC and human HCC, miR-17, 
miR-18 and miR-20 are the members of the miR-17-92 cluster which is generally 
upregulated in cancers while miRNA-93 is the member of the miR-106b-25 cluster which 
is homologous to the miR-17-92 cluster. miR-21 has also been shown to be commonly 
upregulated in both rat and human HCC. The agreement of observations across species 
indicates that these miRNAs may indeed have important oncogeneic roles 
 
However, these pilot studies only demonstrated the possible relationship between miRNA 
deregulation and HCC. The exact role that miRNAs play in HCC has not yet been 
elucidated. 
 
5.5.2 Validation of the Deregulation of miRNAs in HCC 
Deregulated miRNA expression in HCC was identified by the miRNA profiling based on 
expressions of 157 miRNAs in10 pairs of HCC samples. It was necessary to validate the 
results in a larger number of samples. Nine of the most frequently upregulated miRNAs 
were selected and screened in 56 pairs of HCC samples (tumor vs. non-tumor). For all the 
selected miRNAs, the upregulation was detected in about 50% HCC samples as shown in 
Table 5.4. Statistical analysis confirmed the upregulation. Thus, together with the 
agreement between our study and that by Murakami et al and Kutay et al (Murakami et al., 
2006; Kutay et al., 2006), it shows that the RT-real-time PCR based miRNA profiling is a 




5.5.3 The miRNA-106b-25 Cluster as an Oncogenic Cluster 
Among those deregulated miRNAs, miR-25 is of great interest as it is a member of a 
potential oncogenic miRNA cluster. As described in section 5.2.2.3, miR-25 is one of the 
three miRNAs encoded by a polycistronic miR-106b-25 cluster. The miR-106b-25 cluster 
is homologous to the miR-17-92 cluster (Tanzer and Stadler, 2004). Comparison between 
these two clusters shows that miR-106 is a homologue of miR-17, miR-93 is related to 
miR-20, and miR-25 is distantly related to miR-92. Among them, only the miR-92/miR-25 
group has known invertebrate homologues. The evolution of this cluster is governed by an 
initial phase of local (tandem) duplications, a series of duplications of the entire cluster 
and subsequent loss of individual miRNAs from the resulting paralogous clusters. The 
miR-17-92 cluster is probably the best characterized miRNA cluster and has been proven 
to be implicated in tumorgenesis of several types of human cancers (Lewis et al., 2003; 
Ota et al., 2004; He et al., 2005b; O’Donnell et al., 2005; Hayashita et al., 2005; Volinia et 
al., 2006). We detected the upregulation of both the miR-17-92 cluster and the 
miR-106b-25 cluster in HCC. It is possible the miR-106b-25 cluster is implicated in HCC 
development. 
 
In this study, we demonstrated that in 50% of HCC samples, both the precursors and the 
mature forms of the members of the miR-106b-25 cluster were overexpressed. The robust 
overexpression of the miRNA-106b-25 cluster was also detected in 3 human liver cell 
lines derived from HCC (HepG2, Huh7 and 2.2.15) compared to its expression in primary 
hepatocytes. We hypothesized that the aberrant elevated expression of this miRNA cluster 
might block the expression of its target genes which are important in regulating normal 
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cell proliferation or differentiation. The disrupted expression of target genes may finally 
contribute to tumorgenesis. In this sense, the miRNA-106b-25 cluster may function as an 
oncogene cluster, just like its well studied homolog, the miRNA-17-92 cluster.   
 
The functions of only a few miRNAs are confirmed. This could be partially due to the lack 
of functional study tools and the complicated interaction between miRNA and its targets. 
Recently, it was reported that 2’-O-methyl-oligoribonucleotides can serve as 
sequence-specific inhibitors of miRNA function and miRNA-directed RISC activity 
(Meister et al., 2004; Hutvagner et al., 2004; Cheng et al., 2005). These modified 
antisense oligoribonucleotides stoichiometrically bind and inactivate miRNAs, providing 
a valuable tool to disrupt the function of a single miRNA in vitro and in vivo. This strategy 
has been successfully utilized to study the possible function of certain miRNAs (Chan et 
al., 2005). To study the biological significance of overexpressed miRNAs in HCC, 
especially the miRNA-106b-25 cluster, we used this loss-of-function approach in HepG2 
and HeLa cells. Our study demonstrated that knocking down of the expression of 
miR-106b alone inhibited cell proliferation in both HepG2 and HeLa cell lines. Knocking 
down of the expression of all three members of the miRNA cluster inhibited cell 
proliferation much more efficiently, and also suppressed anchorage-independent growth as 
determined by soft agar assay. These findings are consistent with our hypothesis and also 
suggest the collaborative roles of miR-106b, miR-93 and miR-25. Each member of the 
polycistronic miRNA cluster just plays part of the roles that the whole cluster exhibits. 
They may have to work together in order to function properly. Similar collaborative 
effects were also reported for the miR-17-92 cluster in a mouse model by He and 
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co-workers. They found that overexpression of any of the individual members of the 
cluster could not promote tumor growth to the extent that could be achieved by 
overexpression of the whole polycistron (He et al., 2005b). Currently it is unclear how the 
expression of the miR-106b-25 cluster is regulated and the mechanisms for its 
overexpression in HCC remain to be determined. In addition, there is also a need to 
determine the targets for this cluster. 
 
miRNA itself does not encode protein. It can only function by regulating the expression of 
its target genes. So in order to understand the real function of miRNAs it is necessary to 
identify the miRNA targets. Until now only few miRNA targets have been confirmed 
(Table 5.7). The difficulty of identifying miRNA targets lie in the facts that: i) details 
about how miRNAs recognize and regulate their targets remain largely unknown and ii) 
precise rules for functional miRNA-target site structures have not been devised yet. In 
mammalian cells, most of the miRNAs function by inhibiting binding to the 3’UTR of the 
transcript of target genes. As described in section 5.4, we identified E2F5 as the putative 
target of miR-106b, CASP6 as the putative target of miR-93 and TCF2 as the putative 
target of miR-25. We try to correlate our observation to the known physiological functions 
of these genes and found that the correlation is good. The E2F5 plays a crucial role in the 
control of cell cycle and action of tumor suppressor proteins (Hijmans et al., 1995). 
Overexpression of miR-106b may inhibit the expression of E2F5 gene, and this may result 
in uncontrolled cell proliferation and/or inactivation of tumor suppressor proteins, leading 
eventually to tumorgenesis. As an execution-phase caspase, CASP6 plays a crucial role 
during apoptosis (Lee et al., 2006). If the interaction between miR-93 and CASP6 is real, 
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enhanced expression of miR-93 will suppress the expression of CASP6, thus enhancing 
cell survival. TCF2 encodes hepatocyte nuclear factor 1β (HNF1β), a transcription factor 
associated with development and metabolism. TCF2 is inactivated in ovarian, colorectal, 
gastric and pancreatic cell lines, suggesting general involvement of epigenetic inactivation 
of TCF2 in tumorgenesis (Terasawa et al., 2006). Therefore, when miR-93 is upregulated, 
the resulting suppression of TCF2 may contribute to tumorgenesis. The binding of a 
miRNA and its putative targets can be further characterized and confirmed by reporter 
assay as described in various other studies (Felli et al., 2005; Cimmino et al., 2005; Guo et 
al., 2006).  
 
5.5.4 The Deregulated miRNAs as Oncogenes 
Besides the miRNA-106b-25 cluster, miRNA-182, miRNA-221, miRNA-222 and 
miRNA-224 are also significantly overexpressed in HCC. Similarly, we used the 
loss-of-function approach in HepG2 and HeLa cells to study the biological significance of 
these overexpressed miRNAs. Our study demonstrated that knocking down these 
upregulated miRNAs inhibited cell proliferation in both HepG2 and HeLa cell lines as 
determined by MTS assay and also suppressed anchorage-independent growth as 
determined by soft agar assay. These findings are consistent with our hypothesis that these 
miRNAs may function as oncogenes. It has been reported that miRNA-221 and 
miRNA-222 are overexpressed in papillary thyroid carcinoma and can promote human 
cancer cell profiliferation by targeting the p27 (Kip1) tumor suppressor (He et al., 2005a; 
Galardi et al., 2007; le Sage et al., 2007). Currently it is unclear how the expression of the 
miRNA-221 and miR-222 is regulated and the mechanisms for its overexpression in HCC 
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remain to be determined. For miRNA-182 and miRNA-224, little is known about these 
two miRNAs and there is also a need to determine the targets for these miRNAs. 
 
5.6 Conclusion 
In summary, aberrant expression of miRNAs does occur in HCCs as shown by us and the 
studies by Murakami et al and Kutay et al (Murakami et al., 2006; Kutay et al., 2006). In 
this study, we identified 28 upregulated miRNAs and 14 downregulated miRNAs in HCC 
by miRNA expression profiling in paired tumor vs. non-tumor HCC tissues. Among these 
upregulated miRNAs, some have been shown to be oncogenic and differentially regulated 
in human cancers. They are miR-17-5p, miR-20a, miR-21, miR-92, miR-155, miR-221 
and miR-222. Among these downregulated miRNAs, some have also been reported to be 
downregulated in HCCs. They are miR-122, miR-199a, miR-199a* and miR-200a 
(Murakami et al., 2006; Kutay et al., 2006). However, to date, the targets of only a few of 
these deregulated miRNAs have been identified (Table 5.7). Although the targets for 
miR-182, miR-221, miR-222, miR-224 and the miR-106b-25 cluster have not been 
established, it was observed that downregulation of these miRNAs caused reduced cell 
proliferation. In addition, the downregulation of the miR-106b-25 cluster, miR-182, 
miR-221, miR-222 and miR-224 also led to reduced colony formation. However, there is 
still a need to identify the targets of these miRNAs as the knowledge of the interaction of 
the miRNAs to its targets may provide us with a better understanding of the function of the 
miRNA and allow us to determine if any of the deregulated miRNAs could serve as 















6.1 Summary of Important Findings  
HCC remains a global health problem, especially in Asia where HBV infection is 
prevalent. In this study, two groups of small RNA molecules; namely siRNAs and 
miRNAs were examined as they may be useful for diagnosis and treatment of hepatic 
diseases such as chronic HBV infection and HCC. The main findings are summarized as 
follows: 
 
siRNA-mediated suppression of HBV gene expression and viral replication in vitro was 
first examined. siRNAs targeted at two different sites within the HBV S ORF were 
designed and chemically synthesized. Both siRNAs could specifically inhibit the 
expression of HBsAg in PLC/PRF/5 and 2.2.15 cells. This together with a reduction in the 
corresponding mRNAs indicates that this is a true RNAi effect. The siRNA-induced RNAi 
also effectively reduced virion production in 2.2.15 cells as examined by real-time PCR. 
This augurs well for the potential use of siRNAs as therapeutic agents. 
 
In addition, the possibility of off-target effects due to siRNAs was also examined. This 
was done by examining firstly the effects of siRNAs on cell growth and viability. No 
cytotoxic effects were observed over a period of 7 days following siRNA treatments for 
both cell lines used. Further analysis using cDNA microarrays was then employed to 
investigate the change of global gene expressions following introduction of siRNAs into 
HBV gene expressing liver cells. The changes of gene expressions were limited to a small 
magnitude. Few genes were identified that had at least a 2 fold change following siRNA 
treatment. Most of those differentially expressed genes are of unknown functions. In 
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addition, no single pattern of change on gene expressions was identified following the 
treatment of cells with two different siRNAs that target the same region of HBV genome. 
Combined with the previous findings that reported the high specificity of siRNAs (Chi et 
al., 2003; Semizarov et al., 2003), it appears that it is possible to design siRNAs that may 
cause little off-target effects on mammalian cells. 
 
In the second part of this study, changes in miRNA expressions in HCC were examined. 
miRNA profiling was carried out in 10 paired surgical tissues (tumor vs. non-tumor) using 
a RT-real-time PCR based approach. miRNAs that are deregulated in HCC were identified. 
Among them, 28 miRNAs were significantly upregulated in HCC, while 14 miRNAs were 
significantly downregulated. The upregulation of some of the most frequently upregulated 
miRNAs, namely miR-15b, miR-135a, miR-182, miR-221, miR-222, miR-224 and all 
three members of the miR-106b-25 cluster in HCC were further confirmed in 56 pairs of 
HCC clinical samples. In addition, when the expressions of miR-182, miR-221, miR-222 
and miR-224 were knocked down by the corresponding anti-miR miRNA inhibitors, cell 
growth and viability were inhibited. These deregulated miRNAs might play important 
roles in tumorigenesis. 
 
The miR-106b-25 cluster was futher examined as this cluster is homologous to the 
miR-17-92 cluster which has been shown to be oncogenic when overexpressed. The 
upregulation of this polycistronic miRNA cluster was confirmed both in 56 pairs of HCC 
samples and in HCC cell lines. Knocking down of the expression of this miRNA cluster in 
HepG2 and HeLa cells resulted in decreased cell growth and proliferation and decreased 
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anchorage-independent growth on soft agar. Taken together, our data support our initial 
hypothesis that the miR-106b-25 cluster is an oncogenic gene cluster. 
 
Thus, it is evident from this study that siRNAs can be used as powerful tools to inhibit 
HBV gene expression and viral replication effectively and specifically. It is thus possible 
to design siRNAs that are safe for therapeutical use. In addition, our study on miRNAs in 
HCC indicates that miRNAs are deregulated in HCC and the miRNA-106b-25 cluster 
together with some of the most frequently upregulated miRNAs in HCC may function as 
oncogenic genes in HCC. It suggests that miRNA profiling might aid in cancer diagnosis 
and understanding of miRNA function in cancers may provide new therapeutic targets. 
 
6.2 Suggestions for Future Work 
Future work that may extend our understanding of the diagnostic and therapeutic roles of 
small RNA molecules in hepatic diseases is suggested as follows:  
 
Although to date there have been many studies showing that siRNAs targeting various 
regions of the HBV genome can lead to inhibition of HBV gene expression and virion 
replication (Hamasaki et al., 2003; Ying et al., 2003; Konishi et al., 2003), it is still 
worthwhile to first carry out a systematic evaluation of which target regions in the HBV 
genome give the best inhibitory effect. This will allow for the determination of the best 
sites that can be used as potential siRNA therapeutic targets. Secondly, other global 
approaches, such as proteomics, can be employed to further evaluate the effects of siRNA 
on mammalian cells. Thirdly, there is a need to show that siRNAs can reduce HBV 
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replication in animal models for chronic hepatitis B infection. A few recent studies had 
shown that it is possible to inhibit HBV replication in mice (McCaffrey et al., 2003b; 
Giladi et al., 2003; Morrissey et al., 2005). However, these were carried out in models for 
acute infection. Fortunately, some of the models that could be employed to study chronic 
HBV infection and therapy have been established, which include HBV-transgenic mice as 
well as non-transgenic mouse models for chronic hepatitis (Chisari et al., 1985; Huang et 
al., 2006). In addition, one may also consider using tree shews which can be infected with 
human HBV (Yan et al., 1996). These animal models will certainly be useful for 
evaluating the in vivo use of siRNAs as therapeutic agents. They provide the areas to 
examine delivery systems and to examine the efficiency of chemically modified siRNAs. 
Only after the animal studies have been carried out successfully and safely can one 
proceed with examining the use of siRNAs as potential anti-HBV agents in human.  
 
Our study and that of Murakami et al and Kutay et al have shown that there are changes in 
the expression of miRNAs in HCC (Murakami et al., 2006; Kutay et al., 2006). What is 
lacking is the identification of the targets of the miRNAs and how these targets affect the 
progression of HCC. Thus what is critical now is the need to determine the targets of 
miRNAs that are deregulated in HCC and to determine if these miRNAs can serve as 
potential therapeutic or diagnostic targets for HCC. An approach that could be taken 
would be to mine the miRNA target prediction databases and obtain putative targets based 
on their scores for binding and on their physiological functions that would coincide with 
our hypothesis that the miRNAs may function as either oncogenes (if overexpressed) or 
tumor suppressors (if downregulated). The binding of a miRNA and its putative targets 
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can be then further characterized and confirmed by reporter assay as previously described 
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SUPPLEMENTARY  MATERIAL 
Table S1. Clinical characteristics of 56 patients 
NO Diagnosis Aetiology Cirrhosis TNM Age Sex Race 
23 Poorly differentiated HCC HBV + T3 N0 M0 stage IIIA 49 M Chinese 
27 Moderately differentiated HCC HBV + T3 N0 M1 stage IVB 57 M Chinese 
47 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 47 M Chinese 
48 Poorly differentiated HCC HBV - T4 N0 M0 stage IVA 54 F Indonesian 
51 Moderately differentiated HCC HCV + T2 N0 M0 stage II 59 M Chinese 
52 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 55 M Chinese 
57 Moderately differentiated HCC HBV - T3 N0 M0 stage IIIA 46 M Chinese 
67 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 59 F Chinese 
77 Well differentiated HCC Cryptogenic + T3 N0 M0 stage IIIA 67 M Indonesian 
78 Well differentiated HCC HBV + T3 N0 M0 stage IIIA 56 M Chinese 
81 Poorly differentiated HCC Cryptogenic - T3 N0 M0 stage IIIA 71 F Chinese 
83 Poorly differentiated HCC HBV + T4 N0 M0 stage IVA 52 M Chinese 
96 Moderately differentiated HCC HBV - T3 N1 M0 stage IIIB 71 M Chinese 
104 Poorly differentiated HCC HBV + T4 N0 M0 stage IVA 44 M Chinese 
108 Moderately differentiated HCC HBV - NIL 65 M Chinese 
111 Poorly differentiated HCC HBV - T4 N0 M0 stage IVA 39 M Chinese 
117 Poorly differentiated HCC Cryptogenic - T3 N0 M0 stage IIIA 54 M Indian 
118 Moderately differentiated HCC HBV + T4 N0 M0 stage IVA 47 M Myanmar 
120 Poorly differentiated HCC HBV + T3 N0 M0 stage IIIA 66 M Indian 
121 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 63 M Chinese 
123 
Well differentiated clear cell 
HCC Cryptogenic - T2 N0 M0 stage II 56 M Chinese 
125 Moderately differentiated HCC Cryptogenic - T2 N0 M0 stage IIIA 61 M Chinese 
126 Poorly differentiated HCC HBV + T3 N0 M0 stage IIIA 53 M Chinese 
127 Moderately differentiated HCC HBV - T4 N0 M0 stage IVA 52 M Chinese 
129 Moderately differentiated HCC Cryptogenic + T3 N0 M0 stage IIIA 76 F Chinese 
131 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 32 M Chinese 
132 
Well differentiated clear cell 
HCC HCV + T3 N0 M0 stage IIIA 59 M Indian 
135 Poorly differentiated HCC Cryptogenic - T4 N0 M0 stage IVA 62 M Pakistani 
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136 Moderately differentiated HCC HBV + T2 N0 M0 stage II 71 M Chinese 
137 Moderately differentiated HCC HBV + T4 N0 M0 stage IVA 62 M Myanmar 
148 Poorly differentiated HCC HBV + T3 N0 M0 stage IIIA 68 M Chinese 
149 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 65 M Indonesian 
150 Poorly differentiated HCC HBV - T3 N0 M0 stage IIIA 44 M Chinese 
151 Moderately differentiated HCC HBV + T4 N0 M0 stage IVA 82 F Chinese 
153 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 60 M Indonesian 
155 Poorly differentiated HCC HBV + T4 N0 M0 stage IVA 63 M Chinese 
156 Moderately differentiated HCC HBV - T3 N0 M0 stage IIIA 53 M Chinese 
158 Moderately differentiated HCC Cryptogenic + T3 N0 M0 stage IIIA 76 F Malay 
160 Poorly differentiated HCC HBV + T3 N0 M0 stage IIIA 56 M Chinese 
169 Poorly differentiated HCC HCV + T4 N0 M0 stage IVA 67 M Malay 
174 Well differentiated cell HCC Cryptogenic - T2 N0 M0 stage II 68 F Indonesian 
186 Moderately differentiated HCC Cryptogenic + NIL 37 F Chinese 
187 Poorly differentiated HCC HBV + T3N0M0 61 M Chinese 
192 Moderately differentiated HCC Cholangio - NIL 71 F Chinese 
193 Moderately differentiated HCC HBV - T4N0M0 38 M Chinese 
195 Poorly differentiated HCC HCV + T2 N0 M0 stage II 65 M Indonesian 
196 Moderately differentiated HCC HBV + T3N0M0 40 M Chinese 
197 Moderately differentiated HCC Cryptogenic - T3N0M0 72 M Indonisian 
204 Moderately differentiated HCC Cryptogenic - T2NXMX 74 M Chinese 
211 Poorly differentiated HCC Cryptogenic - T3NXMX 57 F Malaysian 
222 NIL HBV - NIL NIL NIL NIL 
233 Poorly differentiated HCC HBV - T1NXMX 53 M Chinese 
240 Moderately differentiated HCC HBV - T2NXMX 70 M Chinese 
246 well differentiated HCC HBV - T2NXMX 54 M Chinese 
247 well differentiated HCC HBV - T3N0MX 44 F Chinese 
248 NIL HBV - NIL NIL NIL NIL 
 
 
